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Reactive oxygen species can cause posttranslational modifications to amino acids, including 
sulfur-containing methionine. Methionine sulfoxide modifications are reduced by methionine 
sulfoxide reductase enzymes. The redox balance between reactive oxygen species and the 
methionine sulfoxide reductase system is disrupted in the aging process. This loss of 
antioxidant homeostasis can result in disease, and neurons may be particularly susceptible to 
the impact of methionine sulfoxide in proteins. Here we present evidence for the disruption of 
cell signaling processes in neuronal protein metabolism, and neurodegeneration in organisms 
lacking the methionine sulfoxide reductase A gene. In addition, we present data supporting the 
novel concept of the compromising effect of methionine oxidation on dopaminergic receptor 
function that is linked to movement regulation. Consequently, it is predicted that enhancing the 
activity of the methionine sulfoxide reductase system may be beneficial in preventing oxidative 
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Posttranslational modifications can change a protein’s structure, function, and solubility. One 
specific modification caused by reactive oxygen species (ROS) is the oxidation of the sulfur 
atom in the methionine (Met) side chain. This modified amino acid is denoted as methionine 
sulfoxide (MetO). Sulfoxides in proteins are of considerable interest as they are involved in early 
posttranslational modification events. Thus, various organisms produce specific enzymes that 
can reverse these modifications. Methionine sulfoxide reductase (Msr) enzymes, known 
collectively as the Msr system, are the only known enzymes that can reduce MetO. The current 
research field of methionine redox cycles is consumed with elucidating its role in regulation, 
redox homeostasis, prevention of irreversible modifications, pathogenesis, and the aging 
process. (Oien & Moskovitz, 2008)  
In 1956, Denham Harman published a theory on free radical damage to organisms and its 
relation to aging (Harman, 1956). This landmark article has evolved to what is now known as 
the free radical theory of aging (Harman, 1973). The free radical theory of aging is in 
accordance with the common hypothesis that aging is a process mediated by oxidative damage, 
and the controversial idea that age-related disease is linked to oxidative damage.   
Oxidative damage to cells can affect multiple cellular components, including lipids and 
proteins. In general, a chemical modification forming after the genetic expression of a protein is 
denoted as post-translational modification. Oxidative modifications to proteins are caused by 
reactive species, such as ROS and reactive nitrogen intermediates. These oxidants are formed 
by a variety of biological processes within cells and tissues at varying rates, and specific toxins 
can induce their production. Examples include hydrogen peroxide, superoxide, oxygen, ozone, 
hypochlorous acid, choramine T (sodium N-chloro-p-toluenesulfonchloramide), N-
chlorosuccinimide, hydroxyl radicals, and peroxynitrite (Savige & Fontana, 1977). Modifications 
via ROS can affect virtually all amino acid side chains and the backbone of the peptide linkage. 
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However, amino acids vary in their vulnerability to become oxidized. Furthermore, the particular 
location of amino acid residues within the structure of a protein may determine the sensitivity 
level towards the oxidants, which contributes to even greater variability.      
Common ROS-mediated side chain modifications can be in the form of a carbonyl or the 
oxidized sulfur atom of Met or cysteine (Cys). Protein-carbonyls are non-enzymatic irreversible 
modifications. They are often catalyzed by metal ions and tend to form on the side chains of the 
amino acids proline, arginine, threonine, and lysine (Dalle-Donne et al., 2006). In contrast, the 
sulfur-containing amino acids are readily oxidized and most modifications are reversible.  
Modifications of Cys residues have various consequences including the alteration of protein 
structure, inactivation of proteins, and formation of disulfide bridges (Jacob, Knight, & Winyard, 
2006). Reversal of the post-translational modifications to Cys residues can be achieved by 
several non-enzymatic reductants and reducing enzymes. However, the reduction of MetO is 
exclusively performed by the Msr system. 
 
A.  Msr System (Oien & Moskovitz, 2008) 
The oxidation of a Met side chain can form either a MetO or a Met sulfone. The former contains 
an oxygen atom double-bonded to the sulfur atom, and the latter contains two oxygens bonded 
to the sulfur atom. Met sulfones are formed in more extreme oxidant conditions following the 
formation of MetO. They are considered irreversible, and cannot be reduced under physiological 
conditions. In contrast, MetO is readily formed relative to other post-translational modifications 
and can be reduced by Msr. Oxidation of the Met sulfur atom can form either one of two 
possible enantiomers; denoted as S and R. With some specific exceptions, there is no general 
evidence to date predicting which enantiomer of MetO will be formed when the side chain of Met 
is oxidized. The S and R enantiomers can be reduced by the enzymes methionine sulfoxide 
reductase A and B (MsrA, MsrB), respectively.   
3 
The Msr enzymes reduce MetO at the expense of becoming oxidized, and thus inactivate 
themselves. The first evidence of a reductase that reduced MetO in peptides was shown in 
1981 (Brot, Weissbach, Werth, & Weissbach, 1981). The enzymes are reduced and reactivated 
primarily by thioredoxin (Trx), thioredoxin reductase (Trr), and NAD(P)H. The reduction 
sequence can be illustrated by the equation: 
 
      NADPH + Trr → Trx  → Msr  → Met (-Methyl-SO to -Methyl-S) 
 
where the arrows depict reduction of each oxidized form of the molecule by the former 
substance. After the reducing enzymes bind to their substrates, they become oxidized and thus 
re-enter the reduction cycle. In some forms of human MsrB, specifically hMsrB2 and hMsrB3, 
thioredoxin has been found less efficient for reduction. In addition, a protein called thionein, 
especially for hMsrB3 (Sagher, Brunell, Hejtmancik et al., 2006), and certain selenium 
compounds make better reducing enzymes to activate these reductases (Sagher, Brunell, Brot, 
Vallee, & Weissbach, 2006). In experimental conditions dithiothreitol is often used to reduce 
Msr, and lipoic acid also can act as a reductant (Biewenga, Veening-Griffioen, Nicastia, 
Haenen, & Bast, 1998). 
The Cys at position 72 is vital for Msr activity and is highly conserved in most species 
(Moskovitz et al., 2000). When Msr is inactivated, the Cys residue is oxidized and forms a 
disulfide bridge with another Cys near the C-terminal (Brot & Weissbach, 2000).   
The Msr enzymes are found in many organisms in nature. In a bacterial strain like 
Escherichia coli, there is one form of MsrA and one form of MsrB. However, in mammals there 
is one form of MsrA and four forms of MsrB, denoted MsrB1, MsrB2, MsrB3A, and MsrB3B.  
The MsrB1 form is a cytoplasmic selenoprotein (Bar-Noy & Moskovitz, 2002; Moskovitz et al., 
2002), MsrB2 and MsrB3B can be targeted to the mitochondria, and MsrB3A is targeted to the 
endoplasmic reticulum (Kim & Gladyshev, 2004). In addition, MsrA also has a long spliced-
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variant form that is transported to the mitochondria (Balog et al., 2003). The msr genes are 
ubiquitously expressed in many organisms, and highly expressed in the liver and kidneys of 
mammals (Moskovitz et al., 1996). The Msr system is considered to be important for survival 
under oxidative stress conditions as manifested by msrA gene knockouts in various organisms 
(Moskovitz, 2005). 
Oxidation of Met residues can be readily reduced by the Msr system. The latter may prevent 
changes resulting from Met oxidation, for example alterations in the properties methyl sulfoxide-
containing peptides, protein structure, biological function, or a combination of all possibilities. 
Met is a hydrophobic amino acid, and the hydrophobicity decreases when the sulfur atom is 
oxidized. However, the sulfoxide formation can alter the native folding and create a more 
hydrophobic protein (Chao, Ma, & Stadtman, 1997). When Met is present in a protein, it can 
scavenge/detoxify the ROS, and this may occur with impunity if Msr is present. Thus, it is further 
speculated that Met residues play a protective role from ROS by their placement on outer faces 
of certain proteins. In this situation, they may serve as a shield from oxidative modification, 
protecting the active site of the protein. Furthermore, lack of MsrA has been shown in some 
organisms to increase protein carbonyl accumulation, an irreversible form of protein oxidation 
(Moskovitz et al., 2001). There is also evidence that Msr levels decrease in various rat tissues 
as they age (Petropoulos, Mary, Perichon, & Friguet, 2001), supporting the link between 
enhanced free radical damaging action and the aging process (Stadtman, Moskovitz, Berlett, & 
Levine, 2002).   
The role of MetO in proteins and the subsequent reduction in the pathogenesis of disease 
and general aging of cells is not completely known. Hence, the Msr system may prove to be a 
key component of oxidative prevention, regulation, or a combination of both. The extent of the 
consequences of these posttranslational modifications and their complete physiological 
significance still require more research.   
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B. Physiological Relevance of Msr Substates (Oien & Moskovitz, 2008) 
Substrates of the Msr system can be loosely classified by the overall effect of the MetO on the 
protein. Regulated substrates utilize Met as a molecular switch to modulate activation; 
scavenging substrates use Met residues to detoxify oxidants and protect important regions of 
the protein; modified substrates are altered by methionine oxidation resulting in various changes 
in their properties including function, activity, structure, and degradation resistance.  
 
  1. Regulated Substrates 
Cell signaling is an important biological mechanism and critical component of cellular regulation. 
Signaling pathways consist of proteins that can be activated and inactivated to modulate a 
response. Activity of the protein is often determined by its structure, and overall by the 
accessibility of reactive site. Modifications that add to cell signaling are covalently bonded and 
reversible. Well known examples of this phenomenon include tyrosine and serine 
phosphorylation/dephosphorylation, and Cys redox modulation (Ciorba, Heinemann, 
Weissbach, Brot, & Hoshi, 1997). It is suggested that the redox properties of Met residues also 
can contribute to signal pathways. Msr enzymes are generally regarded as repair enzymes, but 
the following examples show evidence of the enzymes contributing to cellular regulation. 
 
  2. Scavenging Substrates 
Scavenging substrates do not display any significant loss of biological activity when Met 
residues are oxidized under physiological conditions. This classification is dedicated to 
substrates containing Met that are hypothesized to play a protective role against the oxidation of 
proteins, or other residues of the same protein. Thus, by Met cyclic oxidation and reduction via 
the Msr system, these substrates are considered to be endogenous antioxidants, or oxidant 
scavengers. Theoretically, Met residues can effectively scavenge oxidants before reactive 
species modify residues critical to the structure and function of the substrate (Levine, Mosoni, 
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Berlett, & Stadtman, 1996). In this perspective, the Met residues act as ‘shields’ to the active 
site or ‘molecular sinks’ for reactive species balance. Evidence to support this idea is found in 
the placement of Met residues. They are often described as surface-exposed, protecting an 
opening to the active site, flanking the active site, or a combination.  
  
  3. Modified Substrates with ‘Damaged’ Effects 
The proteins in this classification display altered functions, a loss of biological activity, a change 
in structure, or resistance to degradation after the oxidation of the Met residues. The substrates 
are often linked to respective diseases, where they are discovered in a ‘damaged’ state. 
Evidence demonstrates that MetO may contribute to this state. The role that MetO may play in 
the physical and chemical properties of the protein is based solely on their availability to 
oxidation. Additionally, it is not always clear to what extent the substrate plays a role in the 
pathogenesis development of a respective disease, or rather if it is a consequence of a mature 
pathological state. The Msr system is proposed to play a role in maintaining the integrity of 
these substrates in their reduced form. The role of the Msr system may include repairing MetO-
oxidized proteins by preventing malfunction due to MetO, protecting specific regions of the 
protein from further irreversible modifications and structural changes, or a combination of both. 
The ultimate question is: if indeed MetO residues are responsible for this functional alteration, 
what makes Msr insufficient to counteract this phenomenon? Possibilities include, but are not 
limited to, the decline of Msr presence, decline of Msr activity, and non-compatable 
concentrations of reactive species. In some cases, Met oxidation may serve a modulation role, 
or simply be an ROS scavenger. Evidence may be either lacking in support of these roles or the 
actual functions of the proteins may still be unknown. 
 
  4. Discussion (Oien & Moskovitz, 2008) 
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In summary, there is a broad spectrum of substrates of the Msr system. The physiological 
significance of the MetO in conjunction with the Msr system is based on separate evidence. 
Furthermore, the substrates are classified into the three categories of regulated substrates, 
scavenging substrates, and modified substrates resulting in various changes in properties. The 
complete list of substrates is presented in Table 1. In addition, the substrates are 
subcategorized depending on the experimental evidence of in vivo/ex vivo (including in situ) and 
in vitro.  
 The continuing research will provide new information on the role of the Met redox cycle in 
regulation, redox homeostasis, prevention of irreversible modifications, pathogenesis, and the 
aging process. Moreover, the characterization of Met oxidation and the Msr system may lead to 












Table 1. Substrates for Msr further classified by type of experimental evidence. The key 
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II. Msr in Neurodegenerative Disease 
Increasing evidence suggests a major role of Met redox cycles in neurodegenerative disease. A 
neurodegenerative disease is a condition resulting in the deterioration of neurons, ultimately 
affecting brain function. They often present with problems in movement or memory and 
dementia. Certain neurodegenerative diseases are associated with a specific brain protein. 
Examples are amyloid-beta, alpha-synuclein, and prion (J. Moskovitz, 2005). The functions of 
these brain proteins are unknown, but they are each implicated in a respective 
neurodegenerative disease. Oxidant-mediated accumulation of modified proteins may be one of 
the major causes of age-related neurodegenerative disease (Jackob Moskovitz & Bush, 2005). 
In addition, the Msr system may prevent irreversible protein damage, and thus prevent 
accumulation of posttranslational modified proteins. Overall, Met redox cycles have been 
associated with Alzheimer’s disease, Parkinson’s disease, and Prion-related spongiform 
encephalopathies. (D. B. Oien & Moskovitz, 2008) 
Alzheimer’s disease is a data processing disorder associated with neural cell neurofibrillary 
tangles and the extracellular deposition of the amyloid plaques. Amyloid plaques are 
extracellular plaque filaments with an amyloid structure, and contain the amyloid-beta peptide.  
The amyloid-beta peptide is formed by cleavage of the amyloid precursor protein (Goedert & 
Spillantini, 2006). This cleavage commonly results in an amyloid beta peptide of 40 or 42 
residues. Amyloid-beta-40 concentrates in plaques of cerebral arteries. Amyloid-beta-42 is more 
concentrated in neural plaques. It is neurotoxic and thought to cause neurodegeneration. The 
toxicity of amyloid-beta-42 is suggested to play a central role in Alzheimer’s disease. The 
formation of amyloid plaques is considered one possible pathway of Alzheimer’s disease 
progression. However, this theory is not conclusive.   
Amyloid-beta-42 is a neurotoxin found in extracellular amyloid plaques. It contains 42 amino 
acids, including one Met at position 35. The neurotoxic properties of amyloid-beta may be a 
result of reactive species and free radical formation (Pogocki, 2003). Oxidation of Met35 can 
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reduce the amyloid-beta-42 fibrillation rate (Hou, Kang, Marchant, & Zagorski, 2002). The 
fibrillation rate may be associated with its ability to form the insoluble plaques, although the 
exact role is still unclear. The oxidized Met35 alters the peptide structure and decreases the 
hydrophobicity of the peptide (Barnham et al., 2003). The change in hydrophobicity decreases 
its ability to penetrate lipid membranes, and may contribute to the peptides altered location.  
The Msr system may assist in retaining the structure of amyloid-beta-42 (Jackob Moskovitz & 
Bush, 2005). Moreover, the transduction of MsrA as a fusion protein to cells with amyloid-beta-
42 increases the viability of the cultures (Jung et al., 2003). In addition, Msr activity was shown 
to decrease in Alzheimer’s brains (Gabbita, Aksenov, Lovell, & Markesbery, 1999). The higher 
levels of oxidative stress correlate with the presence of amyloid-beta in the hippocampus and 
cortex.   
Amyloid precursor protein is a glycoprotein expressed throughout the plasma membrane. 
Mutations in the amyloid precursor protein gene are thought to cause a familial form of 
Alzheimer’s disease. For example, Val717 can be changed to a phenylalanine or glycine. This 
substitution stimulates G-protein binding and signal transduction in aged human brain 
membranes (Karelson, Fernaeus, Reis, Bogdanovic, & Land, 2005). The stimulation is 
weakened in the temporal cortex when a methionine at position 722 is oxidized to a sulfoxide 
(Reis, Zharkovsky, Bogdanovic, Karelson, & Land, 2007). Furthermore, oxidized Met722 in the 
V717G mutated peptide causes less mitochondrial damage in neuron cell cultures. The 
neurotoxcity of this mutation may be mediated by methionine oxidation; thus, the Msr system 
may also contribute to this regulation.   
Parkinson’s disease is a neurodegenerative disease that causes alterations in motor 
function and postural stability. The disease is characterized by a progressive loss of 
dopaminergic neurons in the substantia nigra (Wood-Kaczmar, Gandhi, & Wood, 2006). The 
majority of Parkinson’s cases are sporadic, and the cause of the disease is unknown. However, 
over 5% of Parkinson’s disease cases are familial, cause by genetic mutations. These cases 
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include mutations in the alpha-synuclein and DJ-1 genes. Hence, the alpha-synuclein and DJ-1 
proteins may also be implicated in sporadic Parkinson’s disease. 
Alpha-Synuclein is a neural protein that is thought to play a role in multiple diseases, 
collectively termed synucleinopathies. It is found in the lewy bodies of post-mortem Parkinson’s 
disease patients. Lewy bodies are cytoplasmic inclusions mainly in nigral domaminergic 
neurons. Alpha-synuclein is soluble, natively unfolded protein that has no ordered structure 
under physiological conditions (Uversky, Gillespie, & Fink, 2000). Alpha-synuclein has four Met 
residues at positions 1, 5, 116, and 127 (Glaser, Yamin, Uversky, & Fink, 2005). All four Met 
residues can be oxidized with hydrogen peroxide, which inhibits alpha-synuclein fibrillation 
(Uversky et al., 2002). Metals such as titanium, zinc, aluminum, and lead can overcome the 
inhibited fibrillation of the Met-oxidized protein (Yamin, Glaser, Uversky, & Fink, 2003). If the 
reversal of Met oxidation can prevent further irreversible modification to other residues, it may 
be a new target for therapeutic intervention (Jackob Moskovitz & Bush, 2005). 
The DJ-1 protein is ubiquitously expressed and has no known function. However, it is 
associated with various cellular processes, including a oxidative stress response (Lev, 
Roncevich, Ickowicz, Melamed, & Offen, 2006). Mutations in DJ-1 are associated with a genetic 
autosomal recessive form of Parkinson’s disease, and suggested to cause neurodegeneration. 
However, patients with sporadic Parkinson’s and Alzheimer’s disease can accumulate oxidized 
DJ-1 in frontal cortex brain tissues (Choi et al., 2006). Oxidized modifications are found include 
Cys and Met residues, and additionally irreversible carbonyls and Met sulfones. It is suggested 
that irreversible oxidations occur under more extreme oxidant conditions, after Cys and Met are 
oxidized in a reversible state. Moreover, the levels of DJ-1 are increased in Parkinson’s and 
Alzheimer’s brains. All together, reduction systems such as Msr may protect DJ-1 in healthy 
brains, and elevated oxidant conditions in diseased brains may lead to irreversible residue 
modifications. 
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Protease-resistant protein-C is the protein found in prions, which are present in the cells of 
nervous and immune tissue. Prion is a short name for proteinaceous infectious particle, and C 
refers to cellular. Protein-resistant protein-Sc is a disease-associated isomer. The Sc refers to 
scapie, a prion disease in sheep. These proteins can be genetic, sporadic, or infectious. They 
are known to infect brain neural tissue and induce misfolding of other proteins. Diseases 
associated with prions are called spongiform encephalopathies, one example being Creutzfeldt-
Jakob disease (J. Moskovitz, 2005). Creutzfeldt-Jakob disease is a rapidly progressing 
neurodegenerative disease characterized by dementia and loss of memory. Protein-resistant 
protein-C exists in an alpha-helix structure. It can convert into the beta-sheet confirmation of the 
insoluble Sc isomer, probably by conformational changes involving posttranslational 
modification (Jackson et al., 1999). In addition, a polymorphism at residue 129 results in either a 
valine or Met surface exposed amino acid that can affect the susceptibility of developing 
Creutzfeld-Jakob disease (Hill et al., 2003). Hydrogen peroxide can cause Met oxidation, which 
interferes with the conformation change (Breydo et al., 2005). Moreover, Met residues in mouse 
and chicken prion protein can be selectively oxidized and form free radicals by copper (II) ions 
when they refold in vitro (Wong, Wang, Brown, & Jones, 1999). Furthermore, the cellular prion 
protiein level is higher in msrA null mice (Williams, Stadtman, & Moskovitz, 2004). This may be 
a compensation pathway of additional oxidant stress from the lack of an endogenous 
antioxidant enzyme (Jackob Moskovitz & Bush, 2005). It has not been determined if Met29 and 
other Met residues are involved in the prion cascade of events. Prion may function as an 
antioxidant (Wong et al., 2001) or as a signal to increase endogenous antioxidant systems 
(Rachidi et al., 2003). 
The most advanced evidence of methionine oxidation in neurodegenerative diseases is 
found in Alzheimer’s disease, Parkinson’s disease, and spongiform encephalopathies (J. 
Moskovitz, 2005; D. B. Oien & Moskovitz, 2008). The next two articles from our lab present 
studies related to Alzheimer’s disease and synucleinopathies such as Parkinson’s disease. In 
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the section following these two articles, further evidence in these pathologies and prion-
associated changes relating to spongiform encelphalopathies are presented.  
 
 A.  Elevated Levels of Brain-Pathologies Associated with Neurodegenerative 
Diseases in the MsrA Knockout Mouse (Pal, Oien, Ersen, & Moskovitz, 2007) 
One of the posttranslational modifications to proteins is Met oxidation, which is readily reversible 
by the Msr system. Thus, accumulation of faulty proteins due to a compromised Msr system 
may lead to the development of aging-associated diseases like neurodegenerative diseases. In 
particular, it was interesting to monitor the consequential effects of Met oxidation in relation to 
markers that are associated with Alzheimer’s disease as methionine oxidation was implied to 
play a role in amyloid-beta toxicity. In this study, the Msr knockout (MsrA-/-) mouse caused an 
enhanced neurodegeneration in brain hippocampus relative to its wild-type (WT) control mouse 
brain. Additionally, a loss of astrocytes integrity, elevated levels of amyloid-beta deposition, and 
tau phosphorylation were dominant in various regions of the MsrA-/- hippocampus but not in the 
WT. Also, a comparison between cultured brain slices of the hippocampal region of both mouse 
strains showed more sensitivity of the MsrA-/- cultured cells to H2O2 treatment. It is suggested 
that a deficiency in MsrA activity fosters oxidative-stress that is manifested by the accumulation 
of faulty proteins (via Met oxidation), deposition of aggregated proteins, and premature brain cell 
death.  
 
  1. Introduction 
Met oxidation in neurodegenerative diseases. Previously, we have shown that exposing mice to 
100% oxygen caused higher elevation of protein-carbonyl adducts in various tissues of MsrA-/- 
than in control mice (J. Moskovitz et al., 2001). These results correlated with the loss of MsrA 
activity in Alzheimer’s diseased brains while elevated levels of protein-carbonyl were observed 
in normal brains (Gabbita et al. 1999). Met oxidation denatures proteins, and converts the 
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hydrophobic properties of Met into hydrophilic causing structural alterations (Stadtman, 
Moskovitz, & Levine, 2003). Two major proteins, amyloid-beta and alpha-synuclein, are involved 
in the toxicity associated with Alzheimer’s and Parkinson’s diseases, respectively. Both proteins 
have been shown to lose their fibrillation rate due to their Met oxidation (Palmblad, Westlind-
Danielsson, & Bergquist, 2002; Uversky et al., 2002); and in the case with MetO-alpha-
synuclein to re-fibrillate in the presence of metal ions and ROS, in vitro (Yamin et al., 2003). 
Moreover, it appears that oxidation of Met35 in amyloid-beta contributes significantly to its 
toxicity in vitro (Butterfield & Boyd-Kimball, 2005; Schoneich, 2005). It has also been 
demonstrated that MetO-amyloid-beta adducts are present in post-mortem senile plaques 
(Dong et al., 2003).  
To determine whether the MsrA-/- mice exhibit specific protein expression patterns that are 
associated with markers of AD, the levels of the following proteins were monitored:  
(a) Tau protein – Microtubule-associated protein tau is abnormally hyper-phosphorylated and 
aggregated into neurofibrillary tangles in brains of individuals with Alzheimer’s disease and 
other tauopathies (Blennow, Vanmechelen, & Hampel, 2001). Additionally, developmental and 
aging-induced alterations in brain oxidative status exhibit a major factor in triggering enhanced 
predisposition to Alzheimer’s disease (Apelt, Bigl, Wunderlich, & Schliebs, 2004).  
(b) Synaptophysin – Synaptophysin is a 38 kDa calcium-binding glycoprotein that is present in 
the presynaptic vesicles of neurons and in the neurosecretory granules of neuroendocrine cells. 
Decreased levels of synaptophysin in Alzheimer’s disease correlate with duration of disease.  
(c) Glial fibrillary acidic protein (GFAP) – GFAP is considered to be a highly specific marker for 
astroglial cells. A high number or enhanced apoptosis of the glial cells may reflect on the overall 
well-being of the neighboring neuronal cells. Taken together, the current hypothesis is that the 
occurrence of neurodegenerative diseases is linked to the accumulative damages to proteins 
that causes them to unfold and aggregate; thereby interfering with normal neuronal functions 
and survival under oxidative stress conditions. 
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  2. Materials and Methods 
Antibodies 
The antibodies against the following antigens were purchased from the various companies for 
immunohistochemistry analysis: phosphorylated-tau at serine 202/199 or threonine 205 
(Biosource, USA); synaptophysin (Chemicon, USA ); Glial fibrillary acidic protein, GFAP (DAKO, 
Denmark); amyloid-beta 1-42 (anti-human amyloid-beta, 4G8 monoclonal antibodies, which 
probe an epitope between residues 17–24 of A_, Abcam, USA).  
 
Tissue processing and immunohistochemistry and staining analysis 
All mouse experiments were conducted according to guidelines of the University of Kansas 
Animal Care and Use Committee. “Principles of Laboratory Animal Care” (NIH publication no. 
86–23, revised 1985) were followed, as well as special national laws (e.g. the current version of 
the German law on the Protection of Animals) where applicable.  
For all suggested analyses for both mouse strains, we hemisected 12-month-old postmortem 
cerebrum and fixed the left hemisphere for histological quantification and immunohistochemistry 
(using the various primary antibodies above), according to previously described methods 
(Friedlich et al. 2004).  
Generally, coronal brain sections from both mouse strains were processed for 
immunocytochemistry analysis using a specific primary antibody in each case as follows: mice 
were perfused with phosphate-buffered solution (PBS) followed by 4% paraformaldehyde in 
3.8% sodium borate. After completion of the perfusion, brains were decapitated and immersed 
in 4% paraformaldehyde and 10% sucrose over night. Then, the brains were sectioned and the 
slices were washed three times with PBS. For immunohistochemistry analyses, 10 µm-thick 
sections were treated with 3% hydrogen peroxide in methanol for 30 min. After blocking with 1% 
bovine serum albumin and 3% goat serum in PBS, the sections were incubated with the primary 
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antibody for overnight at 4°C. After removal of the primary antibody and rinsing them in 
appropriate buffer they were sequentially incubated with biotinylated goat anti-rabbit or mouse 
IgG (depending on the source), avidin–horseradish peroxide solution, 0.015% diaminobenzidine 
plus 0.001% H2O2, and finally counterstained with hematoxylin (Vector Laboratories).  
For silver stain analysis parallel brain slices were incubated with 10% silver nitrate for 15 min 
and then washed three times with distilled water. To the silver nitrate solution, concentrated 
ammonium hydroxide was added drop-by-drop until the precipitate formed was clear. The slides 
were stained at 40°C for 30 min or until sections became dark brown. Then, the slides were 
incubated with 1% ammonium hydroxide solution for 1 min to stop the reaction. Slides were 
washed in three changes of distilled water and placed in 5% sodium thiosulfate solution for 5 
min. 
For Nissl stain analysis, parallel brain slides were immersed into 0.5% Cresyl echt violet 
solution for 3–5 min. At the end of the staining the slides were rinsed in distilled water. 
Following all staining and immunohistochemical procedures, the brain slides were washed in 
three changes of distilled water and dehydrated through graded ethanols and xylene before 
mounting them with permount (Vector laboratories Burlingame, CA, USA). The slides were then 
visualized using an upright Nikon light microscope, and images were photographed for analysis. 
 
Brain-hippocampus slice culture 
The procedure to grow brain-hippocampus slices in culture was performed according to 
previously published method (Stoppini, Buchs, & Muller, 1991) with some modification. Briefly, 
the brains of 3-week-old mice were dissected-out and transferred immediately into an artificial 
cerebral spinal fluid (aCSF) media containing 124 mM NaCl, 2.8 mM KCl, 2 mM CaCl2, 2 mM 
MgSO4, 26 mM NaHCO3, 1.25 mM NaH2PO4, and 10 mM glucose at pH 7.4. The brains were 
sliced to sections of 200 µm thickness and were immersed in the aCSF media. Intact sections 
were transferred into cell culture inserts that are bathed in fresh growth medium containing 50% 
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MEM w/glutamine (GIBCO), 25% Hanks Balanced Salt Solution (GIBCO), 25% Horse serum 
(GIBCO), 4.5 mg/mL glucose (Sigma), 1 mM glutamine (Sigma), and pen strep (Sigma) 
solution. Every second day, half of the old medium was replaced by equal amount of fresh 
medium. After 7 days in culture the sections were treated with 400 µM of H2O2 for 3 h. Control 
sections were left untreated. Following the incubation, a propidium iodide staining for quantifying 
the level of cell death was applied as shown below.  
 
Propidium iodide staining  
The above medium (±H2O2) was removed and the slices were rinsed twice with PBS, followed 
by incubation for 30 min at 37°C in the presence of 2 mM propidium iodide (PI) for 30 min at 
37°C. The unbound PI was rinsed several times with PBS before viewing with Zeiss LSM 510 
confocal microscope. 
 
  3. Results 
Deposition of amyloid-beta in brain 
Alzheimer’s disease is characterized pathologically by numerous region-specific, extracellular 
amyloid-beta depositions in the brain. An immunohistochemical procedure was followed to 
assess the formation and localization of deposited amyloid-beta in brains of both MsrA-/- and WT 
mouse strains. Postmortem brains of 12-month-old mice (MsrA-/- and WT) were prepared to 
produce slices suitable for immunohistochemical reactions using primary antibody against 
amyloid-beta (as described under “Materials and Methods”). As shown in Fig. 1, there were 
significant differences in the amount and localization of amyloid-beta between the brains of 
MsrA-/- and WT mice. In the WT mice, there was no significant detection of amyloid-beta 
deposits in the hippocampus region shown (Fig. 1, A1, A2). However, in the MsrA-/- mice, the 
staining revealed 2–4 dark brown aggregates stained by the antibody around the cell-body 
areas of CA1 hippocampus (Fig. 1, B1, B2). The cell bodies remained free of any staining. 
21 
These aggregates were localized in the border of stratum pyramidale and oriens and were 
described as basket cell interneurons by several authors (Ashwood, Lancaster, & Wheal, 1984; 
Knowles & Schwartzkroin, 1981; Schwartzkroin & Mathers, 1978). Most interestingly, the 
antibody also labeled at least 10–12 dark-brown aggregates in the MsrA-/- stratum lacuonosum 
layer (Fig. 1, B1, B2). Although the level of the amyloid-beta depositions in the MsrA-/- was lower 
than in the APP mice, it is important to note that the MsrA-/- mice were not manipulated to 
express high levels of amyloid-beta and that it was tested in mid-aged animals.  
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Figure 1. Deposition of amyloid-beta in 12-month-old brains of MsrA-/- and WT mice. Brain 
slices of both mouse strains were stained with monoclonal antibodies 4G8, which probe an 
epitope between residues 17–24 of amyloid-beta. A1) Total WT hippocampal region (40x 
magnification) A2) CA1-hippocampal region of the WT focused on the SLH (100x 
magnification). B1) Total MsrA-/- hippocampal region (40x magnification) B2) CA1-hippocampus 
of the MsrA-/- focused on the lacunosum of the hippocampus proper SLH (100x magnification). 




To assess the formation and localization of phosphorylated tau in brains of both mouse strains 
an immunohistochemistry analysis was performed using a mixture of anti-phosphorylated S202 
and anti-phosphorylated S199 antibodies (anti-phosphorylated T205 showed very limited 
reaction, data not shown). As shown in Fig. 2, a significant immunostaining was observed 
mainly in the hippocampal-CA3 region of the MsrA-/- brain (especially in the cell body, dendritic 
processes of the giant pyramidal neurons, and in the mossy fiber tract), while a much weaker 
staining was detected in the WT hippocampal-region. 
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Figure 2. Tau-phosphorylation in 12-month-old brains of MsrA-/- and WT mice. Brain slices 
of both mouse strains were stained with antibodies against P-tau at S199/202 A) CA3-
hippocampal region of the WT (100x magnification); B) CA3-hippocampal region of the MsrA-/- 
(100x magnification). The arrow indicates the edge of the staining area by the antibodies in the 
CA3 region. C) CA3-hippocampal region of the MsrA-/- (200x magnification, close-up caption of 




Expression of synaptophysin 
We have monitored the levels of synaptophysin in hippocampal regions of both mouse strains 
(at 12 months of age) by immunohistochemistry using antibodies against synaptophysin. As 
shown in Fig. 3, the immunoreactivity in the hippocampal CA1 and CA3 regions of the WT mice 
presented a strong staining pattern in and around the hippocampal pyramidal neuronal cell body 
and dendritic processes (while leaving the perikarya free of staining). The processes were nicely 
delineated and well defined. In contrast, the relative level of synaptophysin immunostaining 
decreased and was more diffuse in the MsrA-/- in comparison to the WT mice in these 
hippocampal regions, suggesting an enhanced neurodegeneration in the MsrA-/-. These results 
were supported by the silver staining and Nissl staining for neuronal degeneration, as shown in 
Figs. 5 and 6. 
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Figure 3. Expression of synaptophysin in 12-month-old brains of MsrA-/- and WT mice. 
Brain slices of both mouse strains were stained with antibodies against syntophysin. A) CA1-
hippocampal region of WT (200x magnification); B)CA1-hippocampal region of the MsrA-/- (200x 
magnification). C) CA3-hippocampal region of the WT (200x magnification); D) CA3-
hippocampal region of the MsrA-/- (200x magnification). The arrows indicate examples of areas 
in which synaptophysin staining around the neuronal surfaces was denser and showed an intact 
structure of the processes and cell bodies in WT mice (A, C). Same areas showed diminished 
and more defuse staining in the MsrA-/- (B, D). 
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Expression of GFAP 
The GFAP antibody labeled both large and small-sized astroglial cells (astrocytes) in or around 
the pyramidal neurons throughout the hippocampus of the WT mice (Fig. 4). The 
immunoreactivity of the processes was very strong; the wavy pattern of the processes was 
clearly outlined by the staining where the nuclei were completely free of any staining. The anti-
GFAP antibody stained both type I and type II of the astroglial cells. Most of the immuno-
positive cells were located in the stratum oriens and entire radiatum (including distal). The 
antibody did not label any cells in the pyramidal area. Similar staining was shown for the MsrA-/- 
mice in the same respected regions. However, a substantial damage to astroglial structure was 
observed and it is possibly due to an enhanced gliosis (Fig. 4). It is clear from the 100x 
magnification of the hippocampus that at least the same number of total astrocytes is present in 
the hippocampal region of both mouse strains. Due to the fact that the MsrA-/- astrocytes are 




Figure 4. Expression of GFAP in 12-month-old brains of MsrA-/- and WT mice. Brain slices 
of both mouse strains were stained with antibodies against GFAP. A1) CA1-hippocampal region 
of the WT (100x magnification); A2 CA1-hippocampal region of the WT (200x magnification); B1 
CA1-hippocampal region of the MsrA-/- (100x magnification); B2) CA1-hippocampal region of the 
MsrA-/- (200x magnification). Note the relative high level of damaged GFAP-stained astrocytes 




We have obtained results with 12-month-old mice of both strains that showed enhanced 
neurodegeneration in the brains of MsrA-/- relative to WT mice. Following Nissl staining (used for 
the detection of neuronal cells) it is eminent that certain regions of the MsrA-/- mouse brain have 
altered neuronal cell density in comparison to WT control, especially in the hippocampus area. 
Pyramidal cells are excitatory cells that are enriched in glutamatergic synapses. The stratum 
pyramidale cells (SP) at the CA2 brain region seemed to be more compact in the WT, relative to 
the MsrA-/- mouse brain (Fig. 5A, A1 vs. B1, respectively). In contrast, the MsrA-/- mouse brain 
had more diffuse and longer pyramidal neurons that seemed to have shorter axonal processes 
(Fig. 5A, B1). This structural neuronal change may reflect a compensatory mechanism for 
neuronal cell loss at that brain region by increasing the number of cell layers. Similarly, the 
neuronal cells in the CA3 region of the WT looked denser with prominent dendritic processes 
compared to the similar cells in the CA3 region of the MsrA-/- mouse (Fig. 5A, A2 vs. B2, 
respectively). Loss of neuronal cells at the CA3 region of the MsrA-/- mouse brain may indicate 
loss of memory and learning capabilities. The CA1 region of the WT mouse brain showed a 
thicker and darker staining of the pyramidal cells indicating denser concentration of the cells in 
comparison to MsrA-/- mouse brain (Fig. 5A, A3 vs. B3, respectively). Loss of pyramidal cells at 
the CA2/CA1 region of the MsrA-/- mouse brain may indicate compromised neurotransmission 
capabilities. Close-up captions of the regions showing differences between the two mouse 
strains are presented in Fig. 5B, respectively. No apparent difference in neurodegeneration in 
the cortex region is observed as judged by Nissl staining (Fig. 5C). Complementary results for 
damaged neurons in regions, where lower neuronal expression was observed, were obtained by 
using silver staining. Accordingly, the regions of the dentate gyrus (DG), SP, and stratum 
radiatum (SR), showed a dark dotted staining in the MsrA-/- mouse, indicating more neuronal 
degeneration in comparison to WT, (Fig. 6A, B1 vs. A1, respectively). However, no significant 
difference in the silver staining of the cortex in brains of the two mouse strains was observed 
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(Fig. 6A, A2 vs. B2, respectively). The latter result confirms the demonstration of same neuronal 
cell integrity in the cortex of both mouse strains, as judged by Nissl staining (Fig. 5C). 
Additionally, heavy silver staining was observed in the auditory nerve region (OPN, olivary 
pretectal nucleons) of the MsrA-/- mouse brain relative to the WT brain, respectively (Fig 6B).  
31 
 
Figure 5. Nissl staining of brain slices of MsrA-/- and WT control mice. A) Histological brain 
sections were performed through the CA1 Weld of the hippocampus (A1, B1; A3, B3), dentate 
gyrus and CA3 Weld (A2, B2) of a 12-month-old WT mouse (A1–A3) and MsrA-/- mouse (B1–
B3). Brain sections were stained with methylene blue. SP stratum pyramidale; SO stratum 
oriens. Note the compact cell layer of the SP in A1 relative to the SP in A2; the denser cell layer 
of the CA3 field in A2 relative to CA3 in B2; the loss of pyramidal cells in CA1 field in B3 relative 
to CA1 Weld in A3. The arrows point to examples of regions showing differences between both 
mouse strains (40x magnification). B) A close-up caption of the regions showing differences 
between the two mouse-strains in A (corresponding to A1–A3 for WT and B1–B3 for MsrA-/- 
mouse, respectively). C) A1–A2, the cortex region in WT brain (A1, 100x magnification; A2, 




Figure 6. Silver staining of brain slices of MsrA-/- and WT control mice. Histological brain 
sections were performed through various regions of 12-month-old brain stained with cupric 
silver stain (100x magnification). A) CA1/CA2 field and dentate gyrus (A1 for WT and B1 for 
MsrA-/- mouse, respectively); Cortex (A2 for WT and B2 for MsrA-/- mouse, respectively). B) 
Olivary pretectal nucleons (A1 for WT and B1 for MsrA-/- mouse, respectively). SP stratum 
pyramidale; SR, stratum radiatum; DG, dentate gyrus; OPN, olivary pretectal nucleons. Note the 
neuronal changes as manifested by the dark dots in the regions shown in A (B1 vs. A1, 
respectively) and continuous dark area in B (A2 vs. A1, respectively). The arrows point to 
examples of areas in which differences were observed. 
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Hypersensitivity of hippocampal cells to oxidative stress  
We have compared hippocampal cells in cultured brain slices of both mouse strains with 
oxidative stress that is mediated by H2O2. As shown in Fig. 7, following propidium iodide 
staining for dead cells, the MsrA-/- cells were more sensitive than the WT cells to 400 µM H2O2 
(~double dead cells in the MsrA-/- cells). 
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Figure 7. Survival of hippocampal cells in slice brain cultures of MsrA-/- and WT control. 
Brain slices of both mouse strains were processed for tissue culture and stained with propidium 
iodide (PI) according to the procedures described under “Materials and Methods”. The brain 
sections were treated with 400 µM of H2O2 followed by the treatment with PI. Respective control 
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sections were left untreated with H2O2, followed by the treatment with PI. The cells were 
visualized by confocal microscope and PI-glowing cells were counted. A) Pictures of regions in 
each slice stained with PI; WT wild-type; MT MsrA-/-; the areas of the counted cells were the 
same in all slices. The + symbol indicates cells treated with H2O2. B) White bar: WT; Black bar: 
MsrA-/-. Each bar represents an average of three separate experiments with P < 0.01 (using 
paired student’s t test). 
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  4. Discussion 
The current study shows that there is an elevated level of deposited-amyloid-beta in the 
hippocampus regions of mid-aged MsrA-/- mice (Fig. 1). The aggregates or plaque-like 
structures that were labeled by the antibodies in the different sub-layers of CA1 pyramidal 
region of the MsrA-/- mice were in consistent with results reported earlier in the brains of 
Alzheimer’s disease transgenic mice model. The neuritic plaques that are preferentially found to 
be localized in the areas of molecular layers of dentate gyrus and stratum lacunosum may be 
due to the accumulative aggregates of amyloid-beta. The interneurons of the CA1 hippocampus 
regions display a high spontaneous discharge rate and a pronounced action potential after 
hyperpolarization. These interneurons are vulnerable to extreme physiological conditions (like 
oxidative stress) that might lead to the release of abnormal amount of amyloid-beta and 
deposition at the sites of dying interneurons. Several amyloid-beta-aggregates were mainly 
observed in the MsrA-/- stratum lacuonosum layer compared to the same brain region in WT 
(Fig. 1B vs. Fig. 1A, respectively). Previous reports demonstrated that, in this layer, there were 
some interneurons that showed immunoreactivity with GABA (Gamrani, Onteniente, Seguela, 
Geffard, & Calas, 1986) and GAD (Kunkel, Hendrickson, Wu, & Schwartzkroin, 1986; Ribak, 
Vaughn, & Saito, 1978). The latter result is in agreement with the selective deposition of 
amyloid-beta in the amyloid precursor protein transgenic mouse to various regions of the 
hippocampus including the SLH and CA2 regions (Su & Ni, 1998). Since stratum lacunosum is 
known to regulate declarative memory function, any cell death caused by either hyper-excitation 
or deposited amyloid-beta-aggregates can lead to a memory malfunction. Taken together, it is 
suggested that the deposited-amyloid-beta in the MsrA-/- that were found mainly in the CA1 
pyramidal and stratum lacunosum regions may represent part of the hippocampal pathologies 
associated with Alzheimer’s disease. We expect that the observed amyloid-beta deposition and 
the amyloid plaque burden will be enhanced with age, especially in the MsrA-/- mice. Similarly, it 
is predicted that the level of neurofibrillary tangles in the MsrA-/- mice will be increased relative 
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to WT mice as a function of age. The region-specific amyloid-beta deposition, accompanied by 
other pathological features is associated clinically with progressive impairment of memory and 
intellectual function of the disease (Morris et al., 1996). Consequently, we suggest that 
observed accumulation of amyloid-beta might contribute to the development of Alzheimer’s 
disease-pathology in the MsrA-/- mice.  
A significant immunostaining of tau-phosphorylation was observed mainly in the 
hippocampal CA3 region of the MsrA-/- brain while not detected in the WT brain (Fig. 2). Among 
the many kinases that are involved in tau-phosphorylation is the active form of the extracellular 
signal-regulated kinase (p-Erk). In human and rhesus monkey brains, anti-Erk immunostaining 
showed that Erk levels are highest in the CA3 region, the mossy fiber zone, and the granule cell 
layer of the dentate gyrus (Hyman, Elvhage, & Reiter, 1994; Hyman, Reiter, Moss, Rosene, & 
Pandya, 1994). P-Erk is increased in neurons containing p-tau and NFTs and in dystrophic 
neuritis in senile plaques in Alzheimer’s disease brains and it is linked to oxidative-stress (Ferrer 
et al., 2001; Hyman, Elvhage et al., 1994; Pei et al., 2002; Perry et al., 1999; Trojanowski, 
Mawal-Dewan, Schmidt, Martin, & Lee, 1993). Moreover, zinc is found in high levels in the CA3 
region and can increase the levels of p-tau and p-Erk (Harris, Brecht, Xu, Mahley, & Huang, 
2004). Taken together, it is suggested that the high p-tau level in the hippocampal-CA3 region 
of the MsrA-/- brain has the similar characteristics of the elevated levels of zinc and p-Erk found 
in Alzheimer’s disease brains. To support this finding, it will be important to determine the levels 
of p-Erk and zinc in the MsrA-/- and WT brains. It is expected that the levels of zinc, p-Erk, and 
tau-phophorylation will be elevated with age relative to WT especially in the CA3 region. 
The strong immunoreactivity of the antibody against synaptophysin in the WT mice implies 
intact membrane structures in the presynaptic vesicles (Fig. 3). Synaptophysin is an integral 
membrane protein of presynaptic vesicles that interacts with other synaptic proteins. It also 
participates in the trafficking, docking and fusion of synaptic vesicles to the membranes and 
facilitates synaptic transmission and exocytosis of transmitters. The overall weak and 
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diminished synaptophysin immunostaining in the same regions of the MsrA-/- mice suggests 
severe axonal transport impairment and a gross failure in the synaptic transmission. 
Consequently, it is concluded that the decreased synaptophysin level in the MsrA-/- mice (Fig. 3) 
reflects enhanced neuronal degeneration in the hippocampal areas that are similarly observed 
in mouse models of Alzheimer’s disease and Alzheimer’s disease-human brains. Generally, we 
expect the MsrA ablation to accelerate pathology associated with Alzheimer’s disease that 
includes the induction of GFAP level. Significantly greater GFAP levels were found in samples 
from individuals diagnosed with Alzheimer’s disease, mixed dementia, and vascular mediated 
dementia. Because elevated levels of GFAP reflect astroglial responses to even subtle forms of 
neural damage, GFAP may provide independent, supporting evidence for the damage 
underlying dementia, even in the absence of other evidence of neuropathology such as the 
presence of neuritic plaques (NPs) and neurofibrillary tangles (NFTs). Moreover, enhanced 
gliosis was observed throughout the course of the illness, and it was attributed to the cleavage 
of GFAP that may contribute to astrocyte injury and damage in the Alzheimer’s disease brain 
(Hol et al., 2003; Ingelsson et al., 2004; Mouser, Head, Ha, & Rohn, 2006). Indeed, our results 
in Fig. 4 demonstrate that the MsrA-/- hippocampal astrocytes are more damaged than the 
astrocytes of the WT brain, suggesting the occurrence of a similar gliosis process described in 
Alzheimer’s disease. GFAP is expected to be elevated in the vicinity of plaques. Consequently, 
it is possible that the activated glia and astrocytes are trying to shift the amyloid-beta deposits 
but instead release H2O2, making the deposited-amyloid-beta stick even more. Moreover, the 
released H2O2 may preferably damage the MsrA
-/- astrocytes causing their gliosis as they are 
likely to be more sensitive to H2O2 (similarly to MsrA
-/- hippocampal cells (Fig. 7) and other MsrA 
knockout cells (J. Moskovitz, 2005) that were shown to be more sensitive to H2O2.  
Generally, it is clear that there is an enhanced neurodegeneration in the MsrA-/- hippocampal 
[Fig. 5A, 5B, 6A (A1, B1)] and auditory (Fig. 6B) regions of the brain of 12-month-old mice. In 
particular, the hippocampal neurodegeneration is supported by the expression of the particular 
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markers for Alzheimer’s disease as shown above, while the auditory nerve degeneration is a 
known phenomenon that is indicative of age-related neurodegeneration. Moreover, lack of an 
obvious difference in neurodegeneration of the cortex between the two mouse strains suggests 
that cell vulnerability, due to a compromised MsrA function, is region-specific [Figs. 5C, 6A (A2, 
B2)].  
In summary, we expect that all the observed-differences between the MsrA-/- and WT mice, 
with regard to the expression and localization of the molecular markers associated with 
neurodegenerative diseases, will be exacerbated as a function of age. Additionally, it will be of 
great interest to compare the hippocampal protein-expression profile between the two mouse 
strains. This approach will identify proteins that are playing an important role in defense against 
oxidative stress (by monitoring which protein-expression levels are affected by MsrA, especially 
in the neurons). 
 
 B. Clearance and Phosphorylation of Alpha-Synuclein are Inhibited in MsrA Null 
Yeast Cells (D. B. Oien, Shinogle, Moore, & Moskovitz, 2009) 
Aggregated alpha-synuclein and the point mutations Ala30Pro and Ala53Thr of alpha-synuclein 
are associated with Parkinson’s disease. The physiological roles of alpha-synuclein and Met 
oxidation of the alpha-synuclein protein structure and function are not fully understood. MsrA 
reduces methionine sulfoxide residues and functions as an antioxidant. To monitor the effect of 
Met oxidation to alpha-synuclein on basic cellular processes, alpha-synucleins were expressed 
in msrA null mutant and WT yeast cells. Protein degradation was inhibited in the alpha-
synuclein-expressing msrA null mutant cells compared to alpha-synuclein-expressing WT cells.  
Increased inhibition of degradation and elevated accumulations of fibrillated proteins were 
observed in SynA30P-expressing msrA null mutant cells. Additionally, Met oxidation inhibited 
alpha-synuclein phosphorylation in yeast cells and in vitro by casein kinase 2. Thus, a 
40 
compromised MsrA function combined with alpha-synuclein overxpression may promote 
processes leading to synucleinopathies. 
 
  1. Introduction 
One of the hallmarks of Parkinson’s disease is the formation of Lewy bodies (Lucking & Brice, 
2000). These neuronal inclusion bodies are composed of aggregated proteins and consist 
mainly of alpha-synuclein fibrils (Baba et al., 1998). The alpha-synuclein protein is a presynaptic 
protein of unknown function and its involvement in the pathogenesis of Parkinson’s disease is 
still not clear. However, the alpha-synuclein point mutations Ala30Pro and Ala53Thr are found in 
autosomal dominant forms of Parkinson’s disease (Kruger et al., 1998; Polymeropoulos et al., 
1997). Overexpression of alpha-synuclein is also associated with the risk of developing 
Parkinson’s disease (Takeda et al., 1998), and alpha-synuclein locus triplication can cause 
Parkinson’s disease (Singleton et al., 2003). When alpha-synuclein is abnormally expressed or 
modified, various studies indicate it may cause alterations in mitochondrial and proteasomal 
function, protein aggregation, and accumulation of ROS (Lindersson et al., 2004; Sawada et al., 
2004; Snyder et al., 2005; Vekrellis, Rideout, & Stefanis, 2004).   
Yeast cells have been used to study events related to alpha-synuclein biology and toxicity.  
This toxicity was shown to be mediated by increased cellular ROS and decreased proteasome 
function (Q. Chen, Thorpe, Ding, El-Amouri, & Keller, 2004; Sharma et al., 2006; Willingham, 
Outeiro, DeVit, Lindquist, & Muchowski, 2003). The monomeric alpha-synuclein forms fibrils at a 
relatively slow rate. We hypothesize that modifications alter the physical properties and 
degradation rate of alpha-synuclein, overall promoting its oligomerization. This is consistent with 
the associated increase in oxidative stress among Parkinson’s disease, aging, and other 
neurodegenerative diseases. Increased ROS and cellular alpha-synuclein levels promote its 
aggregation (Giasson et al., 2000; Hsu et al., 2000). The presence of ROS can cause 
posttranslational modifications, commonly to the sulfur-containing residues Met and Cys. The 
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alpha-synuclein protein does not have Cys, but does contain four Met residues that can be 
readily oxidized to MetO in vitro. Under conditions of oxidative stress, MetO-alpha-synuclein can 
form fibrils when triggered by certain metals (e.g. Zn2+, Al3+, etc.) in vitro (Yamin et al., 2003).  
Furthermore, cellular conditions such as higher alpha-synuclein protein concentrations (Fink, 
2006) and a saline environment (Munishkina, Henriques, Uversky, & Fink, 2004) could increase 
the rate of alpha-synuclein fibril formation. Post-translational modifications can alter the 
solubility of alpha-synuclein, possibly decreasing the clearance of this short-lived protein.  
Cytoplasmic alpha-synuclein can be degraded by the ubiquitin-proteasome system, the 
autophagy system, and lysosomic pathway (Giorgi et al., 2006); however, degradation of alpha-
synuclein is inhibited in Parkinson’s disease. It is plausible the latter inhibition decreases the 
clearance and promotes aggregation of alpha-synuclein. Modifications to alpha-synuclein may 
alter its solubility and interfere with its ability to be degraded, thereby resulting in a decreased 
clearance of alpha-synuclein. 
Overexpression of msrA may suppress dopaminergic cell death and protein aggregation (Liu 
et al., 2008). One hypothesis to explain the late onset of certain neurodegenerative diseases, 
such as Parkinson’s disease, is that they occur in aging neurons when the capacity of the 
quality control system to cope with accumulating misfolded proteins is exceeded (Berke & 
Paulson, 2003). This situation has been modeled in yeast by increasing alpha-synuclein 
expression (Outeiro & Lindquist, 2003). Due to the lack of substantial information about MetO-
alpha-synuclein in vivo, we further explored this by overexpressing alpha-synuclein and two 
mutants in msrA null (msrA-KO) yeast cells. The effects of the alpha-synuclein on protein fibril 
formation, degradation, and phosphorylation were monitored.  
 
  2. Materials and Methods 
Overexpressing human alpha-synuclein in yeast 
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The human alpha-synuclein protein and its mutants were overexpressed in msrA-KO and WT 
Saccharomyces cerevisiae strains with the pYES6 expression vector used previously (J. 
Moskovitz, Berlett, Poston, & Stadtman, 1997). This vector harbors the yeast GAL1 promoter for 
high-level inducible protein expression by galactose. It has a C-terminal peptide encoding a V5 
epitope and a polyhistidine (6His) tag for detection and purification of the recombinant fusion 
alpha-synuclein.  This vector contains the ampicillin and blasticidin resistance genes for 
selection of bacteria and yeast colonies harboring the plasmid, respectively. Three forms of the 
human alpha-synuclein cDNA (wild-type (α-synuclein), Ala53Thr (SynA53T), and Ala30Pro 
(SynA30P)) were inserted into the vector keeping the sequence in frame with the 6His peptide. 
For that purpose, suitable 5’ forward and 3’ reverse complement primers (harboring Hind III and 
Xba I restriction sites, respectively) were used with each of the alpha-synuclein cDNAs (kindly 
provided by Dr. Mikiei Tanaka, NIH, NHLBI) in a routine PCR procedure. The resulting PCR 
products were sub-cloned into the suitable complementary restriction sites on the pYES6 and 
transformed into bacterial cells (DH5α). Each plasmid was isolated from bacterial cells and 
transformed into WT and msrA-KO yeast. Vector-only transformed cells served as controls. 
Following growth selection on media containing blasticidin (Invivogen), all the transformed yeast 
strains (WT and msrA-KO containing either the vector only, vector containing alpha-synuclein, 
or vector containing either SynA53T or SynA30P) were grown in induction media containing 2% 
galactose and 1% raffinose for up to 24 h. At various time points, equal amounts of cells were 
taken from each culture (determined by optical density (OD600nm)) and extracted by glass beads 
and a bead-beater homogenizer apparatus (BioSpec Products, OK). The alpha-synuclein 
proteins were purified from the corresponding extracts by using of ProBond™ Nickel-Chelating 
Resin (Invitrogen). Equal volumes of purified alpha-synuclein proteins were subjected to SDS-
gel electrophoresis and detected by western blotting using anti-6His antibodies (Immunology 
Consultants Laboratories).  
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Total protein degradation and synthesis in yeast expressing alpha-synuclein  
The procedure was performed as done previously (Q. Chen, Ding, & Keller, 2005) with 
modifications. Yeast cells (WT and msrA-KO) expressing the three alpha-synuclein variants 
(alpha-synuclein, SynA30P, SynA53T) were grown in yeast extract-peptone-dextrose (YPD, 
Fisher Scientific) medium to mid-logarithmic phase while shaking at 30°C. The media was 
removed by centrifugation and replaced with 2% galactose and 1% raffinose media lacking Met.  
Next, 50 µCi [35S]Met (Perkin-Elmer) was added and incubated for additional 30 min. The media 
was removed and radioactive labeling was chased by media containing Met without radioactive 
isotopes. At different time intervals, equal aliquots of cells were removed from each culture and 
homogenized. The corresponding protein extracts were mixed with trichloroacetic acid (TCA) at 
a final concentration of 20% (v/v). After incubation at 4°C for 1 hour, the samples were 
centrifuged, and the radioactivity (cpm) of the TCA-insoluble precipitates and soluble material 
was measured by liquid scintillation counting. 
For quantification of protein synthesis, the radioactivity (cpm) of the TCA-insoluble 
precipitate was measured by liquid scintillation counting after labeling with 50 µCi [35S]Met and 
immediate precipitation with TCA.   
 
Phosphorylation of alpha-synuclein in yeast (ex-vivo system)  
The WT and msrA-KO yeast cells expressing alpha-synuclein, SynA30P, and SynA53T were 
grown in YPD medium to mid-logarithmic phase shaking at 30°C. The medium was removed by 
centrifugation and substituted with induction media containing 2% galactose and 1% raffinose 
for 1 h. The cells were then incubated in media with only 10% of the nutrients for 1 h to reduce 
free phosphate. To each culture 5 µCi/mL [32P]orthophosphoric acid (Perkin-Elmer) was added 
and incubated 1 h. The cells were harvested and alpha-synuclein was isolated by resin affinity 
as described above with the addition of NaF and Na2VO4 as phosphatase inhibitors. The alpha-
synuclein was eluted from the resin with 150 mM imidazole. Equal amounts of each eluted 
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protein were subjected to an SDS-gel electrophoresis. At the end of electrophoretic separation, 
the gel was stained with GelCode Blue (Thermo Scientific, Rockford, IL). Bands corresponding 
to the molecular weight of the alpha-synucleins were excised, added to vials with liquid 
scintillation cocktail, and their cpm measurements were determined by liquid scintillation 
counting.   
 
Phosphorylation of alpha-synuclein in vitro  
Recombinant alpha-synuclein, SynA30P, and SynA53T (rPeptide) were incubated overnight in 
200 mM H2O2 at 37°C in PBS buffer. The H2O2 was removed by adding catalase and incubating 
30 min (oxidant removal verified by adding alpha-synuclein after oxidants were removed, this 
served as the non-oxidized alpha-synuclein control). To reduce MetO, recombinant yeast MsrA 
and PilB were produced as previously described (J. Moskovitz et al., 1997; Olry et al., 2002).  
These Msrs were added at a concentration of 0.3 mg/mL with 20 mM DTT for 1 h. Each alpha-
synuclein was phosphorylated by adding 6 mCi [γ-32P]-ATP (Perkin-Elmer), 20 µM cold ATP, 10 
mM MgCl2, and 0.3 µg casein kinase 2 (Upstate) for 1 h. Reactions were stopped by adding an 
equal volume of protein gel sample buffer. Equal amounts of alpha-synuclein proteins were 
subjected to an SDS-gel electrophoresis. At the end of the electrophoretic separation, the gel 
was stained with GelCode Blue Stain reagent and exposed to X-ray film. 
 
Protein fibrillation in yeast strains expressing alpha-synuclein  
In the presence of fibrils, Thioflavin T undergoes a ‘red shift’ where it is excited at a wavelength 
of 442 nm, and emits fluorescence at 482 nm. Yeast cells were grown in YPD and incubated in 
media with 2% galactose and 1% raffinose for 3 h. The cells were precipitated by centrifugation 
and resuspended in 1% Thioflavin T solution. Cells were washed in buffer and aliquots were 
diluted into a 96-well plate. Finally, Thioflavin T fluorescence was imaged and quantified using 




Comparison and calculation of P values was performed using student t-test analysis. Values of 
P < 0.05 were considered significant. 
 
  3. Results and Discussion 
Overexpression of alpha-synuclein in yeast 
To investigate the effects of MetO on alpha-synuclein and its point mutation variants (alpha-
synuclein, SynA30P, SynA53T), they were separately overexpressed in WT or msrA-KO yeast 
cells. Cell aliquots were collected at various time points during the expression period of the 
alpha-synuclein proteins. Following conditional alpha-synuclein purification from the yeast cells, 
bands migrating at ~22 kDa and ~16 kDa positions were detected by western blot analysis (Fig. 
1). The 22 kDa band corresponds to the full length of alpha-synuclein with the 6His tag moiety, 
which is known to cause slower migration in gel electrophoresis due to the added mass and 
positive charge. Accordingly, the 16 kDa and lower detected minor bands correspond to 
degradation products of the 22 kDa band. The three types of alpha-synuclein are degraded at 
an increased rate when expressed in the WT compared to the msrA-KO strain. The time 
dependent degradation of the corresponding alpha-synucleins is trailing in the msrA-KO relative 
to WT strain without complete degradation of the 16 kDa band, which is completely degraded in 
WT strain (Fig. 1). Moreover, among all the types of alpha-synuclein examined, the SynA53T 
type seems to be the most resistant to degradation in the WT strain while the SynA30P appears 
to be the most resistant to degradation in the msrA-KO strain (Fig. 1). Interestingly, the 
degradation of the SynA30P into both the 16 kDA peptide and lower mass peptides was 
inhibited more in the msrA-KO strain as shown by the relative lower amounts of the shorter 
peptides products with time (Fig. 1). The antibodies used in the western blot recognize only 
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alpha-synuclein protein and derived peptides that still contain the 6His tag, which provides 
recognition that is not based on alpha-synuclein conformation.  
The expression patterns of alpha-synuclein suggests the three types of alpha-synucleins are 
degraded faster in the WT compared to the msrA-KO strain (Fig. 1). Moreover, the SynA30P 
variant of alpha-synuclein was the most resistant to degradation in the msrA-KO strain (Fig. 1).  
This result is supported by previous studies showing that WT yeast cells overexpressing 
SynA30P are inhibited in their general protein degradation by the proteasome, compared to 
non-mutated alpha-synuclein (Q. Chen et al., 2005). We suggest the degradation of alpha-
synuclein is inhibited more in msrA-KO cells compared to WT cells, which may be an enhanced 
inhibitory effect of the MetO on cellular degradation. Using MALDI-MS techniques, we have 
verified that SynA30P and SynA53T expressed in the msrA-KO cells had elevated levels of Met 
oxidation relative to same alpha-synucleins expressed in WT cells (data not shown).   
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Figure 1. Presence of alpha-synuclein over time isolated from msrA-KO and WT yeast 
cells. Soluble alpha-synucleins (WT-α-syn, A30P, A53T) were isolated from cells at specified 
time points during alpha-synuclein protein induction. Equal amounts of cells were taken from 
each culture and alpha-synuclein proteins were isolated by resin from the corresponding 
extracts. A) The alpha-synuclein proteins were detected by western blotting using antibodies 
specific to the 6His tag. Left side: alpha-synuclein from WT yeast cells. Right side: alpha-
synuclein from msrA-KO yeast cells. Horizontal axis: Time from start of alpha-synuclein 
induction period (2, 3, 4, 8, and 24 h). B) Densitometry analysis performed on the protein bands 
shown in panel A. To compare the types of synucleins expressed and cells, the pattern of 
resistance to degradation over time was demonstrated as a percent ratio of the protein-
densitometry for each time point relative to the densitometry value of the 2 h point level 
(represented 100% expression level).  
 
Protein degradation and synthesis in yeast strains overexpressing alpha-synuclein  
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The accumulation of alpha-synuclein may be causing a general inhibition of degradation 
processes that is increased in the msrA-KO strain. Following pulse-chase labeling with [35S]Met 
during the induction period of alpha-synuclein synthesis, all types of expressed alpha-synuclein 
lowered the percentage levels of acid-soluble labeled material, mostly in msrA-KO cells (Fig. 
2A; labeled acid-soluble material, soluble degradation products; and labeled non-soluble 
material, newly synthesized proteins; represent total labeled proteins). While SynA53T was the 
only type having a significant reduction effect on the WT total protein degradation rate, all types 
of alpha-synuclein reduced the total degradation rate in the msrA-KO strain compared to control 
(Fig. 2A).   
It is noteworthy that the degradation rate over time was elevated in the msrA-KO versus WT 
yeast strain when sham vector was present. One possible explanation is that accumulation of 
MetO-containing proteins (the case in the msrA-KO strain) induces the action of the degradation 
machinery as an attempt to remove the faulty proteins (Stadtman & Berlett, 1998). However, 
this response is inhibited by excess levels of specific alpha-synuclein types (Figs. 1 and 2A).  
The general inhibition of protein degradation was more pronounced in the msrA-KO cells 
expressing native and A30P alpha-synuclein (Fig. 2A). The overexpressed native alpha-
synuclein effect on cellular degradation may be relevant to its accumulation that is thought to be 
a risk factor for Parkinson’s disease, and specifically impaired alpha-synuclein degradation may 
be involved (Singleton et al., 2003).   
The mechanism by which the nature of alpha-synuclein and MetO modifications to alpha-
synucleins inhibit degradation is not known. The degradation pathways may be inhibited by the 
cellular localization of alpha-synuclein. In yeast, each alpha-synuclein mutant accumulated at 
the same level as non-mutated alpha-synuclein, but the cellular distributions differed profoundly.  
Similar to native alpha-synuclein, SynA53T is concentrated at the plasma membrane, while 
SynA30P dispersed throughout the cytoplasm (Brandis et al., 2006; Bussell & Eliezer, 2003; Jo, 
Fuller, Rand, St George-Hyslop, & Fraser, 2002). Therefore, the cytoplasmic localization of 
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SynA30P may cause the protein to be more prone to oxidation (compared to a membrane 
region), and accordingly less protected from the accumulation of MetO in the absence of 
cytoplasmic MsrA. This may also partly explain the special negative effect of MetO-alpha-
synuclein accumulations on cytoplasmic degradation, as accumulations of oxidized proteins can 
inhibit protein degradation (Starke-Reed & Oliver, 1989).   
Inhibition of protein synthesis by native and Ala30Pro α-synuclein expressed in yeast cells 
was previously described (Q. Chen et al., 2005). Therefore, we examined the contribution of 
msrA ablation to the alpha-synuclein inhibitory effect on protein synthesis. Expression of alpha-
synuclein caused an overall inhibition of protein synthesis in both strains compared to control 
cells expressing the sham vector (Fig. 2B). The inhibition levels were similar in both yeast 
strains expressing either SynA30P or SynA53T. However, a combination of msrA ablation and 
native alpha-synuclein expression in msrA-KO cells caused a stronger inhibitory effect on 
protein synthesis compared to WT cells expressing native alpha-synuclein (Fig. 2B).   
 As discussed by other groups (Q. Chen et al., 2005), the basis for decreased protein 
synthesis in cells expressing alpha-synuclein is unknown. They suggest that the impairments in 
this synthesis may either represent negative feedback (result of impaired protein degradation) or 
alpha-synuclein induction of endoplasmic reticulum stress impairing protein synthesis (Q. Chen 
et al., 2005). It is possible that alterations to the structure and function of native alpha-synuclein 




Figure 2. Total protein degradation and synthesis in msrA-KO and WT yeast cells. A) 
Total degradation of soluble cytosolic proteins. Soluble protein fraction was precipitated by TCA 
following pulse-chase labeling with [35S]Met during alpha-synuclein protein induction. Values 
represent the percent of cpm of the TCA-soluble material divided by the total cpm values (TCA-
soluble material plus precipitated TCA pellet at specified time points). Black bars represent WT 
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yeast cells; white bars represent msrA-KO yeast cells. Top left: Cells expressing sham vector. 
Bottom Left: Cells expressing α-synuclein (WT-α-syn). Top right: Cells expressing A30P α-
synuclein.  Bottom right: Cells expressing A53T α-synuclein. B) For quantification of protein 
synthesis, the radioactivity (cpm) in the TCA-insoluble material was measured following labeling 
with [35S]Met. Black bars represent WT; white bars represent msrA-KO yeast cells. The 
annotation for the type of expression (vector or alpha-synuclein) is the same as in A. Error bars 
represent standard error of three experiments. * denotes P < 0.05 
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Accumulation of fibrillated proteins in yeast strains overexpressing alpha-synuclein   
Fibrillation of protein in general and alpha-synuclein in particular, is associated with 
posttranslational or genetic modifications to a protein. The observations above, suggesting an 
inhibition of degradation and accumulation of oxidized protein in cells expressing alpha-
synuclein, led us to examine the contribution of these events to alpha-synuclein -mediated fibril 
formation. Yeast cells were stained with Thioflavin T, which is commonly used for detection of 
fibrillated proteins (Hawe, Sutter, & Jiskoot, 2008). Cells were imaged by phase-contrast 
microscopy, and the staining of protein fibrils was detected with epifluorescence (Fig. 3A). In 
addition, quantification of stained cells per amount of cells present was determined (Fig. 3B).  
Expression of native alpha-synuclein in the WT strain that had no effect on the percentile of 
cells exhibiting protein fibrillation compared to the sham vector. However, expression of 
SynA30P, and to a lower extent SynA53T, increased the percentile of cells containing protein 
fibrillation. Additionally, the msrA-KO strain shows an increased effect on protein fibrillation over 
the WT values when SynA30P is expressed; and to a lower extent when native alpha-synuclein 
is expressed. In contrast, SynA53T expression had similar effect on the induction of protein 
fibrillation in both WT and msrA-KO strains. In general, it appears that expression of alpha-
synuclein either with point mutations or in the absence of MsrA causes protein fibrillation.   
Several posttranslational modifications can alter the solubility of alpha-synuclein. Oxidation 
will cause a Met residue to be more hydrophilic, but the overall MetO-protein may become more 
hydrophobic by exposing hidden hydrophobic residues (Chao, Ma, & Stadtman, 1997). 
Degradation of alpha-synuclein is inhibited in Parkinson’s disease and thus it is a plausible 
theory that this inhibition (also shown in Figs. 1 & 2) decreases the clearance of alpha-synuclein 
and promotes its aggregation, especially when the protein undergoes modifications that reduce 
its solubility. All types of alpha-synuclein caused enhanced cellular fibrillation in the absence of 
MsrA compared to the vector, while SynA30P had the most effect on forming fibrils in the msrA-
KO strain (Fig. 3). This result would be the expected outcome of enhanced inhibited degradation 
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of the alpha-synuclein A30P (Figs. 1 & 2). Since the SynA53T aggregation is less affected by 
the presence of MsrA (Fig. 3), it may reflect the enhanced aggregation found in Parkinson’s 
disease patients carrying this mutation (Lee, Choi, & Lee, 2002; Ostrerova-Golts et al., 2000).  
However, a combination of a compromised Msr system (from mutations or lowered expression 
with age) and overexpression of SynA30P could cause even greater levels of alpha-synuclein 




Figure 3. Detection of fibrils present in msrA-KO and WT yeast cells by Thioflavin T 
staining. Yeast cells were stained with Thioflavin T after alpha-synuclein (WT-α-syn, A30P, 
A53T) induction of expression and transferring equal aliquots of cells into a 96-well plate. Cells 
were detected by phase-contrast microscopy and staining was detected with epifluorescence, 
both using a Nikon 40X objective of 1.3 N.A. and a standard DAPI/FitC/TxRed B filter set and 
dichroic (Brightline filters, Semrock). A) Representative images of cells collected by IN Cell 
Analyzer (GE Healthcare). For visualization, Image J software was used to make cells appear 
as red, fibrils appear as green, and to make an overlay image. B) Quantification of stained cells 
per number of cells present determined by IN Cell Analyzer provided software. Automated 
image segmentation was achieved independently on each image channel using the Otsu 
“global” method of thresholding. Black bars represent WT yeast cells; white bars represent 




Phosphorylation of alpha-synuclein and its dependency on Msr   
The functional role of phosphorylation to alpha-synuclein is not fully understood. Given our new 
data, it was intriguing to determine whether oxidation of Met could also affect the 
phosphorylation efficiency of alpha-synuclein. To follow the phosphorylation efficiency in both 
yeast strains expressing alpha-synuclein types, [32P]ortho-phosphate was included in the 
expression induction media. Following the induction, the three types of alpha-synuclein protein 
were isolated from the corresponding yeast strains and phosphorylation was quantified by 
measuring the radiolabeling of the protein. All alpha-synuclein types isolated from msrA-KO 
cells showed significantly lower levels of phosphorylation relative to alpha-synuclein isolated 
from WT cells, especially in the native alpha-synuclein and SynA30P (Fig. 4A). The overall 
phosphorylation rate of SynA53T was significantly lower in both yeast strains, which may imply 
that this form of alpha-synuclein is more prone to oxidation even under normal function of the 
Msr system. Lower in vivo phosphorylation levels of α-synuclein in msrA-KO cells suggest that 
increased levels of MetO moiety in msrA-KO cells could partly inhibit the phosphorylation 
efficiency of alpha-synuclein. The two types of alpha-synuclein that are mostly affected by this 
phosphorylation decline in the msrA-KO strain are the native alpha-synuclein and SynA30P, 
similar to the effect of msrA-KO strain on protein fibrillation in the presence of these alpha-
synuclein types (Fig. 3).   
To further investigate the possibility that Met oxidation of alpha-synuclein may contribute to 
the phosphorylation inhibition, we used recombinant alpha-synuclein proteins in reduced and 
oxidized form, [32P]ATP, and casein kinase 2 (a major kinase for alpha-synuclein Ser129 
phosphorylation (Ishii et al., 2007)). To confirm that MetO formed in the oxidized alpha-
synuclein is responsible for the observed effect on phosphorylation level, MsrA and PilB 
(naturally fused MsrA-MsrB protein from Neisseria gonorrhoeae) were added to the reaction 
mixture to reduce alpha-synuclein MetO residues. All samples were subjected to SDS-gel 
electrophoresis, gels were stained with GelCode Blue Stain (Fig. 4B), and phosphorylation was 
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visualized by autoradiography. The oxidation of the three types of alpha-synuclein inhibited the 
phosphorylation by casein kinase 2 (Fig. 4C), while both MsrA and PilB were able to reverse 
this inhibition via MetO reduction. Both of the mutant alpha-synuclein proteins were more 
phosphorylated when reduced by the Msr enzymes (Fig. 4C). Thus, it is possible that 
conformational changes that may occur in these alpha-synuclein mutants may also facilitate 
MetO reduction by the Msr system due to better accessibility of the enzyme to MetO residues.  
It is important to note that casein kinase 2 phosphorylation activities on control samples were 
not altered when Msr enzymes were added. This excludes the possibility that the enhanced 
alpha-synuclein phosphorylation, shown by Msr enzymes, is due to their reducing activity on 
casein kinase 2. Also, using MALDI-MS we have verified that the recombinant alpha-synucleins 
had elevated levels of oxidation relative to non-oxidized and Msr-reduced alpha-synucleins 
(data not shown).  
The role of phosphorylation of alpha-synuclein (especially at Ser129) is controversial. The 
phosphorylation alpha-synuclein at Ser129 by casein kinase 2 forms fibrils faster than unmodified 
alpha-synuclein in vitro (Fujiwara et al., 2002) and increases the formation of cytoplasmic 
inclusion bodies in cell culture models of synucleinopathies (Smith et al., 2005). However, in 
vivo studies showed no obvious correlation between phosphorylated Ser129 and of alpha-
synuclein fibril formation (L. Chen & Feany, 2005). In contrast, another study demonstrated that 
phosphorylation at Ser129 inhibits alpha-synuclein fibril formation in vitro (Paleologou et al., 
2008). With regard to the vicinity of Met127 to Ser129, we have examined the effect of MetO 
modifications on the rate of the in vivo phosphorylation of alpha-synuclein and casein kinase 2-
mediated phosphorylation of alpha-synuclein. The observed decrease in alpha-synuclein 
phosphorylation due to MetO following MsrA ablation in cells (Fig. 4A) may be relevant to 
processes that regulate alpha-synuclein phosphorylation. As the provided yeast system is only a 
model to investigate the role of MsrA in maintaining alpha-synuclein function, further 
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investigations in a parallel mammalian system will greatly contribute to clarify the physiological 
role of MsrA on alpha-synuclein phosphorylation.   
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Figure 4. Phosphorylation of alpha-synuclein isolated from msrA-KO and WT yeast cells.  
A) Each yeast strain expressing each alpha-synuclein type was induced and then incubated in 
medium containing ortho-[ 32P]phosphoric acid. Expressed alpha-synuclein proteins (WT-α-syn, 
A30P, A53T) were isolated by resin binding and phosphorylation was detected by measuring 
cpm. Values represent percentage of cpm value relative to WT-α-syn cpm value in WT yeast 
cells. Black bars represent WT yeast cells; white bars represent msrA-KO yeast cells. Error bars 
represent standard error of four experiments. * denotes P < 0.001; ** denotes P < 0.05 B) A 
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representative gel stained with GelCode Blue Stain reagent. Left lane: SeeBlue Plus2 protein 
standard (Invitrogen). Right lane: typical separation of pure commercial recombinant human α 
alpha-synuclein proteins (WT-α-syn shown as a representative alpha-synuclein; arrow indicates 
the band corresponding to alpha-synuclein). C) Pure commercial recombinant human alpha-
synuclein proteins (WT-α-syn, A30P, A53T) were exposed to H2O2 overnight (Oxidized). Oxidant 
was removed by catalase and Msr enzymes were added where indicated (PilB, MsrA). The 
removal of oxidants was verified by adding alpha-synuclein after oxidants were removed, and 
served as the non-oxidized form of alpha-synuclein (Control). All samples were phosphorylated 
with [γ-32P]-ATP, and casein kinase 2. Equal amounts of alpha-synuclein proteins were 
subjected to an SDS-gel electrophoresis and the gel was exposed to X-ray film, followed by 
developing for visualization.  
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A functional Msr system and Met oxidation may have a role in regulating alpha-synuclein 
and the phosphorylation of other proteins. Recent studies suggested that MetO formation on 
inhibitory factor of NF-kappaB (IkBα) prevents its subsequent degradation. Similar to alpha-
synuclein, the IkBα Met45 residue is close to the phosphorylation sites Ser32 and Ser36. The 
MetO formation, particularly within helices, can cause major conformational rearrangements 
(Bigelow & Squier, 2005), and the oxidation of Met45 may cause a structural disruption that 
makes the protein a less effective kinase target (Kanayama, Inoue, Sugita-Konishi, Shimizu, & 
Miyamoto, 2002; Midwinter, Cheah, Moskovitz, Vissers, & Winterbourn, 2006; Mohri et al., 
2002). In another recent study, MsrA was shown to suppress dopaminergic protein aggregation 
induced by mutant alpha-synuclein via MetO repair. The MsrA was able to reduce several 
oxidized Met residues in recombinant alpha-synuclein (Liu et al., 2008). Overall, it is suggested 
that oxidation of Met in alpha-synuclein inhibits phosphorylation, which may be involved in 
processes relevant to its degradation or aggregation depending on cellular environment.   
In summary, both the nature of alpha-synuclein and presence of MsrA determined the 
overall protein and alpha-synuclein degradation in yeast. Furthermore, Met oxidation of alpha-
synuclein inhibits alpha-synuclein phosphorylation. This occurs parallel to increasing protein 
fibrillation, especially when SynA30P is expressed in msrA-KO cells. To establish the 
relationships between alpha-synuclein overexpression and MsrA function in mammals, similar 
studies will be conducted in transgenic alpha-synuclein mice on an MsrA-/- background.  
 
 C. Met Oxidation of Proteins Associated with Neurodegenerative Diseases 
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The absence of MsrA appears to enhance markers for Alzheimer’s disease in mice (Pal et al., 
2007), alters the biochemical properties in yeast cells of alpha-synuclein which is known to be 
associated with Parkinson’s disease (D. B. Oien, Shinogle et al., 2009), and various previously 
referenced systems. These effects are presumably from the accumulation of MetO. To identify 
MetO in proteins, polyclonal antibodies were developed (anti-MetO-DZS18) and characterized 
(D. B. Oien, Canello et al., 2009). As described below, these novel antibodies have been shown 
to detect MetO in blood serum proteins in the MsrA-/- mouse and patients diagnosed with 
Alzheimer’s disease. In addition, carbonyl modifications can be detected as an alternative to the 
detection of MetO. Theoretically, oxidation of a residue to a carbonyl would follow the oxidation 
of any exposed methionines (D. B. Oien & Moskovitz, 2008). Msr null yeast cells have been 
shown to accumulate carbonyls (D. Oien & Moskovitz, 2007). This method has been applied to 
msrA-KO and WT yeast cells that express alpha-synuclein as shown below. Finally, anti-MetO-
DZS18 antibodies have been used to detect MetO modifications in prions as shown below.  
 
  1. Blood Serum Proteins (D. B. Oien, Canello et al., 2009) 
The major proteins in serum, mouse serum albumin (MSA) as well of intact IgG, were shown to 
react in western blot analysis with the anti-MetO-DZS18 antibodies (Fig. 1). The identification of 
the MSA was confirmed by mass spectrometry analysis using trypsin-digested peptides 
covering about 25% of the protein sequence. Among all peptides analyzed, Met572 was shown 
to be oxidized to MetO. Apparently, Met572 is conserved in all sequenced serum albumins and 
perhaps its structural location promotes its availability to oxidation. The identification of an intact 
IgG as the other target for Met oxidation (Fig. 1) was confirmed by probing a parallel western 
blot with primary rabbit anti-mouse IgG (data not shown). Further western blot analyses for Met 
oxidation in MSA and IgG were performed on serums from wild type and MsrA-/- mice taken at 
various ages. As shown in Fig. 2A, the oxidation of MSA and IgG in its intact form (~150 kDa) 
intensified in MsrA-/- compared to WT serums. The SDS-gel electrophoresis was performed in 
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the presence of β-mercaptoethanol that is expected to reduce the disulfide bonds between each 
IgG monomer as well as between the heavy (~50 kDa) and light (~25 kDa) chains of the protein. 
Accordingly, in serum of 6-month-old mice the IgG molecules were reduced to their monomeric 
components and shown to contain MetO by western blot analysis (Fig. 2A). In contrast, with 
older age, the disulfide bond reduction was inhibited and the relative oxidative levels of intact 
IgG (~150 kDa) and aggregated form of an unknown serum protein (~250 kDa suggested to be 
an aggregated form of IgG (Ag) were increased in both mouse strains as function of age (Fig. 
2A). In comparison to WT, the Met oxidation of the Ag form of IgG was mostly pronounced in 
MsrA-/- serums (Fig. 2A). Densitometry analysis for the intensities of the corresponding MSA, 
IgG and AG bands have confirmed that the MetO levels of the selected proteins increases in 
MsrA-/- versus WT serums (Fig. 2B). Moreover, the levels of the MetO–Ag were increased in an 
age-dependent manner in both strains, while showing the highest levels in the MsrA-/- strain 
(Fig. 2B). The latter observation may be due to the common nature of aggregated proteins of 
being more resistant to degradation, which fosters their accumulation with age. Similar to the 
observed effects of age and lack of MsrA on IgG MetO levels, intact forms of IgGs in serums of 
patients with Alzheimer’s disease were shown to contain MetO while none was observed in 
control serums, respectively (Fig. 3). It is noted that the limited number of human specimens 




Figure 1. The anti-MetO-DZS18 antibodies detect methionine sulfoxide in mouse serum 
proteins. Fifty microgram of mouse serum proteins were subjected to SDS gel-electrophoresis 
and either stained with Coomassie blue (1), or probed with anti-MetO-DZS18 antibodies 
following western blot analysis (2). M, molecular mass markers (in kDa). IgG-Immunoglobulin G 
that was detected in a parallel gel by primary goat anti-mouse IgG antibodies (GenWay; data 
not shown). MSA, mouse serum albumin (detected by mass spectrometry analysis according to 
procedures previously described (D. B. Oien, Canello et al., 2009)). The presented data 





Figure 2. The anti-MetO-DZS18 antibodies detect methionine sulfoxide in mouse 
serum proteins in an age-dependent manner. A) Western blot analysis on mouse serums as 
function of age (6, 12 and 16, represent age in months) using the anti-MetO-DZS18 antibodies. 
Ag, aggregated form of serum protein. IgG, native form of IgG. H-IgG, heavy chain of IgG. L-
IgG, light chain of IgG. MSA, mouse serum albumin. kDa, molecular mass indicators (in kDa). 
B) Densitometry analysis for the intensities of the MSA, IgG and Ag bands shown in panel A. 
The numbers 6, 12 and 16 represent age in months. The (*) symbol represents significant 
statistical difference (P < 0.05; t-test) between the age-matching bands of both mouse strains. 
Also, there were significant statistical differences (P < 0.05; t-test) within the relative levels of 
the Ag bands in each mouse strain: between all age groups of MsrA-/- and between 6 and 12 or 
16 months old of WT mice. The shown data represent three independent experiments. 
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Figure 3. The anti-MetO-DZS18 antibodies detect methionine sulfoxide in IgG in serum 
proteins of Alzheimer’s disease human subjects. Western blot analysis on human serums 
using the anti-MetO-DZS18 antibodies (1–5, samples from control human subjects; 6–10, 
samples of Alzheimer’s disease patients; all samples are aged matched (70–80 years old). A. A 
representative sample of human serum probed with primary rabbit anti-human IgG antibodies 




  2. Carbonylation of Alpha-Synuclein (J. Moskovitz & Oien) 
To investigate the possible link between protein carbonylation, a compromised Msr system, and 
alpha-synuclein in the development of Parkinson’s disease, we are presenting here new 
relevant data. Accordingly, to elucidate the effect of alpha-synuclein and its mutants on the 
accumulation of protein-carbonyl under conditions favoring Met oxidation, the proteins were 
expressed in both a WT stain and msrA null (MT) yeast strains (Yeast strains: The MT (Mata 
∆msrA::URA3 his6 leu2) strain and its parent WT strain were obtained from previous studies by 
Moskovitz et al. (J. Moskovitz et al., 1997)).  
The human alpha-synuclein protein and its mutants were overexpressed in MT and WT 
yeast strains. The expression vector pYES6 is designed for inducible expression of recombinant 
proteins in Saccharomyces cerevisiae. This vector harbors the yeast GAL1 promoter for high-
level inducible protein expression in yeast by galactose and repression by glucose. In addition, it 
has a C-terminal peptide encoding V5 epitope and polyhistidine (6His) tag for detection and 
purification of the recombinant fusion protein (in this case alpha-synuclein). Additionally, the 
vector contains the ampicillin and blasticidin resistance genes for selection of bacteria and yeast 
colonies harboring the plasmid, respectively. Three forms of the human alpha-synuclein cDNA 
(wild type (alpha-synuclein) and naturally occurring mutants: Ala53Thr (SynA53T) and Ala30Pro 
(SynA30P)) were inserted into the pYES6 vector keeping the sequence in frame with the 6His 
peptide. For that purpose, suitable 5’ forward and 3’ reverse complement primers (harboring 
Hind III and Xba I restriction sites, respectively) were designed and used with each of the three 
alpha-synuclein cDNAs (kindly provided by Dr. Mikiei Tanaka, NIH, NHLBI) in a routine PCR 
procedure. Then, the resulting PCR products were sub-cloned into the suitable complementary 
restriction sites on the pYES6 and transformed into bacterial cells (DH5α). Each of the desired 
plasmids were isolated from bacterial cells, selectively grown on media containing ampicillin, 
and then transformed into WT and MT yeast strains. Vector-transformed cells served as 
controls for the alpha-synuclein expressed yeast cells. Following growth selection on media 
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containing blasticidin, all the transformed yeast strains (WT and MT containing either the vector 
only, vector containing alpha-synuclein, or vector containing either SynA53T or SynA30P) were 
grown in the presence of induction media containing 2% galactose and 1% raffinose for up to 24 
hours. At various time points, equal amounts of cells were taken from each culture (as 
determined by optical density (OD600nm)) and extracted by glass beads and bead-beater 
homogenizer apparatus (BioSpec Products, OK). Finally, the alpha-synuclein proteins were 
purified from the corresponding extracts by using of ProBond™ Nickel-Chelating Resin following 
the commonly applied purification procedure (Invitrogen). Equal volumes of purified alpha-
synuclein proteins were subjected to SDS-gel-electrophoresis and detected by western blotting 
using antibodies specific to the 6His tag.  
 
Protein carbonyl determination.  
Disrupted yeast cell protein extracts were monitored for their protein-carbonyl content by the 
use of the western blot-based carbonyl-assay kit manufactured by Cayman Chemical (Ann 
Arbor, MI). In brief, both yeast strains with the sham vector (control) and the three types of 
alpha-synuclein (Syn, SynA30P, SynA53T) were grown in the protein expression induction 
media for 2 h. Next, cells were precipitated and disrupted by glass beads in the presence of 
PBS and protease inhibitors cocktail (Roche). Following high speed centrifugation, equal 
amounts of the soluble protein extracts were reacted with 2,4-dinitrophenylhydrazine (DNPH), 
subjected to SDS-gel-electrophoresis, and detected by western blotting using antibodies 
specific to DNP. In addition, quantification of the relative amounts of the carbonylated proteins in 
the corresponding extracts was performed by monitoring the absorbance of the DNPH-protein 
derivatives at 370 nm. 
Previously we have shown that following oxidative stress or non-replicative senescence, MT 
cells accumulate increased levels of protein carbonyl (D. Oien & Moskovitz, 2007). Moreover, 
accumulations of carbonylated proteins have been shown to cause inhibition of degradation with 
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age (Starke-Reed & Oliver, 1989). Together, it suggests that further protein oxidation prompted 
by Met oxidation may lead to the accumulation of carbonylated proteins especially in the alpha-
synuclein-expressing MT strain. As shown in Fig. 4, compared to vector transformed yeast 
(control), a significant increase in the levels carbonylated proteins was observed when alpha-
synuclein was expressed, especially in the MT strain expressing SynA30P. The latter massive 
accumulation of carbonylated proteins in the SynA30P expressed in MT correlates with the 
prominent inhibition of SynA30P degradation into shorter peptides (unpublished data). It is thus 
suggested that enhanced protein–carbonyl accumulations in MT strain may be due to an 
increased oxidation prompted by MetO (that may cause conformational changes to proteins, 
leading to further irreversible oxidation) along with alpha-synuclein inhibition of degradation 















Figure 4. Accumulation of carbonylated proteins in MT and WT yeast cells expressing 
alpha-synuclein and control vector. Both yeast strains with the sham vector control (Vec) and 
the three types of alpha-synuclein (Syn, A30P, A53T) were grown in the protein expression 
induction media for 2 h. Then, cells were precipitated and disrupted by glass beads in the 
presence of buffer and a protease inhibitor cocktail. Following high speed centrifugation, equal 
amounts of the soluble protein extracts were reacted with DNPH and subjected both to A) SDS-
gel electrophoresis and detection by western blotting using antibodies specific to DNP (W, wild 
type yeast strain; M, msrA null MT yeast strain); and to B) readings by spectrophotometer at 
OD370nm. Black bars represent WT yeast cells; white bars represent MT yeast cells. Vector, Syn, 
A30P, and A53T, represent sham vector, non-mutated, A30P, and A53T alpha-synuclein 
harboring cells respectively. Error bars represent standard error (n=3). * denotes P < 0.05 and 
** denotes P < 0.001 (t-test). 
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Supportive evidence on the effect of SynA30P expression on protein carbonylation comes 
from a proteomic analysis of transgenic mice overexpressing SynA30P (Poon et al., 2005). In 
this study, it was shown that there were more than two-fold selective increases in specific 
carbonyl levels of three proteins in brains of SynA30P mice: carbonic anhydrase 2, alpha-
enolase, and lactate dehydrogenase 2. Furthermore, Activity analyses of these oxidized 
proteins showed decreased functions in these enzymes as well. Accordingly, the authors 
suggested that proteins associated with impaired energy metabolism and mitochondria are 
particularly prone to oxidative stress associated with A30P-mutant alpha-synuclein (Poon et al., 
2005). It is hypothesized that a cross between a transgenic mouse overexpressing SynA30P 
and the MsrA-/- mouse will exacerbate the increase in protein carbonyl levels, both in the above 
selected proteins and in other proteins yet to be identified. 
 
  3. Prion Protein (D. B. Oien, Canello et al., 2009) 
The prion type PrPSc is the modified form of the membranal cellular prion protein (PrPC). 
PrPSc is considered to be a version of prion that is associated with transmissible spongiform 
encephalopathies. Stahl et al. have shown that either one or two Met residues (M206 
and/or M213) were present in the form of MetO in PrPSc (Stahl et al., 1993). Additionally, PrPC 
has been assigned a role in the protection of cells from ROS (Brown, 2005; Nadal et al., 2007) 
and recombinant PrP (rPrP) was a target for oxidation (Redecke et al., 2007; Requena et al., 
2004). Recently, it has been demonstrated by Gabizon et al. that brain PrPSc contains high 
levels of MetO, which are not detected in brain PrPC and its recombinant models (Canello et al., 
2008). Accordingly, we have examined the possibility of detecting MetO in rPrP, oxidized rPrP 
and Proteinase K (PK) resistant hamster PrPSc by the anti-MetO-DZS18 antibodies. As shown 
in Fig. 5, the a-PrP mAb IPCV1 antibodies recognized all forms tested in the figure; a-PrP mAb 
IPC2 antibodies recognized PrP forms that were not oxidized at Met213 (Canello et al., 2008), 
and the anti-MetO-DZS18 antibodies recognized all forms of PrP tested, while exhibiting the 
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strongest reaction against the oxidized form of rPrP. As seen in Fig. 5, while a-PrP mAb IPC2 
antibodies reacted with non-oxidized rPrP and with the lower forms of hamster PrPSc, the anti-
MetO-DZS18 antibodies recognized all the additional PrP forms that react with a-PrP mAb 
IPCV1 antibodies. The fact that the silver stain pattern of PrPSc is similar to the a-PrP mAb 
IPCV1 pattern of PrP recognition suggests the anti-MetO-DZS18 antibodies indeed reacted with 
the fully glycosylated PrPSc form not recognized by a-PrP mAb IPC2 antibodies (primarily the 
~36 kDa band that is mainly presented in the PrPSc form). It is important to note that the gel 
electrophoresis performed prior to the western blot using a-PrP mAb IPC2 antibodies was done 
in the absence of β-mercaptoethanol. This was due to the fact that a-PrP mAb IPC2 antibodies 
can recognize only PrP proteins with intact disulfide bridges (Canello et al., 2008). However, 
oxidation of PrP causing MetO formation interferes with the protein recognition by the a-PrP 
mAb IPC2 antibodies (Fig. 5). Complementary to this observation, it is suggested that the 
presence of β-mercaptoethanol causes the MetO at position 213 to be more surface exposed to 
facilitating its recognition by the anti-MetO-DZS18 antibodies (Fig. 5). These results are 
consistent with the recent publication (Canello et al., 2008) indicating that several Met residues 
are oxidized in PrPSc. This suggests that the anti-MetO-DZS18 antibodies can be an important 
tool to study this modification in prion protein. 
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Figure 5. The anti-MetO-DZS18 antibodies detect MetO in prion protein. The following 
samples were subjected to SDS-gel electrophoresis followed by silver staining and 
immunoblotting with several antibodies. Full length polypeptide chains corresponding to the 
hamster PrP sequence, lacking the N- and C-terminal sequences (rSHaPrP (23–230; denoted 
as rPrP) were expressed and folded to their a-form as previously described (D. B. Oien, Canello 
et al., 2009). The rPrP was then incubated in the presence and absence of 50 mM H2O2 for 30 
min. For the purified PK resistant PrPSc samples, membranes from scrapie infected hamster 
brain homogenates were purified. Following SDS-gel electrophoresis, all samples (1: rPrP; 2: 
oxidized rPrP; 3: PK resistant hamster PrPSc) were subjected to either silver staining or 
immunoblotting with: anti-PrP mAb IPCV1, which recognize all forms tested in the figure (IPC1); 
anti-PrP mAb IPC2, which recognize PrP forms that are non-oxidized at Met 213 (IPC2), as well 
as the anti-MetO-DZS18 antibodies, which recognize MetO in proteins (MetO). kDa, molecular 
mass indicators (in kDa). The presented data represents three independent experiments. 
 
  4. Summary 
The evidence in this section supports an association between MetO oxidation (and 
carbonylation) and the neurodegenerative diseases of Alzheimer’s disease, Parkinson’s 
disease, and spongiform encephalopathies. To date, these three diseases still remain the 
leading frontiers for the antioxidant role of Met redox cycles in neurodegenerative diseases. The 
remainder of this document focuses on the Msr system in locomotor-associated dopamine 
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signaling. This research further supports a connection between Met redox cycles and 
Parkinson’s disease. However, the direct relationship of the Msr system and Met oxidation to 
disease is yet to be determined. 
 
 D. References 
Apelt, J., Bigl, M., Wunderlich, P., & Schliebs, R. (2004). Aging-related increase in oxidative 
stress correlates with developmental pattern of beta-secretase activity and beta-amyloid 
plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev 
Neurosci, 22(7), 475-484. 
Ashwood, T. J., Lancaster, B., & Wheal, H. V. (1984). In vivo and in vitro studies on putative 
interneurones in the rat hippocampus: possible mediators of feed-forward inhibition. 
Brain Res, 293(2), 279-291. 
Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., et al. (1998). Aggregation of 
alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy 
bodies. Am J Pathol, 152(4), 879-884. 
Barnham, K. J., Ciccotosto, G. D., Tickler, A. K., Ali, F. E., Smith, D. G., Williamson, N. A., et al. 
(2003). Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid 
membrane by methionine oxidation. J Biol Chem, 278(44), 42959-42965. 
Berke, S. J., & Paulson, H. L. (2003). Protein aggregation and the ubiquitin proteasome 
pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev, 13(3), 
253-261. 
Bigelow, D. J., & Squier, T. C. (2005). Redox modulation of cellular signaling and metabolism 
through reversible oxidation of methionine sensors in calcium regulatory proteins. 
Biochim Biophys Acta, 1703(2), 121-134. 
77 
Blennow, K., Vanmechelen, E., & Hampel, H. (2001). CSF total tau, Abeta42 and 
phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol, 24(1-
3), 87-97. 
Brandis, K. A., Holmes, I. F., England, S. J., Sharma, N., Kukreja, L., & DebBurman, S. K. 
(2006). alpha-Synuclein fission yeast model: concentration-dependent aggregation 
without plasma membrane localization or toxicity. J Mol Neurosci, 28(2), 179-191. 
Breydo, L., Bocharova, O. V., Makarava, N., Salnikov, V. V., Anderson, M., & Baskakov, I. V. 
(2005). Methionine oxidation interferes with conversion of the prion protein into the 
fibrillar proteinase K-resistant conformation. Biochemistry, 44(47), 15534-15543. 
Brown, D. R. (2005). Neurodegeneration and oxidative stress: prion disease results from loss of 
antioxidant defence. Folia Neuropathol, 43(4), 229-243. 
Bussell, R., Jr., & Eliezer, D. (2003). A structural and functional role for 11-mer repeats in alpha-
synuclein and other exchangeable lipid binding proteins. J Mol Biol, 329(4), 763-778. 
Butterfield, D. A., & Boyd-Kimball, D. (2005). The critical role of methionine 35 in Alzheimer's 
amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys 
Acta, 1703(2), 149-156. 
Canello, T., Engelstein, R., Moshel, O., Xanthopoulos, K., Juanes, M. E., Langeveld, J., et al. 
(2008). Methionine sulfoxides on PrPSc: a prion-specific covalent signature. 
Biochemistry, 47(34), 8866-8873. 
Chao, C. C., Ma, Y. S., & Stadtman, E. R. (1997). Modification of protein surface hydrophobicity 
and methionine oxidation by oxidative systems. Proc Natl Acad Sci U S A, 94(7), 2969-
2974. 
Chen, L., & Feany, M. B. (2005). Alpha-synuclein phosphorylation controls neurotoxicity and 
inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci, 8(5), 657-
663. 
78 
Chen, Q., Ding, Q., & Keller, J. N. (2005). The stationary phase model of aging in yeast for the 
study of oxidative stress and age-related neurodegeneration. Biogerontology, 6(1), 1-13. 
Chen, Q., Thorpe, J., Ding, Q., El-Amouri, I. S., & Keller, J. N. (2004). Proteasome synthesis 
and assembly are required for survival during stationary phase. Free Radic Biol Med, 
37(6), 859-868. 
Choi, J., Sullards, M. C., Olzmann, J. A., Rees, H. D., Weintraub, S. T., Bostwick, D. E., et al. 
(2006). Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer 
diseases. J Biol Chem, 281(16), 10816-10824. 
Dong, J., Atwood, C. S., Anderson, V. E., Siedlak, S. L., Smith, M. A., Perry, G., et al. (2003). 
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman 
microscopic evidence. Biochemistry, 42(10), 2768-2773. 
Ferrer, I., Blanco, R., Carmona, M., Ribera, R., Goutan, E., Puig, B., et al. (2001). 
Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau 
deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability 
and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and 
corticobasal degeneration. Brain Pathol, 11(2), 144-158. 
Fink, A. L. (2006). The aggregation and fibrillation of alpha-synuclein. Acc Chem Res, 39(9), 
628-634. 
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., et al. 
(2002). alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol, 4(2), 
160-164. 
Gabbita, S. P., Aksenov, M. Y., Lovell, M. A., & Markesbery, W. R. (1999). Decrease in peptide 
methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem, 73(4), 1660-
1666. 
79 
Gamrani, H., Onteniente, B., Seguela, P., Geffard, M., & Calas, A. (1986). Gamma-aminobutyric 
acid-immunoreactivity in the rat hippocampus. A light and electron microscopic study 
with anti-GABA antibodies. Brain Res, 364(1), 30-38. 
Giasson, B. I., Duda, J. E., Murray, I. V., Chen, Q., Souza, J. M., Hurtig, H. I., et al. (2000). 
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in 
synucleinopathy lesions. Science, 290(5493), 985-989. 
Giorgi, F. S., Bandettini di Poggio, A., Battaglia, G., Pellegrini, A., Murri, L., Ruggieri, S., et al. 
(2006). A short overview on the role of alpha-synuclein and proteasome in experimental 
models of Parkinson's disease. J Neural Transm Suppl(70), 105-109. 
Glaser, C. B., Yamin, G., Uversky, V. N., & Fink, A. L. (2005). Methionine oxidation, alpha-
synuclein and Parkinson's disease. Biochim Biophys Acta, 1703(2), 157-169. 
Goedert, M., & Spillantini, M. G. (2006). A century of Alzheimer's disease. Science, 314(5800), 
777-781. 
Harris, F. M., Brecht, W. J., Xu, Q., Mahley, R. W., & Huang, Y. (2004). Increased tau 
phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of 
extracellular signal-regulated kinase: modulation by zinc. J Biol Chem, 279(43), 44795-
44801. 
Hawe, A., Sutter, M., & Jiskoot, W. (2008). Extrinsic fluorescent dyes as tools for protein 
characterization. Pharm Res, 25(7), 1487-1499. 
Hill, A. F., Joiner, S., Wadsworth, J. D., Sidle, K. C., Bell, J. E., Budka, H., et al. (2003). 
Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain, 126(Pt 6), 1333-
1346. 
Hol, E. M., Roelofs, R. F., Moraal, E., Sonnemans, M. A., Sluijs, J. A., Proper, E. A., et al. 
(2003). Neuronal expression of GFAP in patients with Alzheimer pathology and 
identification of novel GFAP splice forms. Mol Psychiatry, 8(9), 786-796. 
80 
Hou, L., Kang, I., Marchant, R. E., & Zagorski, M. G. (2002). Methionine 35 oxidation reduces 
fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. J Biol Chem, 
277(43), 40173-40176. 
Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., et al. (2000). alpha-
synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol, 157(2), 401-
410. 
Hyman, B. T., Elvhage, T. E., & Reiter, J. (1994). Extracellular signal regulated kinases. 
Localization of protein and mRNA in the human hippocampal formation in Alzheimer's 
disease. Am J Pathol, 144(3), 565-572. 
Hyman, B. T., Reiter, J., Moss, M., Rosene, D., & Pandya, D. (1994). Extracellular signal-
regulated kinase (MAP kinase) immunoreactivity in the rhesus monkey brain. Neurosci 
Lett, 166(1), 113-116. 
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E. T., Frosch, M. P., 
et al. (2004). Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle 
formation in AD brain. Neurology, 62(6), 925-931. 
Ishii, A., Nonaka, T., Taniguchi, S., Saito, T., Arai, T., Mann, D., et al. (2007). Casein kinase 2 is 
the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: 
Implication for alpha-synucleinopathies. FEBS Lett, 581(24), 4711-4717. 
Jackson, G. S., Hosszu, L. L., Power, A., Hill, A. F., Kenney, J., Saibil, H., et al. (1999). 
Reversible conversion of monomeric human prion protein between native and 
fibrilogenic conformations. Science, 283(5409), 1935-1937. 
Jo, E., Fuller, N., Rand, R. P., St George-Hyslop, P., & Fraser, P. E. (2002). Defective 
membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J 
Mol Biol, 315(4), 799-807. 
81 
Jung, B., Lee, E. H., Chung, W. S., Lee, S. J., Shin, S. H., Joo, S. H., et al. (2003). Increased 
viability of PC12 cells exposed to amyloid-beta peptide by transduction with human TAT-
methionine sulfoxide reductase. Neuroreport, 14(18), 2349-2353. 
Kanayama, A., Inoue, J., Sugita-Konishi, Y., Shimizu, M., & Miyamoto, Y. (2002). Oxidation of 
Ikappa Balpha at methionine 45 is one cause of taurine chloramine-induced inhibition of 
NF-kappa B activation. J Biol Chem, 277(27), 24049-24056. 
Karelson, E., Fernaeus, S., Reis, K., Bogdanovic, N., & Land, T. (2005). Stimulation of G-
proteins in human control and Alzheimer's disease brain by FAD mutants of APP(714-
723): implication of oxidative mechanisms. J Neurosci Res, 79(3), 368-374. 
Knowles, W. D., & Schwartzkroin, P. A. (1981). Local circuit synaptic interactions in 
hippocampal brain slices. J Neurosci, 1(3), 318-322. 
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998). Ala30Pro 
mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 18(2), 
106-108. 
Kunkel, D. D., Hendrickson, A. E., Wu, J. Y., & Schwartzkroin, P. A. (1986). Glutamic acid 
decarboxylase (GAD) immunocytochemistry of developing rabbit hippocampus. J 
Neurosci, 6(2), 541-552. 
Lee, H. J., Choi, C., & Lee, S. J. (2002). Membrane-bound alpha-synuclein has a high 
aggregation propensity and the ability to seed the aggregation of the cytosolic form. J 
Biol Chem, 277(1), 671-678. 
Lev, N., Roncevich, D., Ickowicz, D., Melamed, E., & Offen, D. (2006). Role of DJ-1 in 
Parkinson's disease. J Mol Neurosci, 29(3), 215-225. 
Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W., Hendil, K. B., et al. (2004). 
Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem, 
279(13), 12924-12934. 
82 
Liu, F., Hindupur, J., Nguyen, J. L., Ruf, K. J., Zhu, J., Schieler, J. L., et al. (2008). Methionine 
sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related 
insults. Free Radic Biol Med, 45(3), 242-255. 
Lucking, C. B., & Brice, A. (2000). Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci, 
57(13-14), 1894-1908. 
Midwinter, R. G., Cheah, F. C., Moskovitz, J., Vissers, M. C., & Winterbourn, C. C. (2006). 
IkappaB is a sensitive target for oxidation by cell-permeable chloramines: inhibition of 
NF-kappaB activity by glycine chloramine through methionine oxidation. Biochem J, 
396(1), 71-78. 
Mohri, M., Reinach, P. S., Kanayama, A., Shimizu, M., Moskovitz, J., Hisatsune, T., et al. 
(2002). Suppression of the TNFalpha-induced increase in IL-1alpha expression by 
hypochlorite in human corneal epithelial cells. Invest Ophthalmol Vis Sci, 43(10), 3190-
3195. 
Morris, J. C., Storandt, M., McKeel, D. W., Jr., Rubin, E. H., Price, J. L., Grant, E. A., et al. 
(1996). Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for 
presymptomatic and very mild Alzheimer's disease. Neurology, 46(3), 707-719. 
Moskovitz, J. (2005). Methionine sulfoxide reductases: ubiquitous enzymes involved in 
antioxidant defense, protein regulation, and prevention of aging-associated diseases. 
Biochim Biophys Acta, 1703(2), 213-219. 
Moskovitz, J., Bar-Noy, S., Williams, W. M., Requena, J., Berlett, B. S., & Stadtman, E. R. 
(2001). Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and 
lifespan in mammals. Proc Natl Acad Sci U S A, 98(23), 12920-12925. 
Moskovitz, J., Berlett, B. S., Poston, J. M., & Stadtman, E. R. (1997). The yeast peptide-
methionine sulfoxide reductase functions as an antioxidant in vivo. Proc Natl Acad Sci U 
S A, 94(18), 9585-9589. 
83 
Moskovitz, J., & Bush, A. I. (2005). Methionine Sulfoxide Reductase System:  Possible Roles in 
Protection against Neurodegenerative Diseases. In Y. Luo & L. Packer (Eds.), Oxidative 
Stress and Age-Related Neurodegeneration (pp. 197-210): CRC. 
Moskovitz, J., & Oien, D. B. Protein carbonyl and the methionine sulfoxide reductase system. 
Antioxid Redox Signal, 12(3), 405-415. 
Mouser, P. E., Head, E., Ha, K. H., & Rohn, T. T. (2006). Caspase-mediated cleavage of glial 
fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. 
Am J Pathol, 168(3), 936-946. 
Munishkina, L. A., Henriques, J., Uversky, V. N., & Fink, A. L. (2004). Role of protein-water 
interactions and electrostatics in alpha-synuclein fibril formation. Biochemistry, 43(11), 
3289-3300. 
Nadal, R. C., Abdelraheim, S. R., Brazier, M. W., Rigby, S. E., Brown, D. R., & Viles, J. H. 
(2007). Prion protein does not redox-silence Cu2+, but is a sacrificial quencher of 
hydroxyl radicals. Free Radic Biol Med, 42(1), 79-89. 
Oien, D., & Moskovitz, J. (2007). Protein-carbonyl accumulation in the non-replicative 
senescence of the methionine sulfoxide reductase A (msrA) knockout yeast strain. 
Amino Acids, 32(4), 603-606. 
Oien, D. B., Canello, T., Gabizon, R., Gasset, M., Lundquist, B. L., Burns, J. M., et al. (2009). 
Detection of oxidized methionine in selected proteins, cellular extracts and blood serums 
by novel anti-methionine sulfoxide antibodies. Arch Biochem Biophys, 485(1), 35-40. 
Oien, D. B., & Moskovitz, J. (2008). Substrates of the methionine sulfoxide reductase system 
and their physiological relevance. Curr Top Dev Biol, 80, 93-133. 
Oien, D. B., Shinogle, H. E., Moore, D. S., & Moskovitz, J. (2009). Clearance and 
Phosphorylation of Alpha-Synuclein Are Inhibited in Methionine Sulfoxide Reductase A 
Null Yeast Cells. J Mol Neurosci, In Press. 
84 
Olry, A., Boschi-Muller, S., Marraud, M., Sanglier-Cianferani, S., Van Dorsselear, A., & Branlant, 
G. (2002). Characterization of the methionine sulfoxide reductase activities of PILB, a 
probable virulence factor from Neisseria meningitidis. J Biol Chem, 277(14), 12016-
12022. 
Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J. M., Farer, M., & Wolozin, B. (2000). The 
A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J 
Neurosci, 20(16), 6048-6054. 
Outeiro, T. F., & Lindquist, S. (2003). Yeast cells provide insight into alpha-synuclein biology 
and pathobiology. Science, 302(5651), 1772-1775. 
Pal, R., Oien, D. B., Ersen, F. Y., & Moskovitz, J. (2007). Elevated levels of brain-pathologies 
associated with neurodegenerative diseases in the methionine sulfoxide reductase A 
knockout mouse. Exp Brain Res, 180(4), 765-774. 
Paleologou, K. E., Schmid, A. W., Rospigliosi, C. C., Kim, H. Y., Lamberto, G. R., Fredenburg, 
R. A., et al. (2008). Phosphorylation at Ser-129 but not the phosphomimics S129E/D 
inhibits the fibrillation of alpha-synuclein. J Biol Chem, 283(24), 16895-16905. 
Palmblad, M., Westlind-Danielsson, A., & Bergquist, J. (2002). Oxidation of methionine 35 
attenuates formation of amyloid beta -peptide 1-40 oligomers. J Biol Chem, 277(22), 
19506-19510. 
Pei, J. J., Braak, H., An, W. L., Winblad, B., Cowburn, R. F., Iqbal, K., et al. (2002). Up-
regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with 
the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol 
Brain Res, 109(1-2), 45-55. 
Perry, G., Roder, H., Nunomura, A., Takeda, A., Friedlich, A. L., Zhu, X., et al. (1999). Activation 
of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative 
stress to abnormal phosphorylation. Neuroreport, 10(11), 2411-2415. 
85 
Pogocki, D. (2003). Alzheimer's beta-amyloid peptide as a source of neurotoxic free radicals: 
the role of structural effects. Acta Neurobiol Exp (Wars), 63(2), 131-145. 
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). 
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. 
Science, 276(5321), 2045-2047. 
Poon, H. F., Frasier, M., Shreve, N., Calabrese, V., Wolozin, B., & Butterfield, D. A. (2005). 
Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-
synuclein transgenic mice--a model of familial Parkinson's disease. Neurobiol Dis, 18(3), 
492-498. 
Rachidi, W., Vilette, D., Guiraud, P., Arlotto, M., Riondel, J., Laude, H., et al. (2003). Expression 
of prion protein increases cellular copper binding and antioxidant enzyme activities but 
not copper delivery. J Biol Chem, 278(11), 9064-9072. 
Redecke, L., von Bergen, M., Clos, J., Konarev, P. V., Svergun, D. I., Fittschen, U. E., et al. 
(2007). Structural characterization of beta-sheeted oligomers formed on the pathway of 
oxidative prion protein aggregation in vitro. J Struct Biol, 157(2), 308-320. 
Reis, K., Zharkovsky, A., Bogdanovic, N., Karelson, E., & Land, T. (2007). Critical role of 
methionine-722 in the stimulation of human brain G-proteins and neurotoxicity induced 
by London familial Alzheimer's disease (FAD) mutated V717G-APP(714-723). 
Neuroscience, 144(2), 571-578. 
Requena, J. R., Dimitrova, M. N., Legname, G., Teijeira, S., Prusiner, S. B., & Levine, R. L. 
(2004). Oxidation of methionine residues in the prion protein by hydrogen peroxide. Arch 
Biochem Biophys, 432(2), 188-195. 
Ribak, C. E., Vaughn, J. E., & Saito, K. (1978). Immunocytochemical localization of glutamic 
acid decarboxylase in neuronal somata following colchicine inhibition of axonal transport. 
Brain Res, 140(2), 315-332. 
86 
Sawada, H., Kohno, R., Kihara, T., Izumi, Y., Sakka, N., Ibi, M., et al. (2004). Proteasome 
mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein 
inclusions. J Biol Chem, 279(11), 10710-10719. 
Schoneich, C. (2005). Methionine oxidation by reactive oxygen species: reaction mechanisms 
and relevance to Alzheimer's disease. Biochim Biophys Acta, 1703(2), 111-119. 
Schwartzkroin, P. A., & Mathers, L. H. (1978). Physiological and morphological identification of 
a nonpyramidal hippocampal cell type. Brain Res, 157(1), 1-10. 
Sharma, N., Brandis, K. A., Herrera, S. K., Johnson, B. E., Vaidya, T., Shrestha, R., et al. 
(2006). alpha-Synuclein budding yeast model: toxicity enhanced by impaired 
proteasome and oxidative stress. J Mol Neurosci, 28(2), 161-178. 
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). 
alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302(5646), 841. 
Smith, W. W., Margolis, R. L., Li, X., Troncoso, J. C., Lee, M. K., Dawson, V. L., et al. (2005). 
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation 
in SH-SY5Y cells. J Neurosci, 25(23), 5544-5552. 
Snyder, H., Mensah, K., Hsu, C., Hashimoto, M., Surgucheva, I. G., Festoff, B., et al. (2005). 
beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-
synuclein. J Biol Chem, 280(9), 7562-7569. 
Stadtman, E. R., & Berlett, B. S. (1998). Reactive oxygen-mediated protein oxidation in aging 
and disease. Drug Metab Rev, 30(2), 225-243. 
Stadtman, E. R., Moskovitz, J., & Levine, R. L. (2003). Oxidation of methionine residues of 
proteins: biological consequences. Antioxid Redox Signal, 5(5), 577-582. 
Stahl, N., Baldwin, M. A., Teplow, D. B., Hood, L., Gibson, B. W., Burlingame, A. L., et al. 
(1993). Structural studies of the scrapie prion protein using mass spectrometry and 
amino acid sequencing. Biochemistry, 32(8), 1991-2002. 
87 
Starke-Reed, P. E., & Oliver, C. N. (1989). Protein oxidation and proteolysis during aging and 
oxidative stress. Arch Biochem Biophys, 275(2), 559-567. 
Stoppini, L., Buchs, P. A., & Muller, D. (1991). A simple method for organotypic cultures of 
nervous tissue. J Neurosci Methods, 37(2), 173-182. 
Su, Y., & Ni, B. (1998). Selective deposition of amyloid-beta protein in the entorhinal-dentate 
projection of a transgenic mouse model of Alzheimer's disease. J Neurosci Res, 53(2), 
177-186. 
Takeda, A., Mallory, M., Sundsmo, M., Honer, W., Hansen, L., & Masliah, E. (1998). Abnormal 
accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol, 
152(2), 367-372. 
Trojanowski, J. Q., Mawal-Dewan, M., Schmidt, M. L., Martin, J., & Lee, V. M. (1993). 
Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease 
neurofibrillary tangles and senile plaque neurites. Brain Res, 618(2), 333-337. 
Uversky, V. N., Gillespie, J. R., & Fink, A. L. (2000). Why are "natively unfolded" proteins 
unstructured under physiologic conditions? Proteins, 41(3), 415-427. 
Uversky, V. N., Yamin, G., Souillac, P. O., Goers, J., Glaser, C. B., & Fink, A. L. (2002). 
Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett, 
517(1-3), 239-244. 
Vekrellis, K., Rideout, H. J., & Stefanis, L. (2004). Neurobiology of alpha-synuclein. Mol 
Neurobiol, 30(1), 1-21. 
Williams, W. M., Stadtman, E. R., & Moskovitz, J. (2004). Ageing and exposure to oxidative 
stress in vivo differentially affect cellular levels of PrP in mouse cerebral microvessels 
and brain parenchyma. Neuropathol Appl Neurobiol, 30(2), 161-168. 
Willingham, S., Outeiro, T. F., DeVit, M. J., Lindquist, S. L., & Muchowski, P. J. (2003). Yeast 
genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. 
Science, 302(5651), 1769-1772. 
88 
Wong, B. S., Chen, S. G., Colucci, M., Xie, Z., Pan, T., Liu, T., et al. (2001). Aberrant metal 
binding by prion protein in human prion disease. J Neurochem, 78(6), 1400-1408. 
Wong, B. S., Wang, H., Brown, D. R., & Jones, I. M. (1999). Selective oxidation of methionine 
residues in prion proteins. Biochem Biophys Res Commun, 259(2), 352-355. 
Wood-Kaczmar, A., Gandhi, S., & Wood, N. W. (2006). Understanding the molecular causes of 
Parkinson's disease. Trends Mol Med, 12(11), 521-528. 
Yamin, G., Glaser, C. B., Uversky, V. N., & Fink, A. L. (2003). Certain metals trigger fibrillation 













III. MsrA Ablation Disrupts Locomotor-Associated DA Signaling 
Shortly after the MsrA-/- mice were generated, it was observed that they displayed an abnormal 
walking pattern (Moskovitz et al., 2001). This was the first indication that mice lacking Msr would 
develop movement problems with age. It has since been determined that these locomotor 
abnormalities are related to changes in dopamine (DA) signaling. Furthermore, we suggest 
oxidation of the dopamine D2 receptor (D2DR) plays a central role in observed locomotor 
activities. The MsrA-/- mouse has reduced antioxidant capabilities and manifests abnormalities 
with age. Oxidative stress and aging are well known risk factors in some movement disorders 
such as Parkinson’s disease. Parkinson’s disease is also associated with abnormal DA 
signaling in addition to pathologies from Msr substrates, such as alpha-synuclein. A firm 
relationship between methionine redox cycles and any movement disorder has yet to have been 
established. However, the following research presented in this section postulates a theory of 
possible aging-associated movement abnormalities. The following article reviews the effects of 
MsrA ablation in mice and highlights genomic changes relevant to oxidative stress, 
neurodegeneration, and signal transduction.  
 
A. Genomic and Proteomic Analyses of the MsrA Knockout Mouse  
(D. Oien, Wang, & Moskovitz, 2008) 
In this review we describe the effects of MsrA ablation in mouse tissues on the expression of 
various mRNAs and proteins, with an emphasis on brain tissues. Initially, the expression / 
activity levels of preselected proteins relevant to the Msr system in various tissues are 
discussed (the list of proteins contains: thioredoxin, thioredoxin reductase, MsrB, glucose-6-
phosphate dehydrogenase, gluthathione peroxidase, selenoprotein P, and cysteine 
dioxygenase). Additionally, the consequences from lack of MsrA on protein oxidation 
(carbonylation and Met oxidation) are evaluated. Finally, newly generated unpublished data is 
presented on genomic and proteomic analyses, compared between MsrA-/- and WT control 
90 
brains. The gathered information is sorted out into three major protein groups that are linked to: 
1) oxidative stress / apoptosis / degradation; 2) neuroregulation; and 3) signal transduction / 
transcription / elongation factors. In summary, the importance and relevance of MsrA in 
protecting against the development and progression of neurodegenerative diseases is reviewed.  
  
  1. Effects of MsrA ablation on the Expression Level of Proteins Related to 
the Msr System and Sulfur/Selenium Metabolism 
Selenium and MsrA are positive protein expression regulators of the selenoprotein form of MsrB 
and Trr (Moskovitz et al., 2001; Moskovitz & Stadtman, 2003). In addition, following the 
selenium deficient (SD) diet the following enzymes declined especially in the MsrA-/- mouse: 
MsrB activity in cerebellum; thioredoxin reductase (Trr) activity mainly in liver, and kidneys; 
gluthathione peroxidase (GPx) in brains and livers. Consequently, higher protein-carbonyl 
adducts and protein-MetO were observed especially in MsrA-/- following the SD diet (Moskovitz, 
2007). Elevated levels of these posttranslational protein modifications suggest an enhanced 
oxidative stress in MsrA-/- mouse fed with SD diet. Among all tested tissues only brain-
cerebellum showed a major combined decrease in specific activities of MsrB, Trr, and GPx 
(Moskovitz, 2007). This observation may reflect a possible cerebellum malfunction associated 
with enhanced oxidative stress. It has been already noted that MsrA-/- mice exhibited an atypical 
“tip-toe” walking pattern that is exacerbated as a consequence of SD diet (Moskovitz et al., 
2001; Moskovitz & Stadtman, 2003). Since the cerebellum is also responsible for certain motor 
functions, it is possible that this form of ataxia is at least partially due to the significant loss of 
the above antioxidant activities.  
From these recent studies, it was concluded that enhanced protein oxidation occurs in the 
MsrA-/- mouse tissues following prolonged SD diet. Hearts and lungs of MsrA-/- mice that were 
subjected to the SD diet had significantly elevated expression and activity of glucose-6-
phosphate dehydrogenase (G6PD), relative to control WT mice (Moskovitz, 2007). Both lungs 
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and heart are the first organs that are exposed to high level of oxygen. Thus, it is possible that 
elevated G6PD in these MsrA-/- tissues is an attempt to maintain sufficient reduction power 
(NADPH) to protect the MsrA-/- cells from extensive protein oxidation under selenium deficiency.  
One selenoprotein that is considered to be a good marker for selenium deficiency is the 
secreted protein selenoprotein P (SelP) (Burk & Hill, 2005). Surprisingly, the cellular levels of 
SelP were significantly higher in the MsrA-/- mice compared to control (Moskovitz, 2007). 
Normally, the SelP protein is secreted from cells to the plasma and one of its possible roles is to 
deliver selenium to tissues via its rich selenocysteine residue content (Burk & Hill, 2005; 
Schomburg et al., 2003). Another possible function of SelP is to act as an antioxidant by its 
potential reducing activity. Thus, it is suggested that, like G6PD, SelP may be part of a 
compensatory mechanism aiming at reducing the oxidative stress effects occurring when both 
MsrA and selenium levels are limited. 
The enzyme cysteine deoxygenase (dioxygenase) (CDO) catalyzes the oxidation of Cys to 
Cys-sulfinic acid in the presence of Fe2+ that functions as a cofactor in mammals and yeast.  
The activity of CDO plays an important role in Cys catabolism, taurine synthesis, and 
accumulation of pyruvate and sulfate (Chai et al., 2005; Simmons, Hirschberger, Machi, & 
Stipanuk, 2006; Stipanuk, Dominy, Lee, & Coloso, 2006). The special significance of taurine 
synthesis, mediated by CDO, is mainly due to its involvement in bile salt synthesis, cardiac 
function, and protection of neuronal cells from ischemia–induced damage (Huxtable, 2000; 
Saransaari & Oja, 1996; Satoh, 1996). The cellular levels of the sulfur amino-acids Cys and Met 
regulate the expression level of CDO (Stipanuk et al., 2006). Thus, in the absence of MsrA, 
enhanced oxidation of Cys and Met will cause changes in Cys metabolism and CDO expression 
(especially when both MsrA and CDO are highly expressed in liver). Indeed, under selenium 
adequate (SA) diet the level of free thiol in the MsrA-/- was reduced to be a third of the level in 
WT mice, respectively (D. B. Oien & Moskovitz, 2007). Additionally, following SD diet, the 
absolute free thiol levels were reduced to about third of the corresponding levels following SA 
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diet. With respect to protein-thiol levels, no significant difference was observed between the WT 
and MsrA-/- mice under SA diet. However, following SD diet the level of protein-thiol decreased 
by 18% and 50% in WT and MsrA-/- mice, respectively. One possible explanation is that 
enhanced oxidation of free and protein-bound thiols in MsrA-/- mice seems like a reasonable 
occurrence, which is exacerbated under SD diet. The effect of thiol oxidation is more 
pronounced in the free thiols moiety because protein-bound thiols may not be as accessible to 
oxidation as free thiols (which are mostly present as L-Cys). Lower L-Cys can lead to decline in 
CDO expression via elevated ubiquitin-mediated degradation (Dominy, Hirschberger, Coloso, & 
Stipanuk, 2006). Similarly, the relative lower levels of free thiols in MsrA-/- mice following either 
SA or SD diet lead to a corresponding decline in CDO level, respectively (D. B. Oien & 
Moskovitz, 2007). A compromised Msr system (i.e. lack of MsrA) leads to enhanced oxidation of 
sulfur amino acids. Thus, there is an apparent need to lower the enzymatic oxidation of Cys by 
reduction of CDO expression. The indirect regulation of CDO by MsrA (D. B. Oien & Moskovitz, 
2007) is predicted to involve other proteins that participate in maintaining adequate cellular 
redox balance. Identifying genes that are involved in the regulation of CDO in the MsrA-/- mice 
will provide more information about sulfur amino acids driven  signal transduction events 
activated to protect cells from oxidative modifications to proteins.  
 
  2. Protein Substrates of the Msr System 
Substrates or proteins that interact for the Msr system include MetO residues or methyl 
sulfoxide adducts, and their suitability as substrates for the Msr system was mainly described in 
vitro (D. B. Oien & Moskovitz, 2008). Only a limited number of proteins that interact with Msr 
enzymes or serve as substrates for the Msr system in vivo were identified. For example, in the 
gastric pathogen Helicobacter pylori, the following proteins: GroEL (chaperon), catalase 
(detoxification), SSR (DNA repair), thioredoxin-1 (Trx1, electron transport and a known reducer 
of Msr), seryl t-RNA synthase (protein synthesis), TolB precursor protein (colicine tolerance) 
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have shown to interact with Msr (a fused form of MsrA and MsrB) in a semi-in vivo system 
(Alamuri & Maier, 2006). Additionally, gluthathione perxoidase (Gpx3) showed to regulate the 
function of the yeast MsrA by interacting with MsrA through the formation of an intermolecular 
disulfide bond. Thus, upon an oxidative stress insult, the latter interaction is compromised and 
the free MsrA can reduce Met-oxidized proteins (Kho et al., 2006). Taken together, it is apparent 
that further identification of in vivo substrates for Msrs is required to determine the involvement 
of the Msr system in protein regulation and protection against oxidative modification to proteins.  
One possible approach to identify such proteins is by screening for potential proteins that have 
enhanced Met oxidation in the absence of Msr. The prediction is that proteins that their levels 
are elevated in a Msr knockout animal (compared to a WT control) may represent proteins that 
were extensively oxidized and inactivated, causing an increased synthesis of them as part of a 
compensatory response mechanism (demonstrated by increased mRNA synthesis). 
Complementary, a reduction in the levels of specific proteins in Msr knockout background 
(compared to control) may represent an enhanced degradation of proteins harboring elevated 
levels of MetO (demonstrated mainly by a reduced protein level while mRNA level remains 
unchanged). The mammalian model that we are currently investigating is the MsrA-/- mouse 
(Moskovitz et al., 2001). We have performed genomics and proteomics analyses on MsrA-/- and 
control WT brains.  
 
  3. Proteomics Analysis of MsrA-/- and WT Control Brains 
Protein extracts from both mouse strains were loaded on 1-D gel followed by 2-D gel 
electrophoreses. The procedures for the gel electrophoresis assays were conducted according 
to previously published methods (Lopez et al., 2004). All reagents and precast gels were from 
Genomic Solutions (Ann Arbor, MI, USA), except IPG strips which were from Amersham 
(Piscataway, NJ, USA). Briefly, 18 cm pH 3–10 nonlinear IPG strips were rehydrated in sample 
diluted into a final volume of 400 mL thiourea sample buffer. The strips were focused for a total 
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of 100,000 Vh (maximum voltage, 5000 V; maximum current, 70 mA). The 2-D gels were 
stained with SYPRO Ruby Protein Gel Stain (PerkinElmer or Molecular Probes, Eugene, OR) or 
colloidal Coomassie Blue (Sigma Chemical). Gel images were acquired using a PerkinElmer 
Life Sciences ProXPRESS Proteomic Imaging System using optimized excitation (480/80) and 
emission (650/150) filters for SYPRO Ruby Protein Gel Stain, or white light converter for 
Coomassie Blue-stained gels. Images were acquired at 100 mm resolution. 
Gel images were analyzed in Progenesis Discovery (Nonlinear Dynamics, Newcastle upon 
Tyne, UK). Spot presence in each sample was normalized between the two compared samples. 
Candidate differentially expressed protein spots identified by this process were validated by 
relocation on the original images in Progenesis. Only validated protein spots were excised for 
further analysis by mass spectrometry. We pre-selected protein spots that showed at least a 2x 
difference in their expression levels between the compared samples. Automated in-gel 
digestions, peptide extractions, desalting and concentration and spotting onto MALDI targets 
were carried out on a MultiProbe II Proteomic liquid handling workstation (PerkinElmer) using 
Montage Trypsin digestion kits and Zip Plate (Millipore, Bedford, MA, USA). Spectra were 
automatically acquired and analyzed on a prOTOF 2000 MALDI Mass Spectrometer 
(PerkinElmer). We have identified 21 proteins that their levels were altered in the MsrA-/- relative 
to WT brain, in which the expression of 19  were elevated and 2 were downregulated, 
respectively (Table 1). The presented list of proteins contains only abundant and identifiable 
proteins and it is not complete. Nevertheless, it provides initial information about physiological 
changes that may occur in the MsrA-/- brain. The fact that there are more degradation products 
and pI changes of various proteins in MsrA-/- brain, suggests that there is an enhanced protein 
posttranslational modification and degradation rate in MsrA-/- brain (Table 1).  
The expression levels of certain proteins from the list are suggested to be part of response 
mechanisms to oxidative stress or neurodegenerative diseases: P63 is death inducing protein 
(Jacobs et al., 2005); alcohol toxicity induces dynamin expression (dynamin  is a GTPase 
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protein and is  important in endocytosis) (Saito, Smiley, Toth, & Vadasz, 2002), and 
metavanadate (causes oxidative stress) induces the expression of proliferin (an important 
protein in angiogenesis) (Parfett & Pilon, 1995). Transketolase (TK)-atrophy of murine thymus 
causes abnormality of transketolase (B12 dependent) in the brains of alcoholics. Also, lower 
activity of transketolase was shown in Alzheimer’s disease as well (Gibson et al., 1988). 
Likewise, BB-creatine kinase (BBCK) is important for energy utilization and alteration of 
cytockeleton’s proteins and its activity was shown to decrease in Alzheimer’s disease, while 
having higher carbonyl content (Aksenov, Aksenova, Butterfield, & Markesbery, 2000). Higher 
cellular protein-carbonylation level under oxidative stress or Alzheimer’s disease was also 
considered to be a factor involved in attenuating glyceraldehyde-3-phophate dehydrogenase 
(GAPDH) activity/expression (Opii et al., 2008). Dihydropyrimidinase-like 2 (DRP2) (Collapsin 
response mediator protein-2) hydrolyses adenine to form hypoxanthine and ammonia. The 
enzyme is part of metal dependent deaminases reaction. It is important for adenine utilization as 
a purine and also as nitrogen source. It was shown that the expression levels of DRP2 and 
dynamin-1 (DNM1, its role in maintaining neuronal function is yet to be understood ) were 
among proteins in which their expression levels were significantly increased in brains of old 
versus young mice (Poon, Vaishnav, Getchell, Getchell, & Butterfield, 2006). Taken together, it 
is possible that the observed elevated level of TK, BBCK, DRP2, DNM1 and GAPDH in MsrA-/- 
brain is part of a general compensatory mechanism for lower enzyme activity due to enhanced 
oxidative damage (e.g. increased protein-carbonyl /MetO moiety). The Kallikrein–Kinin system 
influences the permeability of the blood-brain barrier and is activated in stroke. Plasma 
concentrations of tissue kallikrein–Kinin are then elevated. Accordingly, it is possible that 
increased level of tissue kallikrein in MsrA-/- brain is due to increased strokes or stroke–related 
events. Likewise, elevation of MsrA-/- brain CDC16 may be a response to elevated stress 
promoting neurodegeneration, as lack of it causes defects in the proliferation of brain 
neuroblasts and results in the absence of identified neuronal lineages in central and peripheral 
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nervous systems. Only two proteins were identified as downregulated proteins in the MsrA-/- 
brain: Heat shock protein 70 (HSP70) and serine protease inhibitor (SPI). Attenuation of HSP70 
is associated with stress conditions and apoptosis whereas changes in the levels of SPI can be 
monitored in various biological systems. It is possible that the reduced level of brain-SPI 
contributes to the enhanced accumulation of degraded proteins observed in the 2D-protein 
analysis of MsrA-/- brain.  
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Table 1. Proteomics analysis of MsrA-/- versus WT brain. Only top-scored proteins were 
selected and each protein-identification was based on at least 5-6 peptides. We used Mascot 
Software as a search engine and NCBI as the database source. 
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  4. Genomics Analysis of MsrA-/- and WT Control Brains 
To further evaluate protein expression levels in MsrA-/- in comparison to WT brain, genomic 
analyses were performed on 3 mouse brains from each strain. The mRNA was isolated from the 
6-month-old animals and probed for analyses (using Affymetrix Mouse Genome 430 2.0 Array, 
Affymetrix GeneChip System). One of the advantages of using the genomic approach is that it 
facilitates the detection of mRNA levels of low abundant proteins. From a list of 300 genes that 
showed significant expression level changes between the two strains (with statistical 
significance of P < 0.05), genes were selected and sorted into three groups with relevancy to 
either neurodegeneration (group A), oxidative-stress / apoptosis / degradation (group B), or 
signal transduction & transcription / elongation factors (group C) (groups A-C correspond to 
Table 2A-C, respectively). Comparison of the mRNA levels of the genes in the MsrA-/- relative to 
WT brain revealed that: in group A, 6 genes were up regulated and 10 genes were 
downregulated; in group B, 15 genes were up regulated and 9 genes were downregulated; and 
in group C, 12 genes were up regulated and 31 genes were downregulated (Table 2A-C, 
respectively). Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
that manifests as selective upper and lower motor neuron degeneration. From the upregulated 
genes in MsrA-/- brain listed in Table 2A, it is worth noting the genes MPP4 and Als2cr3 (which 
are two potential gene-homologues) are suggested to be involved in the disease ALS type 2. 
Homer proteins regulate signal transduction, synaptogenesis and receptor trafficking, in addition 
to maintaining and regulating extracellular glutamate levels in limbo-corticostriatal brain regions.  
Homer isoforms are involved in behavioral pathologies associated with neuropsychiatric 
disorders (Szumlinski, Kalivas, & Worley, 2006). The upregulation of Homer homolog 2 in MsrA-
/-  brain listed in Table 2A, may indicate abnormal responses that could be linked to abnormal 
behavior of the MsrA-/- mouse manifested by its altered walking pattern (Moskovitz et al., 2001). 
In relation to behavioral traits, the upregulation of the tyrosine hydroxylase activating protein 
gene (Ywhaz) may suggest an increase in dopamine synthesis that may also affect motor 
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behavior.  From the list of downregulated genes in Table 2A, glutamate receptor, ionotropic, 
kainate 1 (Grik 1) was the most affected gene; while lower expression of GABA receptor gene 
(Gabra6) was also observed. It is possible that the expression changes in these receptors, 
which are involved in neurotransmitter regulation, may contribute to the abnormal locomotor 
activity observed in the MsrA-/- mouse (unpublished results).   
With respect to oxidative stress, it is suggested that the genes participating in cellular redox 
regulation (dehydrogenase/reductase (SDR family) member 8, carbonic anhydrase 8, 
peroxiredoxin, superoxide dismutase 3, and Succinate dehydrogenase complex, subunit A) are 
upregulated in the MsrA-/- mouse as a response to enhanced oxidative stress (Table 2B). It is 
hypothesized that this response is an attempt of the MsrA-/- brain cells to reduce the level of the 
oxidative modification to proteins, which may be increased in the absence of MsrA. In contrast, 
the levels of the Heat shock protein 1A and Ataxia telangiectasia mutated homolog (ATM) are 
reduced in the MsrA-/- brain, thus reducing the cellular protection against ROS mediated 
damage (Table 2B). Caspase 12 and Tial 1, and SPI are considered to be inducing factors for 
apoptotic events. SPI was also shown to be downregulated MsrA-/- brain on the protein level 
(Table 1) and thus confirms the respective genomic data. The downregulation of these genes in 
the MsrA-/- brain in conjunction with the elevated expression of antioxidant proteins may reflect 
an attempt to prolong neuronal survival under increased oxidative conditions. The altered gene 
expression in the MsrA-/- brain in Table 2C may be mediated by oxidation of specific proteins 
that play an important role in signaling processes and synthesis of key proteins in various 
pathways. It is still not yet known how multiple processes are either simultaneously affected by 
Met oxidation or the mechanisms controlling the net expressed cellular effect in a specific 
pathway. 
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Table 2A. Genomic analysis of genes involved in MsrA-/- versus WT brain. 
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Table 2C. Genomic analysis of genes involved in signal transduction and transcription in 
MsrA
-/- versus WT brain. 
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  5. Conclusions 
In this review we have presented evidence that MsrA is mainly associated with the expression 
of specific genes/proteins that are involved in pathways that are important for cellular 
antioxidant and redox status. Significant changes found in expression levels may be relevant to 
the processes of neurodegeneration, oxidative-stress / apoptosis / degradation, and signal 
transduction & transcription / elongation factors. Obviously, more detailed research is required 
to better elucidate the role of Met oxidation to specific proteins in vivo. Additionally, a more clear 
understanding of the regulating function of the Msr system may enable future intervention in 
controlling its expression and function under stages of cellular stress/disease. 
  
 B. The MsrA Knockout Mouse Exhibits Abnormal Behavior and Brain DA Levels 
(D. B. Oien, Osterhaus et al., 2008) 
Recent evidence has found oxidized methionine residues in neurodegenerative conditions. 
Previously, we have described elevated levels of brain pathologies and an abnormal walking 
pattern in the MsrA-/- mouse. Here we show that MsrA-/- mice have compromised complex task 
learning capabilities relative to WT mice. Likewise, MsrA-/- mice exhibit lower locomotor activity 
and altered gait that exacerbated with age. Furthermore, MsrA-/- mice were less responsive to 
amphetamine treatment. Consequently, brain DA levels were determined. Surprisingly, relative 
to WT mice, MsrA-/- brains contained significantly higher levels of DA up to 12 months of age, 
while lower level of DA was observed at 16 months of age. Moreover, striatal regions of MsrA-/- 
mice showed an increase of DA release parallel to observed DA levels. Similarly, the expression 
pattern of tyrosine hydroxylase activating protein correlated with the age-dependent DA levels. 
Thus, it is suggested that DA regulation and signaling pathway are impaired in MsrA-/- mice, 
which may contribute to their abnormal bio-behavior. These observations may be relevant to 
age-related neurological diseases associated with oxidative stress.  
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  1. Introduction 
Given the hippocampal sensitivity to oxidative stress and markers of Alzheimer’s disease in the 
MsrA-/- mouse (Pal, Oien, Ersen, & Moskovitz, 2007a), we analyzed this mouse for a decline of 
complex task learning capability in the current study. The previously described “tip toe” walking 
pattern described for MsrA-/- mouse prompted us to look into Parkinson’s disease-associated 
bio-behavioral traits in this mouse strain. In Parkinson’s disease, neurodegeneration (especially 
in the dopaminergic neurons of the substantia nigra) and altered DA levels have been linked to 
abnormal motor behavior, including walking distance and gait. Thus, locomotor activity and gait 
performance of the MsrA-/- mouse, compared to WT mouse, were monitored as function of age. 
The direct natural cause for these neuronal deaths in Parkinson’s disease is yet to be revealed, 
but toxins can produce Parkinsonism via ROS and have been used to create animal models for 
Parkinson’s disease. For example, both 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
and 6-hydroxydopamine (6-OHDA, a neurotransmitter analogue toxic to dopaminergic neurons) 
reduces DA levels in the brain and results in Parkinson’s disease-like motor syndromes. While 
6-OHDA may cause direct elevation of ROS, MPTP is converted to MPP+, which by its 
inhibitory action on mitochondrial complex 1 may elevate ROS production. Therefore, behavioral 
characteristics of MPTP-treated mice served as a guide to demonstrating Parkinson’s-related 
abnormal locomotor behavior in MsrA-/- mice. Since DA is an important signaling molecule 
involved in motor regulation, we also determined the level of brain dopamine (post-mortem 
assay) and electrically stimulated brain DA secretion and reuptake in striatal neurons (in vitro, 
brain slice preparation). Additionally, the response of the mice to amphetamine was determined 
because 1) amphetamine blocks the DA transporter (DAT) ability to clear DA from the synaptic 
space, and 2) amphetamine is transported into the cell which contibutes to the DA efflux 
(Fleckenstein, Volz, Riddle, Gibb, & Hanson, 2007). Together, the current observations show 
significant differences between MsrA-/- and WT mice with regard to bio-behavioral traits and 
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brain DA levels, thereby providing a potential linkage between MetO, abnormal behavior, and 
age-related neurodegenerative diseases.    
 
  2. Materials and Methods 
Operant learning procedures 
Eight MsrA-/- mice and 7 WT mice were exposed to operant conditioning procedures in which the 
mice first acquired the capacity to press a lever to obtain small portions of condensed milk such 
that each lever press produced a reward (this procedure is termed fixed ratio 1 or FR1). The 
initial training, managed entirely by a computer program (McKerchar, Zarcone, & Fowler, 2005), 
occurred when the mice were 1 year old (mean ages of 12.9 months and 12.2 months for MsrA-
/-  and WT mice, respectively; not significantly different). Briefly, the computer-controlled lever-
pressing training procedure used mouse operant chambers that were supplied by Med 
Associates (St. Albans, VT) and programmed to present condensed milk on concurrent FR1 and 
noncontingent variable time schedules of milk reinforcement in two consecutive-day, 2 h 
sessions. These two sessions were followed by 4 consecutive-day FR1 training sessions 30 min 
in duration. The mice were returned to their home cages for a period of about 3.5 months with 
no training, but with daily restriction of food intake. Then the mice were retested for 7 
consecutive daily sessions on FR1. The mice were then exposed to a computer-implemented 
shaping procedure aimed at gradually introducing increasingly greater task demands until they 
reached FR20 (i.e., 20 lever presses per reward). The FR-shaping procedure individually 
monitored each mouse’s behavior, and the FR requirement was increased only if the last two 
interresponse times of the preceding ratio were less than 1 s each. The training procedure was 
stopped after training session 32 when all WT mice reached the FR20 criterion. The dependent 
variable for describing the difference in learning was the number of sessions required by each 
mouse to reach the criterion. Mice not reaching the FR20 criterion were assigned a score of 32 
sessions. Our FR shaping procedure was not a type of progressive ratio that is commonly used 
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in experiments designed to reflect motivation to obtain a reward. In the conventional progressive 
ratio the trained animal is presented with a series of monotonically increasing ratios such that 
each completed ratio results in a reinforcer (reward) and the requirement for obtaining the 
reinforcer is increased in increments, eventually making the ratio of reinforcers to responses 
smaller and smaller until the animal “gives up”- the break point. Importantly, the criterion for 
reinforcement grows steadily without taking account how well the animal is progressing. In the 
procedure we used, the animal was shaped to move on to increasing ratios; if it did not make 
two responses in moderately quick succession (two responses following one another each in 
less than 1 s), it could remain indefinitely at whatever ratio it was on and continue to be 
reinforced. We see our task as measuring the mouse’s sensitivity to the reinforcement 
contingency, which unimpaired animals learn quickly.  
 
Locomotor activity  
Locomotor activity and other behavioral attributes were assessed with four concurrently 
operative force-plate actometers (Fowler et al., 2001b). The actometer and associated 
peripherals, as well as the methods of data collection and analysis, were used as described 
previously (Fowler et al., 2001b). In the current studies, mouse locomotor activity was measured 
for 30 min. Six mice of each genotype (MsrA-/- or WT) and age (6- or 12-month-old) were used 
for the analyses.   
 
Gait dynamics  
The DigiGait system (Mouse Specifics, Inc., MA) provides numerous spatial and temporal 
indices of gait dynamics and posture, including: stride length, stance width, stance duration, 
swing duration, braking duration, propulsion duration, stride frequency, and paw angle. The 
mouse observation compartment is constructed of clear polycarbonate of fixed width with 
adjustable front and rear walls. The DigiGait apparatus performs ventral plane videography of 
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rodents walking on a motorized transparent treadmill belt. A high-speed digital video camera 
continuously images the underside of the walking animals. DigiGait software generates “digital 
paw prints” to measure gait indices, representing the temporal record of paw placement relative 
to the treadmill belt. The gait signal of each limb comprises the stride duration, which includes 
the stance duration when the paw of a limb is in contact with the walking surface, plus the swing 
duration when the paw of the same limb is not in contact with the walking surface. Stance 
duration is subdivided into braking duration (increasing paw contact area over time) and 
propulsion duration (decreasing paw contact area over time). More than twenty gait indices are 
reported by the software, including the sciatic functional index (SFI), stance factor, and the step-
sequence pattern. The incline of treadmill belt is fixed at horizontal. Imaging and analysis 
software automatically quantifies spatial and temporal indices of gait in walking or running 
animals. Additional details have been published previously (Amende et al., 2005; Hampton, 
Stasko, Kale, Amende, & Costa, 2004; Wooley et al., 2005). The experimental design was 
similar to the locomotor activity measurements except that only one measurement session was 
conducted at each of the two age points. The experiments were conducted on the same mice 
(n=6 for each mouse genotype and age) a week after the actometer measurements. The belt 
speed was adjusted to the animals’ ability to walk without moving backwards. Belt speeds were 
kept constant for each age group.   
 
Behavioral effects of amphetamine administration  
In the amphetamine experiment, the doses studied were 5.0, 2.5, and 0.0 mg/kg (in this order, 
administered i.p. in a volume of 5 mL/kg) with 7 to 10 days separating treatments. Doses 
specified are in terms of the d-amphetamine sulfate salt (Sigma-Aldrich, St. Louis, MO).  
Amphetamine was administered 15 min before placement in the actometers. The primary 
behavioral measurement was distance traveled and secondary measurement was stereotypy.   
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DA levels in post-mortem brains  
Animals were sacrificed and their brains were dissected out and stored at –80°C until analysis. 
The DA analysis was performed on whole isolated brain. On the day of the assay, the brain was 
sonicated in 10 volumes (weight/volume), of 0.1 M perchloric acid containing 50 ng/mL 
dihydrobenzylamine as internal standard. After centrifugation at 15,000 X g for 15 min at 4°C, 
20 µL of supernatant was injected onto a C18 reverse-phase HR-80 catecholamine column 
(ESA Inc., Bedford, MA, USA). The mobile phase consisted of 94% 50 mM sodium 
phosphate/0.2 mM EDTA/1.2 mM heptanesulfonic acid (pH 3.2) solution and 6% methanol. The 
flow rate was 1.5 mL/min. Peaks were detected by an ESA 8 Channel CoulArray system. Data 
was collected and processed using the CoulArray data analysis program.   
 
Release and reuptake of DA in the striatum  
Brain slices. Mice were deeply anesthetized by isoflurane inhalation and decapitated. The 
brains were immediately removed and placed in oxygen-saturated ice cold aCSF. From each 
brain, the cerebellum was excised and the cerebrum was glued on a Teflon block. Coronal 
slices of 300 µm thick were made using an NVSL vibratome (World Precision Instruments, 
Sarasota, FL). Brain slices containing the striatum, obtained at +0.3 to +1.5 mm from bregma, 
were stored in ice cold aCSF. A single slice was submerged under aCSF maintained at 34ºC 
and continuously flowing (2 mL/min) through a superfusion chamber (Warner Instruments, 
Hamden, CT). Each brain slice was equilibrated for 30 minutes prior to obtaining 
measurements. 
Electrochemistry. The procedure was based on method previously described by Bath et al. 
(Bath et al., 2000). Carbon-fiber cylinder microelectrodes were made as previously described 
using T650 carbon fibers (Amoco, Greenville, SC) cut to a length of 25 µm. A triangular 
waveform, starting at -0.4 V, increasing to 1.0 V, and scanning back to -0.4 V (versus Ag/AgCl 
reference electrode), was applied to the carbon-fiber working electrode at a scan rate of 300 V/s 
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and an update rate of 10 cyclic voltammograms/s. The carbon-fiber was inserted until the tip 
reached 100 µm below the surface of the brain slice in the dorsolateral caudate region of the 
striatum between the prongs of a bipolar stimulating electrode (FHC, Bowdoinham, ME), 
situated 200 µm apart. To evoke DA release, a single, biphasic stimulating current pulse (2 ms 
each phase, 350 µA in amplitude), was applied to the stimulating electrode. Successive cyclic 
voltammograms were collected every 20 s. The current arising from DA oxidation (at about 0.6 
V) was measured and plotted versus time. To account for the naturally occurring heterogeneity 
of DA terminals in the striatum, DA release readings were obtained at four different randomly 
selected locations in the dorsolateral caudate and the resulting data were averaged and 
counted as a single reading. Electrodes were calibrated against DA standards of known 
concentrations in a flow cell before and after each brain slice experiment. The averages of these 
pre- and post-calibration measurements were used to calibrate the electrode.  
 
Genomic and western blot analyses 
Genomic analysis. The mRNAs from three brains of each mouse genotype at 6 months of age 
were purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). The purified mRNA from each 
brain was used for genomic screening analyses probing with Affymetrix Mouse Genome 430 2.0 
Array (using Affymetrix GeneChip System at the University of Kansas Genomic Facility). Only 
the tyrosine hydroxylase (TH) and TH-activating protein (Ywhaz) genes were evaluated for the 
current study. 
Western blot analysis.  Protein-expression levels of TH and TH-activating protein (Ywhaz) 
were detected by extracting protein from a pool of 5 mouse brains. For each sample, 30 
micrograms of soluble protein were subjected to gel-electrophoresis, followed by western blot 
analysis using primary antibodies against Ywhaz (Abcam) and TH (Millipore). 
 
Statistical analysis.  
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Data presented are the mean ± standard deviation of the mean. Statistical analysis was carried out 
using paired or unpaired student’s t-test to determine if the observed changes between the two 
mouse strains had a significant effect (P<0.05). For locomotor activity, the distance traveled was 
analyzed with a repeated measures 2-way ANOVA with genotype as the between groups factor and 
5-min time block as the repeated measures factor.  
 
  3. Results  
Behavioral effects of MsrA targeted deletion  
Assessment of operant learning. Eight MsrA-/- mice and 7 WT mice were exposed to operant 
conditioning procedures. The mice first acquired the capacity to press a lever to obtain small 
portions of condensed milk such that each lever press produced a reward (FR1). During initial 
training, the two types of mice were not significantly different, but numerically the MsrA-/- mice 
lagged behind the WT mice. The mice were returned to their home cages for a period of about four 
months with no training in this interval. Then the mice were retested for seven consecutive daily 
sessions on FR1. All mice showed evidence of relearning the task and attained similar lever press 
rates on the seventh day. The mice were then exposed to a second computer-implemented shaping 
procedure aimed at gradually introducing increasingly greater task demand until the requirement for 
reward was FR20 (i.e., 20 lever presses per reward). This increase in demand revealed striking 
differences between the MsrA-/- and WT mice. The WT mice learned the FR20 task significantly 
faster than the MsrA-/- mice (Fig. 1). Over the 32 training sessions, the mean number of training 
sessions to reach FR20 was 10.9 for the WT mice and 30.6 for the MsrA-/- mice, t13=6.142, P<0.001 
(t13 refers to a “between-groups” t-test with 13 degrees of freedom). It is important to note that the 
MsrA-/- mice continued to lever press for reward during the FR shaping procedure (i.e., they did not 
“extinguish”). Therefore, the deficit of the MsrA-/- mice was not failure to perform a previously 
acquired habit, but, instead, was a failure to learn a new habit. These results clearly support the 
hypothesis that the MsrA-/- mice have functional behavioral/cognitive impairments at about 16 
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months of age compared to WT control mice, which may be related to the enhanced hippocampal 
neurodegeneration observed in the 12-month-old MsrA-/- mice (Pal et al., 2007a).   
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Figure 1. Operant task in both mouse strains. At the age of ~16 months, the control mice 
quickly learned to transition from FR1 to FR20 schedule of milk reward (WT), but the MsrA-/- 
mice lagged significantly behind the WT mice in learning to perform under these conditions 
(despite the fact that they were not different when the task demand was FR1). WT, n=7; MsrA-/-, 
n=8. Over the 32 training sessions shown, the mean number of training sessions to reach FR20 
was 10.9 for the WT mice and 30.6 for the MsrA-/- mice, t13=6.142, P<0.001( t13 refers to a 
“between-groups” t-test with 13 degrees of freedom). 
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Locomotor activity.  At 12 months of age, the MsrA-/- were less active by up to ~50% relative to 
control mice (Fig. 2). However, no obvious difference in locomotor activity between the two mouse 
strains was detected at 6 months of age (data not shown). Decreased spontaneous motor activity 
was also observed in mice that were shown to have signs of Parkinson’s or Alzheimer’s disease 
(Crocker et al., 2003; Lee et al., 2004).  
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Figure 2. Spontaneous locomotor activity of MsrA-/-- and WT control mice measured in a 
force-plate actometer apparatus. Five WT and 5 MsrA-/- mice (12 months old) were 
individually placed in a dark force-plate actometer apparatus and their behavior was recorded 
for 30 min. The effect of genotype was significant: F (1, 8) =12.106, P=0.008 as was the effect 
of time block: F (5, 40) = 43.259, P<0.001. The interaction effect: F (5, 40) =1.752, P=0.145, 
was not significant.  
 
115 
Gait dynamics.  Gait disturbances including shortened stride length (Salarian et al., 2004; 
Weller et al., 1993) and abnormal stride frequency (Bartolic, Pirtosek, Rozman, & Ribaric, 2005) 
are symptomatic of Parkinson’s disease. A ventral plane videography apparatus using a clear 
treadmill (Amende et al., 2005; Kale, Amende, Meyer, Crabbe, & Hampton, 2004) was chosen 
to analyze the gait indices of mice at a constant speed (Fig. 3), compared to traditional “paw 
painting” techniques that do not control speed. The MsrA-/- displayed significant differences in 
stride length, frequency and duration relative to WT control mice (Fig. 3). Specifically, we 
observed a reduced stride length and stride duration as well as an increased stride frequency in 
MsrA-/- mice. The decreased parameters suggest a lack of motor control, and the increase 
frequency occurs to maintain the animal’s speed as governed by the constant rate of the belt.  
Moreover, this novel technology has been previously used to analyze the gait dynamics of 
MPTP-injected mice (Amende et al., 2005), a common Parkinson’s disease mouse model 
(shown in Table 1 for comparison). The gait data were pooled from all four limbs for analysis, as 
was done in previous analyses (Amende et al., 2005). The values in the graph (Fig. 3) show the 
differences by genotype and age relative to the 6-month-old control mice (WT young mice 
normalized to 100%). Actual numbers of the averaged values are given in Table 1. All stride 
indices were significantly different between the two types of mice, and these differences 
increased with age (aged mice are approximately 16 months of age). Also, Table 1 shows the 
percent change relative to the corresponding genotype. Reduced stride length is indicative of 
basal ganglia dysfunction (Fernagut, Diguet, Labattu, & Tison, 2002). Indeed, the current results 
for MsrA-/- mice are comparable in magnitude to the data reported by Amende et al. (Amende et 
al., 2005) for MPTP-treated C57BL/6 mice (Table 1). There is no evidence that MPTP 
administration and MsrA ablation affect the same biochemical pathway. However, the gait 
abnormalities found in the PD mouse model using MPTP administration and the MsrA-/- mouse 




Figure 3. Gait dynamics of MsrA-/- and WT control mice. The horizontal axis represents the 
type of mouse and the dependent variables from the DigiGait Imaging System. The graphic 
shows differences in stride dynamics of MsrA-/- mice at two age points, 6 months (young, 
slashes) and 16 months (aged, gray solid) versus young and aged WT controls (white and 
black, respectively). Values are given as a percentage relative to the WT young value to show 
progression of abnormalities with age. The DigiGait-treadmill speed: young mice: 26 cm/s; aged 
mice: 15 cm/s, MPTP-injected mice: 34 cm/s. Significance was determined by t-test and 
indicated between strains by * (P < 0.05) or ** (P < 0.001); and between age groups in each 




Behavioral effects of amphetamine administration 
Force-plate actometers were used to measure the locomotor-activating effects of amphetamine 
in MsrA-/- mice and WT controls. Numerical data for distance traveled are shown in Fig. 4 and 
tracings of movement trajectories are shown in Fig. 5. Analysis of variance indicated a 
significant difference between the two types of mice (F(1,9)=7.104, P=0.026). The dose effect 
was also significant (F(2,18)=36.932, P<0.001), as was the dose-by-type interaction effect ( 
F(2,18)=8.245, P=0.003)). A significant three-way interaction (dose X time block X type of 
mouse) was also obtained, (F(10,90)=15.393, P<0.001). The statistical interaction effects were 
the result of the marked divergence of the behavior in the two types of mice at the 5.0 mg/kg 
dose, with the WT mice increasing their activity and the MsrA-/- mice decreasing in activity as 
session time passed. Because it is known that higher doses of amphetamine can induce in 
rodents focused stereotypies that reduce amount of locomotion (Lyon & Robbins, 1975), it is 
important to examine the behavior for indications of  the potential occurrence of focused 
stereotypy in response to amphetamine. Data shown in Fig. 5 (examples for 4 animals per 
mouse strain) can be used to address this issue. Consistent with Figure 4 at the 5.0 mg/kg dose 
of amphetamine, the WT mice exhibited a high degree of locomotor stimulation which was 
accompanied by partial spatial confinement in mice number 3 and number 5, whereas the MsrA-
/- mice showed declining stimulation with time but no spatial confinement of the kind seen for the 
WT mice. There was no focused sterotypies observed at 0.0 dose of amphetamine for either 
mouse strain. Intensified spatial confinement was observed for the WT mice when treated with 
amphetamine 2.5 mg/kg, which was the second dose treatment. The MsrA-/- mice also showed 
evidence of spatial confinement after the 2.5 mg/kg dose, but less than the WT mice. The 
somewhat greater spatial confinement effect in the second dose (even though it was lower than 
the first dose) is consistent with the idea that both types of mice were capable of expressing 
behavioral sensitization. At the 5.0 mg/kg dose the data suggest a deficient ability of the MsrA-/- 
to sustain motor response to amphetamine that may be related to an abnormality in the mouse’s 
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DA neurotransmitter system, which is the predominate modality through which amphetamine 
produces its increase in locomotor activity.  
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Figure 4. Response to amphetamine administered to both mouse strains. Distance 
traveled by MsrA-/- mice (filled circles, n=5) and controls (triangles, n=6) in response to the 
indicated doses of d-amphetamine sulfate (Amp) given i.p. The drug was administered 15 min 
before the 30-min recording session in a force-plate actometer. Mice were about 16 months old.  
Analysis of variance indicated a significant difference between the two types of mice 
(F(1,9)=7.104, P=0.026). The dose effect was also significant (F(2,18)=36.932, P<0.001), as 
was the dose-by-type interaction effect ( F(2,18)=8.245, P=0.003)). A significant three-way 




Figure 5. Movement trajectories for the data shown in Figure 4. Each square represents 6 
min of recording. The top row for each treatment occurred first in time.These mice were 
approximately 16 months old. 
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Assessment of the molecular changes in MsrA-/- mouse brain 
DA levels in post-mortem brains. Changes in brain DA levels are associated with abnormal 
motor behavior. Thus, we measured DA level in total brain extracts of 6-, 12-, and 16-month-old 
mice using reverse-phase HPLC-column linked to an electrochemical detector. Surprisingly, 
brains of the MsrA-/- mice exhibited 47% and 63% more dopamine compared to their counterpart 
WT brains at 6- and 12-month-old brains, respectively (Fig. 6). However, at older age (16 
months), there was a ~50% decline in DA level in MsrA-/- compared to WT mice. It is important 
to note that the DA level in WT brain increased at 16 months of age to the DA level observed in 
MsrA-/- at 12 months. Consequently, it was important to evaluate the possibility of enhanced DA 
synthesis and release as shown by monitoring the expression levels of tyrosine hydroxylase 
(TH), TH-activating protein (TH has been reported to require binding of 14-3-3 proteins (Ywhaz) 
for optimal activation by phosphorylation (Kleppe, Toska, & Haavik, 2001), and DA 
release/reuptake in striatum of brain slices in vitro, as shown below.  
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Figure 6. Concentration of brain DA in MsrA-/- and WT control mice at various ages. 
Neurotransmitter level was assayed by HPLC with electrochemical detection. Dopamine levels 
in the MsrA-/- brains were significantly higher than in the WT mice at ages of 6 and 12 months 
and lower than WT at 16 months of age, respectively, as determined by t-test, P<0.01. The 
higher DA level in WT at age of 16 months relative to ages of 6 and 12 months was also 
significant, as determined by t-test, P<0.01. Each strain, n=6. 
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Release and reuptake of DA in the striatum of brain slices  
To gain insight into presynaptic dopaminergic malfunctions that may occur in MsrA-/- mice, we 
measured electrically evoked DA release and reuptake in striatal brain slices using fast-scan 
cyclic voltammetry (FSCV) at carbon-fiber microelectrodes. Electrodes were placed in the 
dorsolateral caudate because dopaminergic innervation in this brain region comes almost 
exclusively from the nigrostriatal pathway (Gerfen, Herkenham, & Thibault, 1987). As shown in 
a representative concentration-time plot (Fig. 7), a sharp increase in DA concentration is 
measured at the electrode upon application of a single stimulus pulse. This increase is followed 
by a more gradual decrease as DA is taken up by DAT (Jones, Gainetdinov, Wightman, & 
Caron, 1998a). Cyclic voltammograms (upper right in Fig. 7) obtained at the maxima confirm the 
detection of DA. Amplitudes of stimulated DA release obtained from brain slices of MsrA-/- mice 
are dramatically increased (272% of WT on average, aggregated data are shown in Table 2). 
Plots of stimulated DA release at carbon-fiber microelectrodes in brain slices may be distorted 
by diffusional contributions and DA reuptake by DAT (Bath et al., 2000). To account for these 
contributions, concentrations of DA released per stimulus pulse ([DA]p) were estimated by 
modeling the concentration–time curves (Fig. 7). The curved line superimposed over the points 
of the sample DA release plot represents best-fit curve derived using curve-fitting software (Wu, 
Reith, Wightman, Kawagoe, & Garris, 2001). On average, [DA]p was significantly increased 
(333% of WT, P < 0.05, n = 3 mice per genotype, 12 month-old mice) in brain slices harvested 
from MsrA-/- mice (Fig. 8). [DA]p progressively decreased with increasing time in culture of the 
MsrA-/- brain-slices, while remaining flat in the first 90 min for the WT brain slices and increasing 
by 200% at 180 min time point (Fig. 8).  
From the analysis of the stimulated release curves we also determined Vmax, a kinetic 
parameter describing the maximum rate of DA reuptake by DAT. The average values 
determined from MsrA-/- and WT mice were consistent with previously published values of Vmax 
(4 lM/s) in mice (Jones, Joseph, Barak, Caron, & Wightman, 1999). No significant difference in 
125 
Vmax between MsrA
-/- mice and aged-matched WT littermates was found n= 3 mice per 
genotype, data not shown). The KM for reuptake is the concentration of extracellular DA at which 
DAT functions at ½Vmax. The KM serves as a measure of DAT efficiency, whereas, Vmax is 
directly proportional to DAT concentration. Values of KM in the absence of reuptake inhibitors 
have been determined in synaptosomal preparations to be approximately 0.2 M (Jones, Garris, 
Kilts, & Wightman, 1995). Dopamine reuptake follows Michaelis–Menten kinetics (Jones et al., 
1995; Kawagoe, Garris, Wiedemann, & Wightman, 1992; Wightman et al., 1988). Therefore, the 
rate of DA reuptake in a given plot of stimulated DA release is dependent upon DA 
concentration and is independent of the time point in the curve at which the concentration is 
measured. Thus, to qualitatively assess DA reuptake efficiency, we overlaid the averaged MsrA-
/- and WT DA reuptake curves, time shifted so that the initial concentrations were approximately 
equal, from brain slice data obtained. This approach to observing relative DAT efficiency has 
been employed previously (Jones et al., 1995). The MsrA-/- curves are not statistically different 
from their respective WT curves in the concentration range of KM (0.2 µM; p > 0.05, Mann–
Whitney, n = 3, each genotype, 12-month-old MsrA-/- vs. age-matched WT; graphic not shown).  
This suggests that the KM, and therefore the efficiency of DA reuptake by DAT, is similar in 
MsrA-/- and WT mice. 
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Figure 7. DA release in striatal brain slices of MsrA-/- and WT control mice. A 
representative stimulated DA release plot generated from measurements obtained from striatal 
brain slices (from 12-month-old post-mortem brains). FSCV was used to collect DA release 
measurements. The cyclic voltammograms plots (shown above and to the right) confirm the 
presence of DA. Legend: MsrA-/-, closed symbols on release plot, solid line on cyclic 





Figure 8. Peak dopamine release presented from the WT and MsrA-/- slices. Successive 
measurements were collected from striatal brain slices of MsrA-/-, and WT mice 90 min apart. 
Bar graph values represent the average of release measurements collected from four different 
locations within the ventral lateral caudate/putamen. DA release from MsrA-/- brain slices 
diminished over time, whereas it did not diminish in WT slices. Error bars represent ±SEM.  
Significance determined by t-test:  * P < 0.05, ** P < 0.001.   
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Analyses of TH and TH-activating protein 
Increased DA levels observed may be attributed to elevated DA synthesis. We performed brain 
genomic screening analyses and found that the MsrA-/- brain had about 4-fold induction in 
Ywhaz (TH-activating protein) mRNA content over the WT brain gene at age of 6 months, 
respectively (P<0.001). The up-regulation of the Ywhaz gene in MsrA-/- brain was confirmed on 
the protein level following western blot analysis of MsrA-/- and WT brain extracts at ages of 6 and 
12 months (Fig, 9A). Additionally, the protein level of Ywhaz was reduced at 16 months versus 
12 months of age in the MsrA-/- brain and elevated in WT brain at 16 months of age compared to 
12 months of age, respectively (Fig. 9A). Thus, there is a good correlation between the 
expression of Ywhaz gene and brain DA levels across the monitored strains and age. This 
correlation implies that Ywhaz may play an important role in the regulating brain DA synthesis 
as a function of age and performance of the Msr system. Differences in dopaminergic neuron 
quantities can alter the TH-activating protein content. However, the relative expression level of 
TH in both mouse strains was similar across all monitored ages (mRNA data not shown; and 
Fig. 9B for the protein expression level). The unchanged TH level suggests no significant age-
dependent neurodegeneration in MsrA-/- dopaminergic neurons compared to WT, respectively. 
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Figure 9. Protein-expression levels of TH and Ywhaz in WT and MsrA-/- brains. Pool of 5 
mouse brain extracts were subjected to gel-electrophoresis, followed by western blot analyses.  
Thirty microgram of soluble brain proteins were loaded in each lane. A) Expression levels of 
Ywhaz (TH-activating protein) in both mouse strains as function of age (6, 12, and 16 months). 
B) Expression levels of TH as function of age (6, 12, and 16 months). Respectively, β-actin 
levels for each lane are shown in Panel A and panel B. 
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  4. Discussion 
In our previous studies we have found that MsrA-/- mice display elevated brain pathologies and a 
“tip-toe” walking pattern. Here we show evidence that the MsrA-/- mouse exhibits abnormal 
cognitive and locomotor behaviors reminiscent of age-related neurodegenerative diseases. In 
addition, the mice lacking MsrA display atypical dopamine regulation. The initial increased MsrA-
/- DA levels are a finding that, to our knowledge, has only been reported in studies not related to 
oxidative stress. The MsrA-/- mouse was shown to be more vulnerable to oxidative stress and 
showed enhanced neurodegeneration in the hippocampus. Thus, it is possible that the general 
observed hypersensitivity of the MsrA-/-  to oxidative stress may affect the function of specific 
proteins that are involved in DA physiology. 
 Lower locomotor activity present as early as 12 months of age in MsrA-/- relative to WT mice 
(Fig. 2), and measurable gait disturbances detected at 6 months and worsening with age in 
MsrA-/- (Fig. 3), suggests that the motor deficiencies in the MsrA-/- are exacerbated with age; 
relative to WT declining locomotor activity. The data presented in Fig. 3 and Table 1 suggests a 
magnitude of gait abnormality in the MsrA-/- mice that is comparable to what is seen in MPTP 
treated mice. The gait abnormalities found in the PD mouse model using MPTP administration, 
which has also been demonstrated in MsrA-/- mouse, may be a consequence of a common 
response to direct or indirect effects prompted by the ablation of MsrA and MPP+ action in the 
brain. Studies of gait in mouse models will help establish parallels with human pathologies, and 
these parallels may be useful in identifying therapeutic approaches to human neurological 
diseases. Alteration in DA metabolism is strongly associated with abnormal locomotor activity.  
The drug amphetamine blocks the re-uptake of already released DA, by blocking DAT function, 
and thus was used to treat the mice to elevate their locomotor activity. 
 Surprisingly, the presented data showed that amphetamine-treated MsrA-/- mice have a 
compromised response to this treatment (Figs. 4 and 5) at 5.0 mg/kg. From the results obtained 
on DA release and re-uptake from the striatum, using FSCV (Figs. 7 and 8, Table 2), it appears 
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that the DAT in MsrA-/- mice functions properly, while a dramatic increase in DA release is 
observed. Thereby, it is unlikely that the observed high levels of MsrA-/- brain DA at ages of 6 
and 12 months (Fig. 6) are the outcome of insufficient reuptake of DA. Rather, these findings 
imply that the measured high level of MsrA-/- brain DA (Fig. 6) is related to an enhancement in 
DA synthesis. Supportive evidence to this hypothesis arises from the fact that the upregulation 
or downregulation of the activating enzyme of TH (TH-activating protein, Ywhaz) correlate with 
the levels of brain-DA in both mouse strains (Fig. 9A and Fig 6). At an age of 16 months, MsrA-/- 
mice showed reduction in DA level compared to the previous ages (50%), while the WT reached 
the DA levels of the MsrA-/- at ages of 6 and 12 months (Fig. 6). One possible explanation for 
this observation is that, relative to WT, the MsrA-/- brain is functioning under oxidative stress 
conditions from an early age and it is responding by elevating DA levels (possibly as a 
compensatory response). However, at an older age this response mechanism to oxidative 
stress may fail in the MsrA-/- brain. In contrast, MsrA expression and activity in WT brains 
decline only at older ages (Petropoulos, Mary, Perichon, & Friguet, 2001; Stadtman, Moskovitz, 
Berlett, & Levine, 2002). The increase of DA content in 16-month-old WT mice may reflect, in 
light of the DA-data presented for the MsrA KO mice, an enhanced oxidative stress at older age 
before dopaminergic neurodegeneration occurs. Thus, the same phenomenon may occur in 
WT, but it is delayed until MsrA levels are decreased in normal aging.  
 The unchanged levels of TH in MsrA-/- relative to WT brain (Fig. 9B) reduce the possibility of 
enhanced dopaminergic neurodegeneration in MsrA-/- brain up to 16 months of age. Similarly, 
lack of an obvious in vivo dopaminergic neurodegeneration was shown in major genetic mouse 
models for Parkinson’s disease; for example, in the DJ-1 knockout mouse (Yamaguchi & Shen, 
2007) and in various types of mouse models overexpressing alpha-synuclein (Chesselet, 2007).  
The different promoters and mouse transgenes of alpha-synuclein lead to a wide variety of 
phenotypes accompanied by nonexistent, late onset, or non-specific neurodegeneration 
(Chesselet, 2007). Thus, it is proposed enhanced level of dopaminergic neurodegeneration is 
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probably an outcome of multi-component events manifested at late stages of cell death; 
whereas MetO participates in earlier stages of neurodegeneration. Nevertheless, the type of 
brain cell having a compromised MsrA system may determine the level of neurodegeneration. 
For example, it seems that certain cells of the hippocampus are more sensitive to 
neurodegeneration (Pal et al., 2007a) compared to dopaminergic neurons (Fig. 9B).  
 The inability of high DA levels in the MsrA-/- mice to increase their locomotor and gait 
performances (in the absence of DAT abnormality) supports the hypothesis that malfunction of 
downstream signaling events (due to MetO) may be the rate-limiting factors in attenuating the 
MsrA-/- response to DA. Moreover, the increased bio-behavior abnormalities observed in the 
aged MsrA-/- mice may be due to the additional age-dependent general decline in antioxidant 
defense.  For example, it is speculated that the DA receptors in MsrA-/- mice may be more 
affected by MetO with age, thereby causing either lower efficiency in DA receptors binding to 
DA, downregulation of DA-receptors expression, or both.  
 The MsrA-/- mice exhibited a compromised learning capability when challenged with 
increased task demands. As shown in Fig. 1, the WT mice learned the FR20 task significantly 
faster than the MsrA-/- mice. Given the older age of these mice (16 months), this observed 
difference in learning is possibly the result of having malfunctioning proteins involved in the 
learning processes as oxidative damage increases with age. Reduced operant capability is 
indicative of problems residing within the cortico-striatal-thalamo-cortical loops. Thus, it is 
possible that irregularities in DA physiology may contribute to the altered learning capacity in the 
MsrA-/- mice, in addition to the already demonstrated pathologies in the MsrA-/- hippocampus 
(Pal et al., 2007a). 
 The FSCV results (Figs. 7 and 8, Table 2) clearly suggest that there is a rapid exaggerated 
release of DA in MsrA-/- brain upon stimulation. It is well established that DA plays a pivotal role 
in motor behavior activity and that the rate of DA release from dopaminergic neurons 
contributes significantly to its potential action on targeted receptors. Dopaminergic neurons 
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have the capacity to release DA not only from their axon terminals, but also from their 
somatodendritic compartment. The endoplasmic reticulum and its associated tubulovesicles 
have been proposed as possible storage sites for somatodendritic DA. These structures indeed 
appear to contain DA (Groves & Linder, 1983; Hattori, McGeer, & McGeer, 1979; Linder, 
Klemfuss, & Groves, 1987), and similar structures have been shown to express proteins of the 
SNAP-receptor (SNARE) complex, otherwise known to be essential for exocytosis.  
Consequently, one possible explanation for the observed increased DA release in MsrA-/- brain 
is an upregulation of the expression levels of the proteins participating in DA release 
mechanisms.  
      In summary, elevated protein oxidation at older age may cause irreversible MetO leading to 
protein malfunction and/or abnormal accumulation. Thus, irregularities in various physiological 
processes may occur, including abnormalities in neurological functions manifested by 
attenuated locomotor behavior and reduced learning capabilities. The molecular basis for such 
events may involve altered DA synthesis and release (this study) and post-synaptic physiology 
(future studies), which are associated with age-dependent reduction in the proper function of the 
Msr system. Accordingly, it is proposed to use the MsrA-/- mouse as a model to further studies 
on the relationships between MetO, neuronal metabolism, behavioral functions, and aging. 
 
 C. Caloric Restriction Alleviates Abnormal Locomotor Activity and Dopamine 
Levels in the Brain of the MsrA Knockout Mouse  
(D. B. Oien, Osterhaus, Lundquist, Fowler, & Moskovitz, 2010) 
Oxidative stress is associated with the aging process, a risk factor for neurodegenerative 
diseases, and decreased by reduced energy intake. Oxidative modifications can affect protein 
function; the sulfur-containing amino acids, including methionine, are particularly susceptible to 
oxidation. A MetO can be enzymatically reduced by the Msr system. Previously, we have shown 
that MsrA-/- mice exhibit altered locomotor activity and brain DA levels as function of age.  
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Previous studies have demonstrated that a caloric restriction enhances antioxidant defense and 
reduces the action of ROS. Here we examine locomotor behavior and DA levels of MsrA-/- mice 
after caloric restriction (CR) starting at 8 months of age and ending at 17 months. The MsrA-/- 
mice did not have any significant difference in spontaneous distance traveled when compared to 
controls at 17 months of age. In contrast, our previous report showed decreased locomotor 
activity in the MsrA-/- mice at 12 months of age and older when fed ad libitum. After completion 
of the CR diet, DA levels were comparable to control mice. This differs from the abnormal DA 
levels previously observed in MsrA-/- mice fed ad libitum. Thus, CR had a neutralization effect on 
MsrA ablation. In summary, it is suggested that CR alleviates abnormal locomotor activity and 
DA levels in the brain of the MsrA-/- mouse.  
 
  1. Introduction 
Reduced energy intake is known to decrease free radical production and oxidative damage in 
mammals, extend life-span, and slow age-related health problems in multiple species (Martin, 
Golden, Egan, Mattson, & Maudsley, 2007). An ongoing study with rhesus monkeys supports 
the latter concept (Colman et al., 2009). Furthermore, CR is neuroprotective (Maalouf, Rho, & 
Mattson, 2009) and has benefits that oppose brain aging, including oxidative stress pathways 
and related pathological states (Contestabile, 2009). In rodents, feeding conditions have been 
found to affect locomotor activity (Govic, Levay, Kent, & Paolini, 2009; Minor et al., 2008), and 
restrictive diets can increase DA signaling (Carr, Tsimberg, Berman, & Yamamoto, 2003; 
Gelegen et al., 2008).   
Previously, it was shown that MsrA-/- mice exhibit lower locomotor activity with age (D. B. 
Oien & Moskovitz, 2008). The MsrA-/- brains contained significantly higher levels of DA up to 12 
months of age relative to WT control mice, while lower levels of DA were observed at 16 months 
of age. Moreover, MsrA-/- mice were less responsive to amphetamine, the release of DA was 
increased in the striatal regions, and the expression pattern of tyrosine hydroxylase activating 
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protein correlated with age-dependent DA levels. Thus, it was suggested that DA regulation and 
signaling pathways are impaired in MsrA-/- mice, which may contribute to their abnormal 
behavior. Here we describe MsrA-/- mice on CR conditions and compare the results to our 
recent experiments showing abnormal locomotor behavior and DA levels in brain (D. B. Oien & 
Moskovitz, 2008). The MsrA-/- mice were placed on feeding restrictions starting at eight months 
of age, and these restrictions were continued until up to the age of 17 months. The mice were 
analyzed for locomotor behavior and brain DA levels.  
 
  2. Materials and Methods 
The MsrA-/- mice have been previously described (Moskovitz et al., 2001; D. B. Oien & 
Moskovitz, 2008). The methods for reduction in food availability, locomotor measurements, and 
euthanasia were approved by the KU Institutional Animal Care and Use Committee. 
 
Caloric restriction  
The MsrA-/- and WT control mice were both fed on an ad libitum (AL) diet until they reached 
eight months of age. Initial weights prior to caloric restriction were calculated by taking the 
average weight over three days for each mouse. Each mouse was then fed daily an amount of 
chow equal to 10% body weight until the weight of the mouse was reduced by 15%. All mice 
achieved this reduction within the first two weeks of restriction. Each mouse was maintained at 
this body weight for the duration of the experiment by adjusting food availability. The average 
weight losses within each mouse type and between the mouse groups did not significantly differ 
(P<0.05; data not shown). Likewise, it was previously reported that the weights of MsrA-/- and 
WT mice are not different, and there are no differences between the groups with age on an AL 
diet (Moskovitz et al., 2001).   
 
Total distance traveled 
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Locomotor activity was assessed with four concurrently operative force-plate actometers 
(Fowler et al., 2001b). The actometer and associated peripherals, including the methods of data 
collection and analysis, were used as described previously (Fowler et al., 2001b). In this study, 
the total distance traveled for each MsrA-/- and WT control mouse on CR was measured for 30 
minutes. Measurements were taken before CR at the age of eight months and each subsequent 
month while mice were on CR. Measurements were taken at the same time of day each month.  
Data presented are the mean ±standard deviation. The distance traveled was analyzed with a 
repeated-measures two-way ANOVA with genotype as the between-groups factor and month as 
the repeated-measures factor. Significance was further determined by the polynomial trend 
order 2 post-hoc test. 
 
DA concentrations in brain tissue 
The concentration of DA in the brain tissue was analyzed when mice on CR were 12 months old 
and 17 months old. The DA concentrations in MsrA-/- and WT control mice were measured 
immediately after the respective analysis of distance traveled by methods described previously 
(D. B. Oien & Moskovitz, 2008). Briefly, postmortem brain was dissected and cerebrum was 
weighed after olfactory bulb and cerebellum removal. The cerebrum was homogenized with in a 
solution containing 0.2 M perchloric acid and dihydrobenzylamine as the internal standard.  
Insoluble material was removed by centrifugation and supernatants were injected into a C18 
reverse-phase HR-80 catecholamine column (ESA Inc., Bedford, MA). The mobile phase 
consisted of 94% 50 mM sodium phosphate/0.2 mM EDTA/1.2 mM heptanesulfonic acid (pH 
3.2) solution and 6% methanol. The flow rate was 1.5 mL/min. Peaks were detected by an ESA 
8 Channel CoulArray system.  Data were collected and processed using CoulArray data 
analysis. Data presented are the mean ±standard deviation. Statistical analysis was carried out 
using Student's t-test to determine if the observed changes between the two mouse types had a 
significant effect (P<0.05).   
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Detection of methionine sulfoxide proteins and tyrosine hydroxylase  
Post-mortem brains (cerebra) from both mouse types at 12 months of age, fed either CR (four 
months) or AL diets were homogenized in buffer, and following centrifugation the corresponding 
supernatants were collected. Equal protein amounts (50 µg) from each brain extract were 
separated by gel-electrophoresis in 4-20% SDS-gel followed by western blot analysis using the 
primary anti-MetAO antibodies or anti-tyrosine hydroxylase antibodies, as previously described 
(D. B. Oien, Canello et al., 2009).  
 
  3. Results  
Total distance traveled of MsrA-/- and WT mice on reduced food availability 
Changes in spontaneous locomotor activity can be indicative of neuronal dysfunction and 
neurodegenerative diseases (Hausdorff et al., 2000). In a previous study, the MsrA-/- mice 
showed significantly less locomotor activity when compared to WT mice, including the 
spontaneous distance traveled. There was no significant difference between MsrA-/- and WT 
mice for distance traveled in the overall experiment (Fig. 1; P=0.661, main effect). Also, there 
were no significant differences found between distances traveled among the genotypes during 
both the beginning and the end months of the CR diet (Fig. 1). The MsrA-/- mice traveled 
significantly more only in the intermediate months as judged by the polynomial trend order 2 
post-hoc test (P=0.001, month-by-type interaction effect). The lack of difference before the CR 
diet (when mice were fed AL at 8 months of age; Fig. 1) is comparable to the distances traveled 
by MsrA-/- and WT mice at 6 months of age that were also fed on an AL diet (D. B. Oien & 
Moskovitz, 2008). The increase and later non-significant difference of MsrA-/- mice on a CR diet 
is a contrast to the ~50% decrease in distance traveled by MsrA-/- mice when on an AL diet at 
the age of 12 months (D. B. Oien & Moskovitz, 2008). 
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Figure 1. Total distance traveled by MsrA-/- mice on caloric restriction diet. Mouse 
spontaneous locomotor activity was measured starting before feeding the CR diet (8 months).  
These measurements were continued at the end of each month of the CR diet. Locomotor 
activity was measured as total distance traveled in a force-plate actometer for 30 minutes. 
Values represent average distance traveled of MsrA-/- mice (filled squares) and WT mice (open 
diamonds).  Error bars represent standard deviation. The MsrA-/- mice traveled significantly 
more only in the intermediate months as judged by the polynomial trend order 2 post-hoc test 
(P=0.661, main effect; P=0.001, month*type interaction effect). 
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DA concentrations in brain tissues of MsrA-/-and WT mice on reduced food availability 
DA levels from the nigrostriatal pathway can influence the direct and indirect movement 
pathways. In a previous study, abnormal DA levels in the brain tissue of MsrA-/- mice were 
found, relative to WT mice (D. B. Oien & Moskovitz, 2008). The concentration of DA in the brain 
tissue of MsrA-/- and WT mice did not significantly differ at the ages of 12 months and 17 months 
(Fig. 2) when on CR. There was a small, non-significant relative decline in DA levels of MsrA-/- 
mice at 17 months of age, which may be similar to the significant decrease between MsrA-/- and 
WT mice when fed on an AL diet (Table 1) (D. B. Oien & Moskovitz, 2008). This latter 
observation suggests that the positive effect of the CR diet on MsrA-/- DA levels may be limited 
in advancing age. Furthermore, the increased DA concentration of 16-month-old WT control 
mice on an AL diet (D. B. Oien & Moskovitz, 2008) was not detected in WT mice fed on a CR 
diet at 17 months of age. This observation suggests that the CR diet reduced brain oxidative 
stress below levels that normally prompt DA elevation (D. B. Oien & Moskovitz, 2008). 
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Figure 2. DA concentration in the brain tissue of MsrA-/- mice on CR diet.                                                      
Cerebral DA levels were determined for MsrA-/- mice (filled) and WT mice (open) after reduced 
food intake as described in “Materials and Methods”. Values represent the amount of DA per 
weight of cerebral brain tissue after four months of caloric restriction diet (left), or after nine 
months of caloric restriction diet (right). Error bars represent standard deviation of 6 MsrA-/- mice 
and 5 WT mice at four months and 5 MsrA-/- mice and 7 WT mice at nine months. P=0.597 and 
P=0.054, respectively, by the student’s t-test.  
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Table 1. Comparison of dopamine levels in brain tissue of MsrA-/- mice on caloric 
restriction diet and ad libitum diet. Cerebral DA levels are listed by the respective age after 
reduced food intake (CR diet) or on ad libitum feeding (AL diet) from our previous study* (D. B. 
Oien & Moskovitz, 2008). Relative DA values and standard deviations are depicted as 
percentage of DA levels in WT control mice at 6 months of age fed on an AL diet. Variance (±) 
represents standard deviation of 5-7 mice per group. 
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Met oxidation of 15 kDa protein in brain tissue of MsrA-/- and WT mice on CR and AD diet 
We have applied our novel anti-MetO antibodies (D. B. Oien, Canello et al., 2009) to identify 
MetO proteins in brain extracts of both mouse types under AL and CR diets. There was an 
enhanced Met oxidation in a ~15 kDa brain protein from MsrA-/- mice under AL diet, and to 
lesser extent in WT mice (Fig. 3). Interestingly, under CR diet, the levels of Met oxidation in this 
protein were reduced in both mouse types. Other MetO-containing proteins were detected in the 
western blot analysis, but their band intensities were not sufficient to determine the effect of CR 
diet due to the assay sensitivity limits. Further purification and enrichment of this protein will be 
performed to facilitate the identification of this protein by mass spectrometry analysis. Also, we 
have shown no change in tyrosine hydroxlase expression in all cases, which serves both as an 
internal control for protein loading and evidence for lack of obvious neurodegeneration in the 




Figure 3. MetO detection in a 15 kDa protein from brain tissues of MsrA-/- and WT mice on 
CR and AD diet. Soluble protein extracts were made from MsrA-/- and WT brain tissue of 12-
month-old mice after four months of restricted feeding (CR diet) and from age-matched mice 
maintained with no feeding restrictions (AL diet). Equal protein amounts from each brain extract 
were separated by gel-electrophoresis followed by western blot analysis using the primary anti-
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MetO antibodies or anti-tyrosine hydroxylase (TH) antibodies, as previously described (D. B. 
Oien, Canello et al., 2009). A) Representative gel showing an unidentified protein with a mass 
of ~15kDa (mass estimated by the separation of prestained molecular mass markers; data not 
shown). TH is shown as a loading control. B) Average density of the 15 kDa protein. Density 
was determined by using the densitometry ImageJ (NIH). Error bars represent standard 
deviation of three brains per group. *P<0.05 for the effect from diet and †P<0.05 for the effect of 
genotype on the AL diet, student’s t-test.     
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  4. Discussion 
The MsrA-/- mice are hypersensitive to oxidative stress and exhibit accelerated age-related 
pathologies (Moskovitz & Oien, 2009; D. B. Oien & Moskovitz, 2008; Pal, Oien, Ersen, & 
Moskovitz, 2007b). We have previously reported that the MsrA-/- mice exhibit decreased 
locomotor activity and abnormal DA levels in the brain tissue. Here, it is demonstrated that 
reduced availability of food can alleviate abnormal locomotor activity and DA levels in the brain 
of MsrA-/- mice. However, there is a lack of solid evidence for mechanisms involved in alteration 
of MetO content and DA signaling via Met oxidation. Thus, it is still difficult to predict if a 
decrease in reactive oxygen species or compensatory response prompted by the CR diet, or 
both, are responsible for the observed changes. 
 The reduced availability of food and corresponding loss of body weight has been shown to 
correspond to a reduction of oxidative stress and reactive oxygen species (Martin et al., 2007).  
In this study, the mice had reduced access to the same food that was given when fed on an AL 
diet. No differences in the feeding habits of MsrA-/- and WT mice were observed, and this is 
further supported by a previous report demonstrating that the weights of MsrA-/- and WT mice 
are not different on an AL diet (Moskovitz et al., 2001). In addition, there is not a difference of 
body weight between these mice with age (Moskovitz et al., 2001). Furthermore, a 20% 
reduction in body weight has been shown to improve DA receptor signaling in rodents (Carr et 
al., 2003). The MsrA-/- mice have been previously reported to exhibit decreased locomotor 
activity and abnormal DA levels in the brain tissue relative to WT mice (D. B. Oien & Moskovitz, 
2008). In this study, it is shown that MsrA-/- mice after nine months of caloric restriction do not 
significantly differ from the WT mice (Fig. 1). This supports the idea that the reduced energy 
intake decreases the activity of ROS, whereas normally fed MsrA-/- mice are hypersensitive to 
oxidative stress (Moskovitz et al., 2001; Pal et al., 2007b). However, MsrA-/- mice were 
significantly more active than the WT mice before the end of the experiment (Fig. 1). This latter 
finding supports the concept that the food restriction had an effect by reducing MetO-mediated 
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cellular changes while increasing the function of already up-regulated genes in MsrA-/- brain (D. 
Oien, Wang et al., 2008); alternatively, this could also be by activating specific compensatory 
mechanisms yet to be discovered. Regarding DA levels, it has been determined in this study 
(Fig. 2) that CR significantly alleviated the differences in DA levels observed between the MsrA-/- 
and WT mice when fed AL (D. B. Oien & Moskovitz, 2008). Thus, it may be that this is a result 
reflects the hypothesis above, which suggests the CR effects on cellular metabolism are linked 
to Met oxidation via the absence of MsrA. It is important to note that in contrast to the elevated 
DA levels in 16-month-old WT mice fed on an AL diet, the WT mice fed on a CR diet at 17 
months of age had a decreased concentration of DA in their brain tissue (Table 1). If indeed 
higher DA levels represent a response to elevated oxidative stress conditions, the latter 
decrease in DA levels in the WT brain may reflect lower oxidative stress conditions in older WT 
mice on food restriction. 
 The efficacy of CR diet in reducing the accumulations of MetO in specific brain proteins is 
evident from the data presented in Fig. 3, showing an example of one protein in which its MetO 
moiety can be reduced by the diet. Other tissues can be analyzed for the presence and 
reduction of MetO under AL diet versus CR diet using the anti-MetO antibodies; the positive 
effect of CR in lowering methionine sulfoxide content is probably not limited to brain. The data in 
Fig. 3 suggest that up-regulation of antioxidants during the course of the CR diet is a valid 
possible explanation for the prevention of brain abnormalities associated with oxidative stress in 
general, and Met oxidation in particular. 
 Oxidative stress and Met oxidation have been implicated in neurodegenerative movement 
disorders such as Parkinson’s disease (Choi et al., 2006; Dong et al., 2003; Moskovitz & Oien, 
2009). In Parkinson’s disease, the DA-mediated movement pathways are disrupted. Dietary 
restriction has been shown to improve the behavioral outcome and reduce neurodegeneration 
of the MPTP rodent model of this disease (Duan & Mattson, 1999). Furthermore, the addition of 
MsrA has been shown to prevent Parkinson’s disease-like symptoms in Drosophila when alpha-
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synuclein is expressed (Wassef et al., 2007). Alpha-synuclein, a protein that binds to DA and is 
associated with the pathogenesis of Parkinson’s disease, is a substrate for Msr (D. B. Oien & 
Moskovitz, 2008; D. B. Oien, Shinogle, Moore, & Moskovitz, 2009b). Despite a growing body of 
evidence, the association between Met oxidation, DA, and alpha-synuclein in movement 
disorders is still not clear. However, it is a plausible hypothesis that ROS are causing 
modifications to Met residues of proteins, including or excluding alpha-synuclein, involved in DA 
signaling (D. B. Oien & Moskovitz, 2008).   
 In summary, we suggest that CR reduces oxidative stress effects, including Met oxidation.  
Furthermore, our studies support the concept that Met oxidation alters protein function, which 
may contribute to neurological diseases associated with oxidative stress and aging.   
 
 D. Reserve Pool DA Mobilization in Msr Null Mice  
(Ortiz, Oien, Moskovitz, & Johnson, Manuscript) 
Abnormal DA regulation has been associated with multiple neurodegenerative disease states. 
Nevertheless, the role of DA reserve pool storage and mobilization in many of these pathologies 
has not been fully investigated. MsrA-/- mice suffer from increased oxidative stress and have 
previously been found to have chronically elevated brain DA content levels relative to control 
mice. Additionally, these high levels parallel increased presynaptic DA release. In this work, 
FSCV at carbon-fiber microelectrodes was used to provide evidence that the DA reserve pool is 
enhanced in the striatum and that this increase correlates with increased DA levels in knockout 
mice. Amphetamine-induced DA efflux was measured in brain slices from knockout and WT 
mice in the presence of α-methyl-p-tyrosine, a DA synthesis inhibitor. Additionally, the 
stimulated release of reserve pool DA, mobilized by cocaine, was measured. Both efflux and 
stimulated release measurements where enhanced in slices from knockout mice suggesting that 
these mice have greater reserve pool DA stores than WT and that these stores are effectively 
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mobilized. Moreover, differences in release were likely not caused by altered calcium response 
or a difference in the levels of DAT protein molecules.   
 
  1. Introduction 
The abnormal regulation of DA has been associated with multiple neurodegenerative disease 
states (Bird & Iversen, 1974; Morgan, May, & Finch, 1987), yet the role of DA reserve pool 
storage and mobilization in the pathophysiology is now just being revealed. For example, 
previous studies have shown that in Huntington’s disease (HD) model R6/2 mice stimulated DA 
release is impaired and the number of DA reserve pool vesicles is diminished (Ortiz, Kurth, 
Osterhaus, & Johnson, 2010). Basal levels of striatal DA in this mouse model are 40% less than 
respective control mice (Johnson, Rajan, Miller, & Wightman, 2006). Theoretically, the overall 
amount of DA within presynaptic terminals may be dependent upon the overall number of 
vesicles.  
A key trigger for exocytosis is calcium (Nachshen & Sanchez-Armass, 1987) and 
presynaptic DA release is dependent on available calcium (Kume-Kick & Rice, 1998). The 
movement between neurotransmitter release-ready vesicle pools and reserve pools is also 
thought to require calcium (Rose et al., 2002). In addition, plasma membrane calcium ATPase 
modulates calcium levels associated with neurotransmitter release (Palacios, Sepulveda, Lee, & 
Mata, 2004). In aging tissues, the activity of the calmodulin, a calcium regulatory protein, 
decreases when acting on the plasma membrane calcium ATPase (Michaelis et al., 1996). The 
oxidation of specific Met in calmodulin results in about a 50% reduction of plasma membrane 
calcium ATPase activation (Bartlett et al., 2003). Oxidized calmodulin can accumulate in brain 
tissues as a result of low antioxidant levels and it is speculated that oxidation of Met on 
calmodulin may be acting as a molecular switch in calcium regulation and oxidative stress 
(Bigelow & Squier, 2005). Furthermore, oxidants can modulate synaptic DA release and this 
regulation is dependent on the available calcium (Chen, Avshalumov, & Rice, 2001). In contrast, 
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Met oxidation of calcium/calmoduilin kinase II can cause calcium-independent activation of 
calcium channels (Erickson et al., 2008). Moreover, neuronal activity and blocking calcium 
channels can regulate DAT function via calcium/calmoduilin kinase II signaling (Padmanabhan 
& Prasad, 2009). 
Here, we used FSCV at carbon-fiber microelectrodes to study the mobilization and efflux of 
reserve pool DA in striatal brain slices from MsrA-/- mice and WT control mice. In order to 
measure reserve pool DA, brain slices were treated with alpha-methyl-p-tyrosine (aMPT), a DA 
synthesis inhibitor, and then with amphetamine (AMPH), which induces DA efflux. To measure 
exocytotic DA release from mobilized reserve pool vesicles, slices were treated with aMPT and 
then cocaine (COC), which mobilizes reserve pool vesicles. Stimulated DA release was then 
measured. There were no differences in DAT levels and calcium regulation, suggesting that DA 
in reserve pool vesicles accumulate in the MsrA-/- striatum.    
 
  2. Materials and Methods 
Animals  
The MsrA-/- and WT control mice have been described previously (Moskovitz et al., 2001). All 
mice used in these experiments were fed ad libitum, housed with 12 h of light per day, and 
caged individually. All procedures and conditions of live mice, including euthanasia, were 
approved by the University of Kansas Institutional Animal Care and Use Committee.   
 
Brain Slice Preparation  
Brain slices of 12-week-old MsrA-/- mice and age-matched WT mice were prepared as 
previously described (Johnson et al., 2006). Mice were anesthetized by isoflurane inhalation 
and then decapitated. The brain was immediately removed and placed in ice cold artificial 
cerebrospinal fluid (aCSF) consisting of (mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, CaCl2 2.4, 
MgCl2 1.2, NaHCO3 25, HEPES 20, and D-Glucose 11. Using 1 M HCl, the pH of the aCSF was 
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adjusted to 7.4. The cerebellum was removed from the brain using a razor blade and the brain 
was then mounted on an aluminum block. A vibratome slicer (Leica, Wetzlar, Germany) was 
used to make 300 µm thick coronal slices. Each brain slice was equilibrated in the superfusion 
chamber which was maintained at 34°C, through which aCSF flowed at a continuous rate of 2 
mL/min, prior to obtaining measurements. 
 
DA Release in Brain Slices  
Caron-fiber microelectrodes were fabricated using a single 7 µm diameter carbon-fiber 
(Goodfellow Cambridge Ltd, Huntingdon, U.K.) that was aspirated through a glass capillary tube 
(1.2 mm outer diameter, 0.68 mm inner diameter, 20 mm long, A-M Systems, Inc. Carlsborg, 
WA), and was pulled using a heated coil puller (Narishige International USA, Inc., East Meadow, 
NY) (Kraft, Osterhaus, Ortiz, Garris, & Johnson, 2009). The carbon-fiber was trimmed to about 
25 µM and further insulated using with epoxy resin (EPON resin 815C, EPIKURE 3234 curing 
agent, Miller-Stephenson, Danbury, CT, USA), and then cured at 100°C for 1 h. The electrodes 
were backfilled with 0.5 M potassium acetate to provide an electrical connection between the 
carbon fiber and an inserted silver wire. 
A triangular waveform was applied to the carbon-fiber electrode starting at -0.4 V, increasing 
to +1.0 V, and then back down to -0.4 V. A scan rate of 300 V/s and an update rate of 60 V/s 
were used. A headstage amplifier (UNC Chemistry Department Electronics Design Facility, 
Chapel Hill, NC) was interfaced with a computer via a breakout box and custom software 
provided by R.M. Wightman and M.L.A.V. Heien (University of North Carolina, Chapel Hill). A 
Ag/AgCl reference electrode consisted of a choridated silver wire. The carbon fiber 
microelectrode was inserted 100 µm into the dorsolateral caudate-putamen region of the 
striatum between the prongs of a bipolar stimulation electrode (Plastics One, Roanoke, VA), 
which was separated by a distance of 200 µm. A single pulse at 60 Hz was applied to the brain 
slice and the current was then measured at the peak oxidation potential for DA (about +0.6 V 
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versus Ag/AgCl reference electrode). Working electrodes were calibrated with DA standards of 
known concentration in a flow cell before and after each use. The average of pre- and post-
calibration measurements was used as the calibration factor.   
After a location with stable DA release was found, 50 µM aMPT was added into the aCSF 
using a three-way valve. Stimulated DA release was measured every 5 min until the DA release 
diminished. Once the DA release was diminished 20 µM AMPH was added to the aCSF/aMPT 
solution. A 25 min long file was then collected using a scan rate of 300 V/s and an uptake rate 
of 5 V/s.   
In order to mobilize DA reserve pools, a similar study was done using aMPT and COC. The 
slice was perfused with of 50 µM aMPT and stimulated DA release was measured every 5 min 
until the DA release was diminished. Next, 20 µM COC was added to the slice and a single-
pulse stimulation was continuously applied every 5 min and the reserve pool DA was measured. 
 
Calcium sensitivity of DA release  
To measure changes in the sensitivity to calcium in MsrA-/- mice the slices were treated with 
aCSF that contained 0 mM calcium. Once the DA release was diminished, the brain slices were 
treated with aCSF containing 0.6, 1.2, 1.8, and 2.4 mM calcium. Each concentration was 




MsrA-/- and WT brains were dissected from post-mortem mice. Each cerebrum was placed in a 
glass tube and homogenized with Teflon in 50 mM HEPES buffer pH 7.4 plus protease 
inhibitors (Roche) at 4°C. Homogenized extract was centrifuged for 20 min to separate the 
membrane fraction. Buffer containing 50 mM HEPES, 0.62% CHAPS, and 150 mM NaCl was 
added to each membrane fraction and agitated for 30 min. Each fraction was centrifuged for 20 
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min. Protein concentration of the supernatant was determined by BCA Protein Assay Kit 
(Pierce). Equal protein amounts (20 µg) of each soluble membrane fraction was loaded into a 
HEPES 4-20% Protein Gel (Pierce) and submitted to electrophoresis. Proteins were transferred 
to a nitrocellulose membrane and blocked overnight in 5% dry milk in buffer. Protein was 
detected using rabbit anti-DAT antibody (1:1000; Chemicon). Primary antibodies were detected 
by horseradish peroxide-conjugated goat-anti-rabbit secondary antibodies (1:2000; Bio-Rad). 
Protein bands were visualized by chemiluminescent substrate and exposure to autoradiography 
film. Densitometry analysis was done using ImageJ software (NIH). 
 
Statistical Analyses   
Data were analyzed by ANOVA or students t-test. All numerical values are represented as 
mean ± SEM.   
 
  3. Results 
Reserve Pool DA Levels 
 
It has been previously demonstrated that, in MsrA-/- mice, stimulated DA release evoked by a 
single-pulse electrical stimulation is significantly higher than WT controls (D. B. Oien, Osterhaus 
et al., 2008). To determine if reserve pool DA is similarly more abundant in 12-month-old MsrA-/- 
mice, striatal brain slices were subjected to treatment with aMPT and AMPH induced efflux was 
measured. Each slice was treated with 50 µM aMPT to inhibit tyrosine hydroxylase, the rate 
limiting enzyme in DA synthesis. A stimulus pulse was then applied to the slice every 5 min until 
the DA release was diminished. At this point, DA remaining in terminals consisted of reserve 
pool DA. The slices were then exposed to 20 µM AMPH, a competitive DAT inhibitor that 
causes DA efflux from vesicles inside the pre-synaptic terminals. AMPH enters the pre-synaptic 
terminals in one of two ways: either by lipophilic diffusion through membranes or by passage 
through DAT protein molecules (Fischer & Cho, 1979; Liang & Rutledge, 1982). AMPH also 
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displaces vesicular DA into the cytoplasm where it can be released by reverse transport caused 
when AMPH enters through the DAT causing allosteric translocation of the transporters (Chiueh 
& Moore, 1975; Jones, Gainetdinov, Wightman, & Caron, 1998b). The AMPH induced efflux of 
DA was measured over the course of 25 min and the amplitude of the DA peak ([DA]AMPH) was 
used to determine the amount of DA released (Fig.1a). In 12-month-old MsrA-/- mice there was a 
significant increase in the amount of AMPH-induced DA efflux after treatment with aMPT (Fig. 
1b; P = 0.022; MsrA-/-, 7.02 ± 1.42 µM, n = 5 mice; WT, 5.63 ± 0.33 µM, n = 4).   
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Figure 1. AMPH induced DA efflux is increased in 12-month-old MsrA-/- mice in comparion 
with age-matched WT mice. A) Representative data from 12-month-old WT mice. The brain 
slice was exposed to 50 µM aMPT while applying a single stimulus pulse every 5 min until the 
DA release diminished. The slice was then exposed to 20 µM AMPH for 25 min, and [DA]AMPH 
was measured. A CV is provided from the time of peak release, and confirms the release of DA. 
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B) In 12-month-old MsrA-/-, [DA]AMPH is significantly higher than in WT mice ( *P = 0.022; MsrA
-/-, 
7.02 ± 1.42 µM, n = 5 mice; WT, 5.63 ± 0.33 µM, n = 4).   
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Mobilization of Reserve Pool DA 
To determine if the DA reserve pools mobilize differently in 12-month-old MsrA-/- mice compared 
to age-matched WT mice, aMPT and COC was used. COC has previously been shown to 
mobilize reserve pool DA (Venton et al., 2006). Using a single electrical stimulus pulse, DA 
release was measured using FSCV (Fig. 2a). Once the DA release was constant, 50 µM aMPT 
was added to the brain slice in order to stop DA synthesis and the slice was continuously 
stimulated every 5 min. After the DA release was diminished, 20 µM COC was added into the 
aMPT/aCSF solution and the slice continued to be stimulated every 5 min. This caused the DA 
release to reappear for a longer amount of time in the MsrA-/- mice then in the WT mice (Fig. 
2b). The WT slices were treated for a shorter amount of time (90 min) after the addition of COC 
compared to MsrA-/- mice (120 min; Fig. 2b), but there was not a significant difference in the 






Figure 2. The mobilization of reserve pools lasts for a longer duration of time in MsrA-/- 
mice in comparion with WT mice. Slices from 12-month-old MsrA-/- and WT mice were 
exposed to 50 µM aMPT while applying a single-pulse stimulus every 5 min. Once the DA 
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release disappeared, 20 µM COC was added to the slice and the application of a single-pulse 
stimulation continued to be applied every 5 min to the brain slice. A) Representative data from 
MsrA-/- and WT slices. The addition of COC after pretreatment with aMPT resulted in an 
increase in stimulated DA release.  Stimulated plots taken immediately after the addition of 
aMPT, during the time that DA release was diminished have been omitted for clarity. B) Pooled 
data from MsrA-/- and WT mice after the addition of COC. Each data point represents the 
average value (± SEM) of [DA]stim obtained from 5 MsrA-/- mice and 6 WT mice. 
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DAT Protein Levels 
 
The DAT is a transmembrane protein that moves DA from the synaptic cleft into the presynaptic 
neuron. It is also well known to interact with COC and AMPH. In membrane fractions of MsrA-/- 
and WT mice, no difference in DAT protein levels was detected (Fig. 3). These data are 
consistent with a previous report that showed synaptic DA clearance was similar between MsrA-





Figure 3. DAT protein levels are unchanged in MsrA-/- mice. MsrA-/- and WT cerebral 
membrane fractions were solubilized and equal amounts of protein were separated by gel 
electrophoresis. A) Protein bands detected by anti-DAT antibodies indicate similar amounts of 
the protein at about 70 kDa. B) Densitometry of protein bands shown as an average density 




Extracellular Calcium Sensitivity 
Calcium levels are associated with the movement of vesicles between storage pools (Rose et 
al., 2002), change the ability of oxidants to modulate synaptic DA release (Chen et al., 2001), 
and can interfere with DA release measurements by FSCV (Jones, Mickelson, Collins, 
Kawagoe, & Wightman, 1994). In order to evaluate whether calcium-dependent release was 
altered in 12-month-old MsrA-/- mice, brain slices were treated with various concentrations of 
extracellular calcium and the stimulated DA release was measured (Fig. 4). DA release was 
normalized to the peak DA release at 2.4 mM calcium. DA release was not detected in the 
absence of calcium. At all calcium concentrations used there was not a significant difference in 
DA release between the MsrA-/- and WT mice (Fig. 4; P > 0.05; MsrA-/-, n = 4 mice, WT, n = 6 




Figure 4. Calcium-dependent release was unchanged in 12-month-old MsrA-/- mice in 
comparion with age-matched WT mice. Brain slices were treated with 0, 0.6, 1.8, and 2.4 mM 
concentrations of extracellular calcium and the stimulated DA release was measured for 15 min 
at each concentration. DA release was normalized to the peak DA release at 2.4 mM calcium. 
At 0 mM calcium no DA release was detected. At all calcium concentrations used there was not 
a significant difference in DA release between the MsrA-/- and WT mice (P > 0.05; MsrA-/-, n = 4 
mice, WT, n = 6 mice).  
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  4. Discussion 
Previous studies using MsrA-/- have shown that DA release evoked using a single-pulse 
stimulation is increased (D. B. Oien, Osterhaus et al., 2008). This is in contrast to 12-week-old 
R6/2 mice where the stimulated release was inhibited, as was the amount of vesicles in the 
reserve pool (Ortiz et al., 2010). In this study, differences in DA reserve pool storage and 
mobilization in striatal brain slices from MsrA-/- mice were examined. AMPH-induced DA efflux 
was increased in 12-month-old MsrA-/- brain slices after treatment with aMPT compared to age-
matched WT mice. Furthermore our data suggest that a greater amount of DA reserve pool 
vesicles were mobilized after COC treatment in MsrA-/- mice compare to WT controls. Thus, a 
greater number of reserve pool vesicles are present in the MsrA-/- striatum and it is possible to 
make a correlation between the amount of RRP DA and the reserve pool DA. Enhanced DA 
release likely did not arise either from altered sensitivity to extracellular calcium or from a 
change in the number of DAT protein molecules. 
Experiments were aimed at determining if alterations in either DAT or calcium regulation 
preferentially enhance release in MsrA-/- mice. A previous report suggested that the efficiency of 
DA reuptake by DAT is similar in MsrA-/- and WT mice (D. B. Oien, Osterhaus et al., 2008). The 
data used to support this conclusion was based on similar FSCV measurements after in vitro 
stimulation. Furthermore, here we show that DAT protein levels are similar in MsrA-/- and WT 
mice (Fig. 3).  This result further supports the concept that DAT function and protein levels are 
not altered in the absence of MsrA. Therefore, we predict that COC and AMPH effects on the 
DAT would be similar in both mice genotypes.  
Calcium modulation can affect oxidant regulation of DA release (Chen et al., 2001) and 
movement between RRP and reserve pools (Rose et al., 2002). The release of DA during 
synaptic transmission is mediated by calcium-dependent fusion with the active zone (Kavalali, 
2006). An increase in the intrasynaptic calcium levels causes the vesicles to fuse to the active 
site, where DA is released and then the vesicles collapse onto the plasma membrane (Heuser 
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and Reese, 1973; Cremona and De Camilli, 1997). Furthermore, Met oxidation of calcium 
regulatory proteins, such as calmodulin (Michaelis et al., 1996) and calcium/calmodulin kinase II 
(Erickson et al., 2008), would suggest that this is associated with the increase of DA reserve 
pools in the MsrA-/- mice (Figs. 1 & 2). By changing the extracellular calcium concentrations, the 
lack of significant differences between MsrA-/- and WT mice suggests that calcium regulatory 
proteins in both mice are functioning in a similar manner (Fig. 4). Furthermore, the similarity of 
measurements between both mouse types is important for the integrity of FSCV measurements 
of DA release (Jones et al., 1994; Kume-Kick & Rice, 1998) and the normal functioning of DAT. 
The DAT function and abundance is dependent on calcium and calcium/calmodulin kinase II 
(Padmanabhan & Prasad, 2009). Also, the AMPH-induced efflux of DA through the DAT is 
associated with calcium levels and calcium/calmodulin kinase II activity (Kantor, Zhang, 
Guptaroy, Park, & Gnegy, 2004). Overall, the lack of changes in MsrA-/- DAT (Fig. 3 & Oien et 
al., 2008b) and calcium regulation (Fig. 4) support our DA reserve pool studies (Figs. 1 & 2), 
and further narrow down the possibilities of an underlying mechanism for DA associated 
abnormalities in MsrA-/- mice. 
The DA reserve pools were examined using various pharmacological agents. Treating the 
brain slices with aMPT coupled with electrical stimulation depletes the DA in the RRP vesicles, 
and DA in the extracellular space will be packaged and also released, leaving only DA in the 
reserve pool vesicles (Ortiz et al., 2010). Upon the addition of AMPH, the DAT is reversed and 
the DA in the reverse pool vesicles is leaked out and we are able to measure the DA efflux. We 
found that 12-month-old MsrA-/- mice have an increased AMPH induced DA efflux after 
treatment with aMPT, indicating that MsrA-/- mice have an increased supply of reserve pool 
dopamine. This increase parallels both the enhancement of stimulated DA release and the 
increase in striatal DA content found previously in MsrA-/- mice (D. B. Oien, Osterhaus et al., 
2008).  
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COC was also used to mobilize the reserve pool DA. COC is commonly known to block the 
DAT and inhibit DA uptake. By treating the slices with aMPT and COC the differences in DA 
release in the MsrA-/- and WT mice would arise from differences in the number of reserve pool 
vesicles. The peak DA release evoked by single-pulse stimulation after treatment with aMPT 
and COC is the same between the MsrA-/- and WT mice, implying that there are the same 
number of DA molecules contained in each mobilized reserve pool vesicle. Additionally, 
because the peak DA release is attained earlier in WT mice than in MsrA-/- mice, impaired 
mobilization of reserve pool vesicles in the MsrA-/- cannot be ruled out. 
One potential cause of increased stimulated DA release found previously in MsrA-/- mice is a 
mechanism by which enhanced reserve pool DA levels result incease the number of vesicles 
available for stimulated DA release. Vesicles containing DA are thought to be in one of three 
distinct vesicle pools: the RRP, the recycling pool, and the reserve pool. On average, within 
presynaptic terminals, the RRP consists of 1-2% of the total vesicles. In contrast, the reserve 
pool makes up about 80 to 90% of vesicles (Neves & Lagnado, 1999; Zucker & Regehr, 2002). 
Thus, the large amount of reserve pool DA vesicles could be transferred into the RRP, which 
then undergoes exocytosis upon application of a mild electrical stimulus pulse applied by our 
electrochemical system. This mild pulse is intended to simulate the occurrence of a natural 
action potential; therefore, this increase in reserve pool vesicles likely enhances naturally 
occurring DA release events in MsrA-/- mice.   
The mechanism of the chronically increased DA levels in MsrA-/- mice is still unknown. The 
abnormally high brain DA in MsrA-/- mice can be alleviated by caloric restriction (D. B. Oien et 
al., 2010), suggesting metabolism and oxidative stress related mechanisms are involved in this 
phenomenon. Previous studies suggest an increase of the tyrosine hydroxylase activating 
protein 14-3-3zeta mRNA (D. Oien, Wang et al., 2008) and protein (D. B. Oien, Osterhaus et al., 
2008) may be associated with the increased levels of DA by enhanced DA synthesis. In 
addition, we have recently reported that Met oxidation of the dopamine D2 receptor may 
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participate in DA signaling in MsrA-/- mice (Derek B. Oien et al., In Press-b), which may include 
the presynaptic D2 autoreceptor isoform. Another possible explanation for this abnormal DA 
regulation is increased methionine sulfoxide levels in alpha-synuclein that may interfere with its 
interaction with DA (D. B. Oien & Moskovitz, 2008; D. B. Oien, Shinogle, Moore, & Moskovitz, 
2009a; Outeiro et al., 2009). This theory is further supported by defective mobilization of DA 
from reserve pools in alpha-synuclein knockout mice and A30P mutated alpha-synuclein 
transgenic mice (Yavich et al., 2005; Yavich, Tanila, Vepsalainen, & Jakala, 2004). 
In summary, the increased AMPH induced efflux in MsrA-/- mice after treatment with aMPT in 
12-month-old mice, versus age-matched WT mice, indicates that MsrA-/- mice have more striatal 
reserve pool DA. The stimulated release of reserve pool DA, mobilized by treatment with COC, 
was longer lasting in MsrA-/- slices compared to WT slices, indicating that MsrA-/- mice have a 
greater number of DA reserve pool vesicles. Thus, this study identifies MsrA-/- mice as a model 
of neurodegeneration in which the DA system is overactive.  
 
 E. D2DR Function is Compromised in the Brain of the MsrA Knockout Mouse  
(DB Oien et al., In Press-a) 
Previous research suggests that brain oxidative stress and altered rodent locomotor behavior 
are linked. We observed bio-behavioral changes in MsrA-/- mice associated with abnormal DA 
signaling. Compromised ability of these knockout mice to reduce MetO enhances accumulation 
of sulfoxides in proteins. We examined the D2DR function and expression, which has an 
atypical arrangement and quantity of Met residues. Indeed, protein expression levels of D2DR 
were higher in knockout mice compared with WT. However, the binding of D2DR agonist was 
compromised in the same fractions of knockout mice. Coupling efficiency of D2DR to G-proteins 
was also significantly reduced in knockout mice, supporting the compromised agonist binding. 
Furthermore, presynaptic DA release in knockout striatal sections was less responsive than 
control sections to D2DR ligands. Behaviorally, the locomotor activity of knockout mice was less 
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responsive to the inhibitory effect of quinpirole than WT mice. Involvement of specific Met 
residue oxidation in the D2DR third intracellular loop is suggested by in vitro studies. We 
conclude that ablation of Msr can affect DA signaling through altering D2DR physiology and 
may be related to symptoms associated with neurological disorders and diseases.  
 
  1. Introduction 
The MsrA-/- mouse exhibits age-dependent lower locomotor activity and abnormal gait indices 
(D. B. Oien, Osterhaus et al., 2008) relative to control mice. Lower DA levels are associated 
with altered motor performance (Carlsson, Bjorklund, & Kirik, 2007). Surprisingly, our recent 
observations showed that MsrA-/- brains in adult mice contained significantly higher levels of DA 
(D. B. Oien, Osterhaus et al., 2008). Moreover, presynaptic neuronal DA in MsrA-/- striatal slices 
is released at higher DA pulses than WT slices as measured by FSCV. These results raise the 
possibility that DA function is impaired in MsrA-/- mice. Moreover, MsrA-/- mice were less 
responsive to amphetamine treatment as assayed by locomotor activity and stereotypy, 
suggesting alteration of DA signaling. Dysfunctions of the corpus striatum and dopaminergic 
signaling are linked to a range of disorders including Parkinson’s disease (Hornykiewicz, 1962), 
Huntington’s disease (Hickey, Reynolds, & Morton, 2002), schizophrenia, and obsessive-
compulsive disorder (Saxena, Brody, Schwartz, & Baxter, 1998). 
The observed MsrA-/- locomotor deficits and DA abnormalities prompted us to further 
examine DA signaling events that are associated with striatal movement pathways. The 
dopamine D1 receptor (D1DR) and D2DR are closely associated with movement regulation, and 
theoretically are the DA receptors most related to the MsrA-/- locomotor phenotypes (D. B. Oien, 
Osterhaus et al., 2008). Additionally, D2DR is also expressed in its short form (D2DRS) that 
serves as an autoreceptor for dopaminergic neurons. Thus, Met oxidation in either the long form 
of D2DR or D2DRS or a combination of both may be related to the elevation in DA levels 
observed in MsrA-/- brains (D. B. Oien, Osterhaus et al., 2008). In the current study we 
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investigate the ligand-binding capabilities of DA receptors and their coupling efficiency to G-
proteins in MsrA-/- versus WT mice. The presented data support the hypothesis that MetO 
modification to D2DRs participates in the MsrA-/- behavioral and biochemical phenotypes.  
 
  2. Materials and Methods 
Materials 
The radioligands [3H]SCH23390 (85 Ci/mmol), [3H]raclopride (84 Ci/mmol), [3H]quinpirole (50 
Ci/mmol), were purchased from Perkin Elmer. Non-radioactive sulpiride, quinpirole, SKF82958, 
and GTPγS were purchased from Sigma. Mouse and goat antibodies against D2DR were 
purchased from Abcam. Mouse β-actin antibodies were purchased from Molecular Probes.  
 
Mice 
 Mice used in these studies were WT (C57BL6/129 Sv) and MsrA-/- on the same genetic 
background at an age of 6-8 months unless otherwise noted. Both types of mice were 
littermates born to MsrA+/- heterozygous parents (Moskovitz et al 2001). All procedures using 




Coronal brain sections from 12-month-old WT and MsrA-/- mice were processed as 20 µm-thick 
brain sections. Sections were treated with 3% H2O2 in methanol for 30 min. After blocking with 
1% bovine serum albumin and 3% horse serum in PBS, the sections were incubated for 24 h 
with primary goat antibodies against D2DR (1:500 dilution, stock concentration of 1.5 mg/mL). 
Sections were then incubated with biotinylated mouse anti-goat IgG antibodies (Santa Cruz 
Biotechnology), avidin–horseradish peroxide solution, 0.015% diaminobenzidine, 0.001% H2O2, 
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and finally counterstained with hematoxylin. The brain slides were washed, dehydrated, 
mounted, and visualized using a brightfield microscope with a 100X objective lens.  
 
Immunoblot analysis 
Equal amounts of striatal membranal protein extracts or cytosolic brain proteins (extracted as 
described below for receptors fraction) were subjected to SDS-gel electrophoresis. Immunoblot 
analyses with anti-goat D2DR antibodies (1:1000 dilution, stock concentration of 1.5 mg/mL) 
were performed according to common procedures. β-actin (loading control) was detected by 
primary anti-β-actin mouse antibodies. 
 
Antagonists and agonists binding of D1DR and D2DR ligands 
Saturation curves of receptor binding were determined by using the common membrane 
filtration assay (Bylund & Toews, 1993). Briefly, brains (striatal region of each mouse type) were 
dissected and glass-Teflon homogenized in PBS with protease inhibitor cocktail (Roche). 
Following centrifugal precipitation at 20,000xg for 20 min, the supernatant was removed and 
saved (cytosolic fraction in immunoblots), and the membranal pellet was washed and 
precipitated again by centrifugation. Final pellet was homogenized in 1.0 mL of 50 mM Tris pH 
7.4. Membranal protein fractions of 100 µg were used per assay, determined by BCA Protein 
Assay Kit (Thermo Scientific). Total ligand binding was determined following incubation of 
membranal fractions with incrementing concentrations of radioligand for 2 h at room 
temperature. Non-specific ligand binding was determined using the same conditions with the 
addition of non-radioactive ligands, 1 mM DA for D1DR and 1 µM sulpiride for D2DR. Bound 
radioligand was separated using a Brandel harvester (Brandel). Radioligand bound to the filter 
was measured by liquid scintillation counting. Specific ligand binding values were calculated by 
subtracting non-specific ligand binding from total ligand binding. The ligands used in the tests 
were: [3H]SCH23390 and [3H]raclopride as D1DR and D2DR antagonists, respectively, and 
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[3H]quinpirole as a D2DR agonist. The range for radioactive materials used was between 0.03-
4.0 nM (increments by serial dilution).  
The effect of MsrA enzyme on quinpirole and raclopride binding was tested by using 
recombinant yeast MsrA (10 µg) (Moskovitz, Berlett, Poston, & Stadtman, 1997) with 15 mM 
dithiothreitol (DTT; this alone did not affect binding). D1DR binding to the agonist SKF82958 
was determined using the same conditions above, except for the addition of 2 nM 
[3H]SCH23390 to quantify the competitive binding of non-radiolabeled SKF82958 ligand 
(performed due to limited sources of commercially available radiolabeled D1DR agonists).   
 
GTPγS-induced inhibition of radiolabeled quinpirole binding to D2DR 
 The ability of agonists to stimulate the dissociation of GDP and association of GTP from G-
protein was assessed using GTPγS, a non-hydrolyzable analogue of GTP (Y. Zhang et al., 
2001). When the agonist binds to the receptor, GDP is released from the G-protein and GTPγS 
binds (Harrison & Traynor, 2003). The G-protein uncoupling on [3H]quinpirole binding to the 
D2DR was investigated by measuring the inhibition of [3H]quinpirole binding at incrementing 
GTPγS concentrations. The membrane portion of homogenized striatal regions were isolated 
and lysed in 5 mM Tris buffer by glass-Teflon homogenation. Membranal extracts (30 mg/mL; 
80 µg per assay) were incubated with [3H]quinpirole (1 nM) and GTPγS (0.1, 1, 10, 100, and 
1000 nM) in 50 mM Tris buffer for 2 h at room temperature in a total volume of 1 mL. To 
determine non-specific binding, identical assays were performed in the presence of sulpiride (1 
µM; racemic mixture). Unbound ligand was removed by Brandel filtration and the remaining 
bound ligand was quantified by liquid scintillation counting.  
 
Stimulated release of DA in striatal brain sections in the presence of quinpirole and sulpiride 
measured by FSCV 
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 Brain sections were prepared as previously described (Johnson et al., 2006). Mice were 
anesthetized by isoflurane inhalation. The brain was immediately removed and placed in ice 
cold artificial CSF. Artificial CSF consisted of 126 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 2.4 
mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3, 20 mM HEPES, and 11 mM D-Glucose at pH 7.4 
and was continuously saturated with 95% O2/5% CO2 throughout the experiment. Coronal 
sections of 300 µm in thickness were made using a vibratome slicer (Leica). A single section 
was placed in the superfusion chamber with artificial CSF flowing at 34°C and a continuous rate 
of 2 mL/min. Each brain section was equilibrated for 60 min prior to obtaining measurements. 
Quinpirole and sulpiride in artificial CSF were maintained in a separate reservoir and introduced 
through a three-way valve. 
Carbon-fiber microelectrodes were fabricated as previously described (Kraft et al., 2009). A 
single carbon-fiber with a 7 µm diameter (Goodfellow Cambridge Ltd.) was aspirated through a 
glass capillary tube (1.2 mm outer diameter, 0.68 mm inner diameter, 4 inches long, A-M 
Systems, Inc.) and pulled using a heated coil puller (Narishige International USA, Inc.). 
Electrodes were trimmed to 20 µm from the glass seal, further insulated with epoxy resin (EPON 
resin 815C, EPIKURE 3234 curing agent, Miller-Stephenson), and then cured at 100°C for 1 h. 
Prior to experimentation, electrodes were backfilled with 0.5 M potassium acetate.  
A triangular waveform starting at -0.4 V, increasing to +1.0 V, and scanning back to -0.4 V 
was applied at the carbon-fiber working electrode. A scan rate of 300 V/s was used with an 
update rate of 10 Hz. A head-stage amplifier (UNC Chemistry Department Electronics Design) 
was interfaced with a computer via breakout box and custom software provided by R.M. 
Wightman and M.L.A.V. Heien. A choridated silver wire was used as an Ag/AgCl reference 
electrode. The carbon fiber was inserted 100 µm into the dorsolateral caudate-putamen region 
of the striatum. The fiber was between the prongs of a bipolar stimulation electrode (Plastics 
One), which were separated by 200 µm. Current was measured at 0.6 V, which is the oxidation 
potential for DA. DA release was measured in the presence of either 1 µM quinpirole or 5 µM 
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sulpiride as previously described (Fawaz, Martel, Leo, & Trudeau, 2009) using a 30-pulse 
stimulus train at a stimulation frequency of 60 Hz. During stimulation and DA release, stabilized 
scans of 15 s were collected every 2 min and averaged as 4 min time blocks. 
 
Locomotor activity measured by force-plate actometer 
The force-plate actometer and methods of data analysis have been previously described 
(Fowler et al., 2001a). Briefly, the force-plate actometer consists of a low mass and highly stiff 5 
mm thick plate (28 cm X 28 cm). This plate is supported by four Sensotec Model 31 load cells 
(0-250 g range). Each force plate is positioned below a Plexiglas cage that confines the mouse 
to the force-sensing plate and is encased in sound-attenuating cubicle. Horizontal movements 
of the mouse were recorded along the sensing surface with a spatial resolution of 1 mm and a 
temporal resolution of 0.01 s.  
The duration of recording sessions was based upon preliminary experiments and relevant 
literature assessing spontaneous locomotor activity (Geter-Douglass, Katz, Alling, Acri, & 
Witkin, 1997; Usiello et al., 2000; Wang et al., 2000). The effects of the drugs used on 
locomotor activity were apparent within the initial period of 45 min following drug injection. Thus, 
45 min periods were determined to be sufficient to monitor the locomotor response to the 
performed treatments. Total distance traveled per animal was measured and analyzed by 2-way 
ANOVA (2 mouse types) with repeated measures on the time block and session factors.  
 
Administration of agonists of D1DR and D2DR for locomotor activity analyses  
Prior to treating the mice with D1DR or D2DR agonists, the WT and MsrA-/- mice received 
intraperitoneal injection with 0.9% saline as a vehicle control and spontaneous locomotor 
activity was monitored for 45 min using force-plate actometers. After 4 days, the same mice 
were injected with either quinpirole (D2DR agonist, 0.1 and 0.5 mg/kg) or SKF82958 (D1DR 
agonist, 0.3 and 1.0 mg/kg) and locomotor activity was monitored for 45 min. A minimum of 4 
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days between trials was used to minimize potential carryover effects. Different sets of animals 
were used for each drug to prevent cross-reactivity and carryover effects between drugs. The 
drugs were administered at volume of 5 mL/kg.  
 
MetO residues in recombinant long form of D2DR third intracellular loop 
The long form of rat D2DR third intracellular loop (D2DRL-IC3) was expressed as a GST fusion 
protein in bacteria (gift from Dr. Kim Neve, Oregon Health & Science University) and purified 
according to published procedures (Lan, Liu, Bell, Gurevich, & Neve, 2009). The protein was 
oxidized overnight with 200 mM H2O2 and excess oxidants were removed by catalase. In 
parallel, oxidized protein was reduced with recombinant poly-His-tagged yeast MsrA (10 µg) 
(Moskovitz et al., 1997) in the presence of 20 mM DTT for 1 h at 37°C (DTT alone does not 
reduce MetO residues under these conditions). After reduction, all proteins (non-treated, H2O2-
treated, and MsrA-reduced) were subjected to gel-electrophoresis followed by Commassie blue 
staining for the isolation of the corresponding GST-D2DRL-IC3. Bands corresponding to the 
predicted weight of ~54 kDa were excised and protein was isolated. The protein was subjected 
to tryptic digestion prior to analysis by a LCT Premier electrospray ionization tandem mass 
spectrometer (Waters Corp.). The mass spectrometry analyses of the peptides and their MetO 
content were performed according to previously published methods (L. Zhang et al., 2010). 
 
  3. Results 
Expression levels and ligand binding capabilities of D2DR in MsrA-/- striatum 
Post-mortem brain sections from MsrA-/- and WT mice were immunostained with anti-D2DR 
antibodies. The MsrA-/- striatal region exhibited higher reaction levels with the antibodies 
compared with this region in WT mice (Fig. 1A). D2DR expression levels were quantified by 
immunoblot analysis on brain extracts followed by densitometry analysis (Fig. 1B). Similar to the 
increase of DA in MsrA-/- brains (D. B. Oien, Osterhaus et al., 2008), the upregulation of the 
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D2DR may be part of compensatory response for the dysfunction of the DA system in the MsrA-
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Figure 1. Immunohistochemistry and immunoblot analyses of D2DR in MsrA-/- and WT 
striatum. A) Immunohistochemistry of coronal brain sections using primary antibodies against 
D2DR. Slides were visualized using light microscope with a 100X objective lens. Brownish 
structures correspond to the presence of D2DR. Scale bars represent 10 µm. B) Immunoblot 
analysis using primary antibodies against D2DR. Representative bands are shown in the small 
window followed by densitometry analysis for the corresponding D2DR band in each extract 
(relative density in WT represents 100%; P<0.01, t-test). The densities of D2DR were corrected 
for the relative densities of β-actin.  
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The binding of the D2DR to appropriate ligands can reflect their expression levels and 
function in signaling. Binding of the D2DR antagonists are independent of G-protein coupling 
and more reflective of D2DR expression levels. Binding of the D2DR agonists are dependent on 
G-protein coupling and more reflective of D2DR function in signaling. Accordingly, the 
calculated Bmax value of D2DR antagonist [3H]raclopride was higher in MsrA-/- membranal 
fractions (250 ±20 fmole/mg protein) compared with the value of WT (140 ±4 fmole/mg protein) 
(Fig. 2A). In addition, the Kd value for [3H]raclopride in both mouse types was similar (Kd of 0.70 
±0.10 nM), suggesting no difference in the binding affinity of the bound antagonists to D2DR (it 
is noteworthy that the Kd values in these mice are different than rats, see “Discussion”). The 
[3H]raclopride Bmax values also provide further supportive evidence to the observed elevated 
levels of the D2DR in MsrA-/- brain (Fig. 1). The calculated Bmax value of D2DR agonist 
[3H]quinpirole was lower in MsrA-/- membranal fractions (56 ±7 fmole/mg protein) when 
compared with the value of the WT (140 ±10 fmole/mg protein), while the Kd value for 
[3H]quinpirole binding was similar in both mouse types (0.40 ±0.05 nM) (Fig. 2A). These 
observations suggest that the coupling ability of the MsrA-/- D2DR to the respective G-proteins is 
compromised, in spite of the higher number of receptors in MsrA-/- mice (Fig. 1). Additionally, 
adding recombinant MsrA to the binding reaction mixture caused significant recovery of the 
MsrA-/- [3H]quinpirole Bmax value to the WT Bmax value (Fig. 2B). This latter result strengthens 
the hypothesis that lack of MsrA enhances MetO formation in D2DR, which affects D2DR 
function and expression. In contrast to relative D2DR agonist-to-antagonist Bmax differences 
between the two mouse types (Fig. 2A & 2B), no significant differences were found for D1DR 
ligand binding to the antagonist SCH23390 or agonist SKF82958 between these mouse types 
(Figs. 2C & 2D). At relatively high concentrations, [3H]SCH23390 was bound to MsrA-/- and WT 
striatal fractions to a similar extent (Fig. 2C). Similar results were found when SKF82958 was 
used (Fig. 2D). The SKF82958 ligand was not radiolabeled, thus binding efficiency was 
determined by its competitive binding in the presence of 2 nM [3H]SCH23390 as previously 
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described (Nwaneshiudu & Unterwald, 2009). The amounts of [3H]SCH23390 bound to the 
striatal fractions were significantly decreased (P<0.05) by the presence of 16 nM of SKF82958. 
This supports the hypothesis that MsrA ablation primarily impacts the D2DR.  
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Figure 2. Binding efficiency of ligands to D2DR and D1DR in MsrA-/- and WT membranes. 
Specific ligand binding was calculated from subtracting non-specific ligand binding from total 
ligand binding as described in “Materials and Methods”. A) Representative [3H]raclopride and 
[3H]quinpirole specific ligand binding curves of D2DR. B) Bmax of [3H]quinpirole binding 
presented as percent of WT Bmax value (represents 100% binding) in the absence (Control) 
and presence of recombinant yeast MsrA (rMsrA Added). C) Binding of [3H]SCH23390 at a 
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saturating concentration (Bmax value WT, under these conditions, represents 100% binding). 
(D) Relative binding of [3H]SCH23390 at a concentration of 2 nM (as in panel C) in the presence 
of 2 nM and 16 nM SKF82958 concentrations. For all graphs, n=3. Significance is denoted by * 
or † indicating P<0.05 using t-test for difference by mouse type or by condition, respectively.  
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G-protein coupling efficiency to D2DR in MsrA-/- striatum 
The non-hydrolyzable GTPγS analog will reduce the binding of  [3H]quinpirole to D2DR 
(quinpirole binds with lower affinity to uncoupled D2DR compared with coupled receptors). 
Consequently, competition curves were performed by inhibiting [3H]quinpirole binding with 
increasing concentrations of GTPγS. Accordingly, the maximal inhibition from the competition 
curve reflects the number of D2DR coupled to G-proteins, while the 50% binding inhibition 
concentration (IC50) from the curve reflects the potency of GTPγS to dissociate the D2DR and 
G-protein complex. The maximum binding of  [3H]quinpirole to D2DR in MsrA-/- was ~50% of the 
maximum binding of the agonist to the receptors in the WT brain (Fig. 3; WT = 50 ±6 and MsrA-/- 
= 26 ±3 fmole/mg protein in the presence of 1µM [3H]quinpirole). The IC50 was found to be 
similar for both mouse types (10 ±1 nM), which is in agreement with current literature (Y. Zhang 
et al., 2001). These data suggest reduced G-protein and D2DR coupling in the MsrA-/- brain. 
Moreover, the similar IC50 in both mouse types suggests that the dissociation rates of the 
receptors from the G-proteins are similar. The reduced interaction of G-proteins with D2DR in 
MsrA-/- brains could be a consequence of either lower G-protein expression or interference in 
the initial binding of G-proteins to the third intracellular loop of D2DR. There was no significant 
difference in expression of Gαi/o proteins between the two mouse types (Fig. S1), suggesting 
that the observed limitation in MsrA-/- D2DR agonist binding is probably not because of reduced 
Gαi/o levels. Since the expression levels of these G-proteins seem to be similar in the two 
mouse types (Fig. S1), data in Fig. 3 are supportive of compromised D2DR agonist binding in 
MsrA-/- brains (Fig. 2A) and also may reflect interference in binding of MsrA-/- G-proteins to the 





Figure S1. Gαi/o protein expression levels in MsrA
-/- and WT brains. A) Membranal and 
cytosolic protein extracts of the striatal region (25 µg each from 6 month-old-mice) were 
subjected to SDS gel-electrophoresis, followed by immunoblot using primary antibodies against 
Gαi/o (rabbit antibodies, 1:1000 dilution, stock concentration for both forms: 0.2 mg/mL; Santa 
Cruz Biotechnology) and secondary HRP-conjugated goat ant-rabbit antibodies (Bio-rad). B) 
The relative densities of the protein bands were determined by densitometry analysis using 
ImageJ (NIH). The same immunoblot was probed for the levels of β-actin that were used as 
loading controls. The densities of Gαi/o were corrected for the relative densities of β-actin. The 
relative densities of the Gαi/o in MsrA





Figure 3. Inhibition of D2DR agonist binding in striatal membrane extracts of MsrA-/- and 
WT mice in the presence of GTPγS. The Y axis values of the graph represent the specific 
binding percentage of [3H]quinpirole at GTPγS concentrations of 0.1, 1, 10, 100, and 1000 nM. 
The value at 100% specific binding represents maximum binding of WT D2DR to [3H]quinpirole 
at 0.1 nM GTPγS. The maximum binding values were not significantly different from values 
obtained in the absence of GTPγS; data not shown. n=3. 
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Presynaptic stimulated dopamine release of MsrA-/- striatal tissue sections in response to D2DR 
ligands   
A shorter form of the DRD2 receptor, D2DRS, serves as an autoreceptor on the presynaptic 
membrane of dopaminergic neurons. This receptor has a third intracellular loop that is truncated 
by 29 amino acids, but still retains four of the eight Met residues. D2DRS has been previously 
demonstrated to respond to the D2DR agonist quinpirole and D2DR antagonist sulpiride by 
decreasing and increasing the presynaptic release of DA, respectively (Fawaz et al., 2009). 
Using a similar experimental design as Fawaz et al., the presynaptic DA release in the striatal 
area from MsrA-/- and WT coronal sections was measured in the presence of quinpirole (Fig. 4A 
& 4B) and sulpiride (Fig. 4C & 4D). Presynaptic DA release was detected by FSCS every 2 min, 
initially without any treatment and followed by treatment with a saturating dose of quinpirole. In 
the presence of quinpirole, MsrA-/- sections were less responsive than WT sections when both 
were compared to the respective initial stimulation and detection without the presence of drug. 
The DA release of the MsrA-/- presynaptic neurons was significantly higher than the decreased 
release of the WT presynaptic neurons (P<0.05; two-way repeated measures ANOVA). 
Moreover, the MsrA-/- presynaptic neurons were also less responsive to sulpiride than WT. After 
sulpiride treatment, the changes in DA concentration from the initial non-treated measurement 
of MsrA-/- sections were significantly lower than the increased DA concentration changes of the 






Figure 4. DA release in striatal sections from MsrA-/- and WT mice treated with D2DR 
agonist and antagonist. Coronal sections were stimulated using a 30 pulse-stimulus train and 
DA scans were collected by fast scan cyclic voltammetry. A) A representative stimulated DA 
release plot generated from measurements in the presence and absence of quinpirole. WT, 
open squares; MsrA-/-, filled diamonds. B) The DA release measured in 4 min time blocks of WT 
and MsrA-/- sections in the presence of quinpirole. The basal initial measurements without drug 
treatment (time block 0) were set to 100%. All subsequent measurements with quinpirole are 
represented as a percentage of this value. C) A representative stimulated DA release plot 
generated from measurements obtained in the presence and absence of sulpiride. WT, open 
squares; MsrA-/-, filled diamonds. D) The DA release measured in 4 min time blocks of WT and 
MsrA-/- sections in the presence of sulpiride. The initial basal measurements without treatment 
(time block 0) were set to 100%. All subsequent measurements with sulpiride are represented 
as a percentage of the initial 100% values. For both experiments, n=3 and P<0.05 for genotype 
determined by two-way repeated measures ANOVA. The basal DA concentrations in the 
absence of drug were WT=1.63 ±0.44 µM and MsrA-/- =5.47 ±0.36 µM.  
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Locomotor activity of MsrA-/- mice after injections of dopamine receptor agonists  
The in vitro and brain section findings suggest functional changes in the DA system that should 
be expressed at the behavioral level. Consequently, we investigated the behavioral effects of 
D1DR and D2DR selective agonists on locomotor activity in MsrA-/- and WT mice. A significant 
difference in locomotor activity was observed between the mouse strains when injected with 
quinpirole. At a dose of 0.5 mg/kg, the MsrA-/- exhibited ~40% more locomotor activity than WT, 
and at a dose of 0.1 mg/kg the MsrA-/- exhibited ~35% more locomotor activity than WT (Fig. 5A; 
repeated measures ANOVA for mouse type effect, P<0.02). No significant difference in 
locomotor activity was observed between the two mouse types when injected with saline (Fig. 
5), which is consistent with previous experiments (D. B. Oien, Osterhaus et al., 2008). Given the 
higher expression level of the D2DR in MsrA-/- mice, these data suggest that the compromised 
responsiveness of the MsrA-/- D2DRs to the inhibitory effect of quinpirole may be due to 
irregularities in either DA binding or abnormal function of further downstream signaling events. 
Moreover, the lack of a significant dose effect in the quinpirole concentrations used is consistent 
with published data, illustrating by similar analyses that there was no dose effect in mice even at 
broader and higher dose ranges (Wang et al., 2000).  
Additionally, MsrA-/- and WT mice were injected with two doses of the D1DR agonist 
SKF82958, and ensuing locomotor activity behavioral effects were assessed in 45 min sessions 
(Fig. 5B). The ANOVA applied to these distance traveled data indicated no effect of mouse type, 
a significant effect of SKF82958 dose effect (repeated measures ANOVA; P<0.01), and no 
dose-by-type interaction. These data show that the D1DR agonist did not differentially affect the 
two types of mice (no type effect, no interaction effect). As expected from the literature for 
several types of inbred mice, SKF82958 substantially increased locomotor activity in the dose 
range used here (Niimi, Takahashi, & Itakura, 2009). These data strengthen the idea that 
methionine oxidation in the D2DR third cytoplasmic loop plays an important role in the MsrA-/- 
phenotype (the D2DR third intracellular loop contains eight methionines, and the D1DR C-
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terminus cytoplasmic region contains only one methionine; both of these regions are directly 




Figure 5. Locomotor activity after D2DR and D1DR agonist administration in MsrA-/- and 
WT mice. Total distance traveled was measured for 45 min after intraperitoneal injections of 
saline (vehicle) or indicated drug. A) Quinpirole injection at doses of 0.5 mg/kg and 0.1 mg/kg. 
WT, n=7; MsrA-/-, n=10. †P<0.01 for quinpirole effect and *P<0.02 for the genotype effect, 
determined by ANOVA. B) SKF82958 injection at doses of 0.3 mg/kg and 1.0 mg/kg. WT, n=7; 
MsrA-/-, n=10. There was no significant effect of mouse type on SKF82958 effect,  SKF82958 
increased locomotor activity in the dose range used (†P<0.01) and no dose-by-type interaction 




MetO residues in recombinant long form D2DR third intracellular loop 
Oxidation vulnerability was examined with recombinant GST-D2DRL-IC3 and peroxide exposure. 
Non-H2O2 oxidized GST-D2DRL-IC3 protein, H2O2 oxidized GST-D2DRL-IC3 protein, and H2O2 
oxidized GST-D2DRL-IC3 proteins treated with MsrA were all subjected to mass spectrometry 
analysis following gel-electrophoresis separation and tryptic digestion. The procedure used to 
detect peptides by this mass spectrometry analysis (L. Zhang et al., 2010) normally causes 
some Met oxidation. To compensate for this, averaged MetO levels detected in the non-H2O2 
oxidized GST-D2DRL-IC3 peptides were subtracted from the H2O2 oxidized forms of the protein 
(+/- MsrA and DTT). A 17-amino-acid peptide produced by collision-induced dissociation was 
found to contain the highest quantity of oxidized Met (276-AQELEMEMLSSTSPPER-292; Fig. 
6). Furthermore, the Met283 residue (present in daughter ion Y10) of the peptide was found to 
be relatively more oxidized in comparison with the Met281 residue (present in daughter ion Y12; 
data not shown). The net oxidation level of Met283 treated with H2O2 in vitro was on average 
2% (Fig 6). This oxidation level resembles the basal physiological level of MetO in unpublished 
observations and in yeast cells without H2O2 in the growth media (Moskovitz et al., 1997). 
Accordingly, the current in vitro condition of oxidation may resemble physiological Met oxidation. 
The addition of MsrA and DTT to oxidized GST-D2DRL-IC3 protein was able to reduce the 
sulfoxide of Met283 by 60% (Fig. 6). The MsrA enzyme can reduce only the S-form of MetO. 
Empirically, the distribution ratio of S to R forms of MetO is 1:1 (D. B. Oien & Moskovitz, 2008). 
Typically, we observed that in vitro oxidation of Met by H2O2 results in 60% S-MetO and 40% R-
MetO (determined by amino acid analysis separation; unpublished results). Thus, the ability of 
the MsrA to reduce 60% of the total oxidized Met283 reflects the expected maximum reduction 
capability of the enzyme in an expected MetO racemic mixture of R and S forms following Met 
oxidation by H2O2. In addition, the preferred oxidation of Met283 suggests this residue is more 
vulnerable to oxidation and also readily accessible to the reducing function of MsrA. 
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Figure 6. Oxidized Met residues in D2DRL-IC3 recombinant protein. The short and long form 
D2DR differ by a 29-amino-acid region in the third cytoplasmic loop, which begins after amino 
acid 241 in the rat sequence (underlined). The Mets (m) are in bold. The corresponding 
recombinant fusion protein GST-D2DRL-IC3 was isolated and resulting peptides were subjected 
to tandem mass spectrometry after trypsin digestion. The sequence of the major oxidized 
peptide identified is shown and also indicated in the sequence by parenthesis. Representative 
relative signal levels for the daughter ions of the major peptide detected after collision-induced 
fragmentation are presented as relative intensity of each ion. The difference in percent Met 
(Y10) oxidation between the presence and absence of rMsrA was found to be significant (3 
experiments, P<0.05 by t-test). 
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  4. Discussion 
This study describes for the first time the possible effects of Met oxidation on DA receptor 
function in vivo by using MsrA-/- mice. Previously, we observed an inverse relationship between 
abnormally high levels of DA accompanied by lowered locomotor activity in MsrA-/- mice (D. B. 
Oien, Osterhaus et al., 2008). This is paradoxical because chronically low levels of brain DA are 
associated with Parkinson’s disease-like motor effects including low levels of locomotor activity. 
These unexpected results led us to investigate the possibility that alteration of DA receptor 
function and expression may be involved.  
Both the D1DR and the D2DR modulate striatal information processing that is integral to the 
translation of cortical plans into actions by providing for the expression of selected motor 
responses with concurrent suppression of unwanted responses (“responses” may be cognitive 
or motor). The D2DR are of particular clinical interest because of their role in neuropsychiatric 
disorders, such as schizophrenia, where D2DR antagonists are therapeutic (Lieberman et al., 
2008), or their role in the movement disorder, Parkinson’s disease, where D2DR agonists are 
known to benefit patients (Pahwa, Lyons, & Hauser, 2004). Thus, we predicted a reduced 
expression of striatal D2DR in MsrA-/- mice to explain the relative lower locomotor activity (D. B. 
Oien, Osterhaus et al., 2008). Surprisingly, there was an increase of D2DR expression in MsrA-/- 
mice (Fig. 1). Higher levels of [3H]raclopride binding to D2DR confirmed this increase (Fig. 2). 
The higher protein levels of the D2DR in MsrA-/- may be part of a compensatory mechanism for 
the accumulation of oxidized D2DR. In spite of the higher D2DR levels observed, the binding of 
[3H]quinpirole suggests a compromised agonist binding of the D2DR in MsrA-/- brain (Fig. 2A). 
Supportive in vivo data to this phenomenon are demonstrated by the lesser D2DR agonist 
inhibitory effect on locomotor function in MsrA-/- mice (Fig. 5A). Agonist occupation of G-protein 
coupled receptors leads to a cellular response that wanes, or desensitizes, with prolonged 
agonist exposure. MetO in the intracellular loops of the D2DR may cause a conformational 
change that may result in uncoupling of the receptor to G-protein subunits. The relative 
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compromised binding of the D2DR to [3H]quinpirole suggests lower efficiency in D2DR-G-
protein coupling. Indeed, our data show that although the levels of Gαi/o are similar in both 
mouse types (Fig. S1), the coupling of D2DR to G-proteins is reduced by ~50% in MsrA-/- 
relative to WT brain (Fig. 3). This suggests that the total Gαi/o coupling capacity is reduced in 
MsrA-/- brain rather than their coupling affinity to D2DR. 
The ability of MsrA to restore D2DR agonist binding in MsrA-/- striatal extracts (Fig. 2B) 
supports the theory that methionine oxidation of D2DR occurs in the MsrA-/- brain. Accordingly, it 
may be beneficial to cause striatal overexpression of Msr to prevent MetO related abnormalities 
manifested by oxidized D2DR. Furthermore, the selectivity of the effect of Met oxidation on 
D2DR (by MsrA ablation) was demonstrated by the similar binding of D1DR to striatal extracts in 
both mouse types (Figs. 2C & 2D). Data presented in Fig. 4 suggest the autoreceptor function of 
D2DR in MsrA-/- striatum is compromised in its functional response to quinpirole and sulpiride 
compared to WT D2DRS. The in vivo observation that MsrA
-/- mice are less responsive to the 
inhibitory effect of quinpirole on locomotor activity (Fig. 5A) supports the conclusion that there is 
a general malfunction of MsrA-/- D2DR. Furthermore, the in vivo specificity of the MsrA ablation 
effect for D2DR is strengthened by the similar response of both mouse types to D1DR agonist 
(Fig. 5B). According to the literature, the use of the administrated doses of 0.1 and 0.5 mg/kg 
quinpirole are within the common range used in mice. In mice, there is no increased locomotor 
response as the dose is increased; instead, a suppression of locomotor activity is observed 
(Geter-Douglass et al., 1997; Usiello et al., 2000; Wang et al., 2000). Mice are different from 
rats in their response to quinpirole. In rats there is an increase of locomotor response with a 
higher quinpirole dose (Eilam, Clements, & Szechtman, 1991; Koeltzow, Austin, & Vezina, 
2003). This observation may be linked to the observed difference in the ligand Kd values in rats 
(Levant, Grigoriadis, & DeSouza, 1992) versus mice (current study).  
Taken together, it is suggested that lack of MsrA leads to Met oxidation in both long and 
short forms of D2DR and diminishes their overall function. The generally lowered MsrA-/- 
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response to quinpirole, both in vitro and in vivo (Figs. 2 & 5) implies that conserved regions of 
both D2DR subtypes are primarily affected in the MsrA-/- mouse (this does not exclude 
involvement of the 29 amino acid sequence that is not present in the D2DRS). The compromised 
G-protein coupling in MsrA-/- may be a result of oxidative modification of specific Met residues, 
especially in the cytoplasmic loops of the D2DR that are important for G-proteins coupling (i.e. 
D2DRL-IC3) (Ilani et al., 2002; Montmayeur, Guiramand, & Borrelli, 1993). To assess the 
possibility of Met oxidation in D2DRL-IC3 and reversal by MsrA in vitro, a recombinant GST-
D2DRL-IC3 protein was oxidized and treated with recombinant MsrA. An oxidation of a specific 
Met (Met283) in recombinant GST-D2DRL-IC3 protein occurred and was reduced to Met by 60% 
with MsrA (Fig 6). Met283 is present in both subtypes of D2DR and may be an important target 
for oxidation that affects the general function of this receptor. Future experiments are underway 
to monitor in vivo MetO levels and location in the D2DR of MsrA-/- mice. Overall, the collective 
evidence indicates that primarily D2DR related signaling is affected in MsrA-/- mice. However, 
the contributions of other signaling events to the observed abnormalities will still need further 
investigations. 
Mechanistically, we suggest that oxidation of specific Metresidues may also affect 
phosphorylation of adjacent amino acids in D2DRL-IC3, thereby altering DA signal transduction 
pathways. For example, a regulatory role of MetO in protein phosphorylation was recently 
reported (Emes, 2009; Hardin, Larue, Oh, Jain, & Huber, 2009; D. B. Oien, Shinogle et al., 
2009a). Accordingly, it is possible that specific MetO residues in D2DRL-IC3 inhibit 
phosphorylation events that are important for proper coupling of the receptor to G-proteins as 
well (Namkung, Dipace, Javitch, & Sibley, 2009).  
Our data can be interpreted to suggest that lack of MsrA in mouse brain causes D2DR 
malfunction via G-protein uncoupling leading to the production of higher DA levels (as a 
potential compensatory mechanism), reduced locomotor activity, and diminished behavioral 
responsiveness to D2DR agonists (D. B. Oien, Osterhaus et al., 2008). Understanding the role 
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of MsrA and MetO in DA physiology may result in identifying other proteins and neurotransmitter 
receptors that are altered by oxidative modification of Met.   
Recently it was reported that mutations in the upstream region of MsrA may be potential 
markers for schizophrenia. If this proves true, research clearly supports the relevance of the 
MsrA-/- DA system to the occurrence of DA-related abnormal behavior (Walss-Bass et al., 2009). 
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IV. Conclusions and Future Directions 
One of the main foci of our laboratory is Met redox cycling as a means for cell signal regulation. 
Theoretically, this means that ROS normally oxidize Met residues and they are reduced by Msr. 
Furthermore, there is an inherent layer of modulation of protein function by ROS, as a natural 
product or byproduct, and a reversal via Msr. Ultimately, this may act as a molecular switch, 
turning protein functions on and off, or switching proteins from one function to another. Possibly, 
one aspect of this regulation may be a compensatory mechanism to deal with abnormal sources 
of ROS, arising from genetic, lifestyle, and environmental impacts. Evidence to support Met 
redox cycles as a method of cell signal regulation comes from potential benefits from Msr 
substrate-methionine sulfoxide formation and from an ROS scavenging role in other Msr-
substrates (D. B. Oien & Moskovitz, 2008). Moreover, there is evidence to suggest that Msr 
expression is increased in the presence of Met oxidation in peptides (ongoing study; 
unpublished observations). The Msr system of higher-order organisms is seemingly more 
evolutionarily complex, possibly as a result of more complex environmental hazards, different 
lifestyles, and longer life spans. Extrapolating from these theories and the Free Radical Theory 
of Aging, some aging-related diseases could be associated with increases in ROS and 
inadequate antioxidant systems. Neurodegenerative diseases associated with age and oxidative 
stress are the basis of my research. Determining the mechanisms of disease signs and 
symptoms related to the Msr system may lead to new pharmaceutical approaches in the future. 
 
A. Conclusions 
In summary, we have found multiple pathologies in the absence of MsrA that correlate to 
neurodegenerative diseases. We have found elevated brain pathologies related to Alzheimer’s 
disease biomarkers in the hippocampal regions of the MsrA-/- mouse (Pal, Oien, Ersen, & 
Moskovitz, 2007). Furthermore, bio-behavioral differences in complex task learning were 
detected in the MsrA-/- mouse (D. B. Oien et al., 2008). The latter results may or may not be 
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related to the former results. Alternatively, any hippocampal region-associated results may be 
attributed to changes in the D2DR (discussed below), as this receptor is known to be highly 
expressed in that region. These results need further exploration, and indicate a major future 
direction. Separately, we have found novel changes in the clearance and phosphorylation of 
alpha-synuclein when expressed in MsrA null yeast cells (D. B. Oien, Shinogle, Moore, & 
Moskovitz, 2009a). These results may be associated with Parkinson’s disease and other 
synuclienopathies. It was interesting that total degradation was inhibited in these cells, in 
addition to the clearance of alpha-synuclein. This may provide evidence of a mechanism by 
which alpha-synuclein accumulates as fibrils in these cells and in the Lewy bodies of 
Parkinson’s disease. Also, the cell survival rate changed in the same MsrA null yeast cells when 
exposed to oxidants.  
Survival of yeast strains overexpressing alpha-synuclein (unpublished). In attempt to 
evaluate the effect of oxidative stress on alpha-synuclein expressing cells, the cells were 
exposed to either H2O2 or paraquat and their survival rate was monitored by their consequential 
growth levels (which represent the amount of living cells). Previously it was shown that msrA-
KO yeast cells were most sensitive to H2O2 compared to WT (H2O2 has a minor specificity for 
sulfur amino acids (Moskovitz, Berlett, Poston, & Stadtman, 1997; Moskovitz et al., 1998)). As 
expected, following exposure to H2O2 the msrA-KO harboring the sham vector showed much 
lower survival rate compared to the WT strain, respectively (Fig. 1). The expression of all forms 
of alpha-synuclein showed enhanced survival rate in the WT strain under all conditions tested 
compared to the control (vector expressing cells in each condition) (Fig. 1). However, this 
survival enhancement was less pronounced in msrA-KO cells expressing alpha-synuclein and 
was shown to be effective mainly in H2O2 treated cells (Fig. 1). Interestingly, under oxidative 
stress mediated treatment (H2O2 or paraquat) the highest survival difference between WT and 
msrA-KO alpha-synuclein -expressing cells was observed when SynA30P was expressed 
followed by SynA53T expression, respectively (Fig. 1). The latter result is consistent with the 
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lower degradation rate, enhanced protein oxidation, and aggregation levels when SynA30P is 
expressed in msrA-KO cells (D. B. Oien et al., 2009a). This result seems inconsistent with the 
degenerating neurons in the Parkinson’s disease pathology. However, a recent study in our lab 
indicates an increase of Msr expression in the presence of oxidized peptides (unpublished 
results). This may explain the increased survival rates of alpha-synuclein expressing cells, and 
the decrease in survival of msrA-KO cells. This idea could further be extrapolated to a 
mechanism in which Parkinson’s disease is age-related. Thus, as Msr decreases with age, 




Figure 1. Survival of msrA-KO and WT yeast cells expressing alpha-synuclein and 
control vector. Yeast cells (at logarithmic growth phase) expressing the three types of alpha-
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synuclein and control vector were subjected to the induction media for 2 h and then incubated 
with either 10 mM H2O2, 10 mM paraquat, or only media (control) for an additional 1 h at 30°C.  
The relative survival rate was monitored by inoculating each culture (1:500 dilutions) into a 
complete synthetic media followed by monitoring growth levels in logarithmic phase by 
measuring OD600nm. The percent survival rate of each culture represents the percent of optical 
density measurements at the same time for each culture relative to the corresponding WT (†) or 
msrA-KO (‡) cells, harboring the sham vector in non-treated media. Error bars represent 




The role of Met redox cycles in transmissible encephalopathies has not been established to 
the extent of Alzheimer’s and Parkinson’s disease. We have detected an increase of MetO in 
the scapie prion, compared to the non-infectious cellular prion protein. However, other reports of 
specific Met residue oxidation, Met213, claim that this modification is probably not associated 
with the disease (Silva et al., 2010). In contrast, other reports state that the sulfoxide on Met213 
can destabilize the structure of the cellular prion protein, which may be essential for the 
pathogenic conversion (Colombo, Meli, Morra, Gabizon, & Gasset, 2009). This report also 
claims another Met modified to sulfoxide, M206, can cause similar structural changes. The role 
of this Met, and all other Mets, in prion-related disease has yet to be determined. 
After creation of the MsrA-/- mouse, several characteristics were noticed including an 
abnormal “tip-toe” walking pattern (Moskovitz et al., 2001). We later performed a gene array (D. 
B. Oien & Moskovitz, 2008) and behavioral tests (D. B. Oien et al., 2008) concurrently to better 
characterize this genotype. After genomic analysis, we found that 14-3-3zeta expression was 
changed in 6-month-old MsrA-/- mice. This protein is an activating protein for tyrosine 
hydroxylase, and key enzyme in DA synthesis. Together with locomotor behavior deficits and a 
decreased response to amphetamine injection, we concluded there was a possible problem in 
DA signaling. Surprisingly, DA levels were elevated in younger MsrA-/- mice. The abnormal 
locomotor and DA levels were alleviated when the mice were on a CR diet (D. B. Oien, 
Osterhaus, Lundquist, Fowler, & Moskovitz, 2010). Food restriction theoretically reduces 
oxidative stress, and in our experiments reduced DA levels in WT mice and increased DA levels 
in MsrA-/- mice. There are several methods of restricting the diet in mice. We choose a common 
method of basing the diet on body weight (Fig. 2). This method also resulted in reduced MetO 
content of several proteins, including an unknown 15 kDa protein. These proteins have not been 
identified, however immunoblotting confirmed the 15 kDa protein is not alpha-synuclein. 
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Figure 2. The average body weight of the MsrA-/- mice on CR diet by percent of ad libitum 
starting weight. The amount of food available to each mouse was restricted after eight months 
of age as described in “Materials and Methods” (D. B. Oien et al., 2010). Mice were fed an 
amount of food proportional to their ad libitum starting weight (8 months) until each achieved a 
loss of 15% original body weight, which occurred within 15 days (8.5 months). Based on 
semiweekly weight monitoring, each mouse was maintained at 15-20% of the respective original 
weight by adjusting the daily available food. The monthly average body weight of the MsrA-/- 
mice on CR diet as a percent of the ad libitum starting weight. Y axis represents the average by 
percent of original weight for each mouse. X axis represents each month of the CR diet. Black 
squares - MsrA-/- mice. Open diamonds – WT control mice. No significant difference was 
detected by repeated measures ANOVA. The three-month body weight average of the MsrA-/- 
mice on CR diet. The three-month average body weight in grams at 8 months (Pre-CR diet), 
and at 4 and 9 months of CR  diet (12 month- and 17 month-old mice, respectively) was 
218 
determined by semiweekly monitoring. Bars represent average of MsrA-/- mice (filled) and WT 
mice (open). No significant difference was detected between mouse genotypes within 
respective age groups by the Student’s t-test. Error bars represent standard deviation of 11-13 
mice per genotype in both graphs.   
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Presynaptic DA levels were also increased in coronal brain sections of MsrA-/- mice (D. B. 
Oien et al., 2008). Further studies indicated that DA reserve pools were increased (Ortiz, Oien, 
Johnson, & Moskovitz, Manuscript). These results and prior data indicate that there is an 
increase in DA synthesis. Importantly, presynaptic DA release of MsrA-/- mice was also 
examined in the presence of incrementing calcium levels. No significant change was observed, 
suggesting that calcium regulatory proteins in MsrA-/- mice were functioning properly. The 
significance of this target comes from multiple literature sources that have noted calcium 
regulatory proteins, such as calmodulin and calcium/calmodulin kinase II, as Msr substrates. As 
calcium levels are involved in vesicle mobilization and release, this result further suggests that 
natural physiological DA release is not increasing or decreasing, at least based on calcium level 
regulation. The increase in DA synthesis may be due to a lack of autoreceptor signaling, which 
is modulated via a D2DR isoform. 
Several results indicated a potential abnormality in D2DR signaling. Decreased locomotor 
activity, cognitive deficits, and unresponsiveness to increases in extracellular DA (via 
amphetamine injection) (D. B. Oien et al., 2008) can all be all be related to poor DA receptor 
signaling. In addition to increased synthesis, the MsrA-/- mice were later found to be less 
responsive to the D2DR agonist quinpirole indicating poor D2DR autoreceptor signaling 
(quinpirole is known to decrease locomotor activity in mice at the concentrations used, 
presumably by decreasing presynaptic DA) (DB Oien et al., In Press). All together, these results 
indicate a problem with D2DR signaling. This was confirmed by receptor binding studies in 
which a D2DR agonist bound to receptors with less affinity than a D2DR antagonist. In contrast, 
receptor binding results with a D1DR agonist and antagonist did not show any significant 
difference in the MsrA-/- mice, suggesting a particular specificity for the D2DR. The D2DR has 
more Met residues where G-proteins couple (third intracellular loop) than other DA receptors. 
Indeed, D2DR agonist binding could be restored by the addition of Msr and G-protein coupling 
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was decreased in MsrA-/- mice (DB Oien et al., In Press), suggesting MetO formation in the 
D2DR third intracellular loop. D2DR purification experiments to detect MetO were unsuccessful.  
 
B. Hypotheses and Future Directions 
The role of the Msr system in neurodegenerative diseases is still being evaluated. We have 
found that Alzheimer’s disease-related biomarkers were elevated in MsrA-/- mice (Pal et al., 
2007). In addition, Met oxidation of the amyloid-beta peptide, known to form amyloid plaques in 
Alzheimer’s disease, can be neurotoxic (Schoneich, 2005). This is in contrast to increases in 
(yeast) cell survival in when an Msr substrate (alpha-synuclein) was overexpressed in WT cells 
(as shown in Fig. 1). However, an ongoing study has shown evidence that Met oxidation of 
substrates can increase Msr expression (new results; data not shown). Based on previous 
reports that show Msr expression decreases in aging tissues, including brain tissues 
(Petropoulos, Mary, Perichon, & Friguet, 2001; Stadtman, Moskovitz, Berlett, & Levine, 2002), 
we hypothesize that Met redox cycles are disrupted in Alzheimer’s disease. This hypothesis 
includes the aging component of this neurodegenerative disease; thus, the genetic, lifestyle, 
and environmental impacts are negligible until an older age is reached and Msr capability has 
decreased. This concept is supported by reports of decreased Msr in Alzheimer’s disease 
brains (Gabbita, Aksenov, Lovell, & Markesbery, 1999). Obviously, there are many more factors 
that may affect the etiology of Alzheimer’s disease, but the role of the Msr system in Alzheimer’s 
disease, and to what extent this role is, remains a future direction.  
The role of the Msr system in Parkinson’s disease and other synucleinopathies may be 
similar to that hypothesized for Alzheimer’s disease. However, a decrease of Msr expression 
and activity has not been shown in Parkinson’s disease patients to date. In spite of this missing 
information (that is major future direction), our studies (D. B. Oien, Shinogle, Moore, & 
Moskovitz, 2009b) and studies from other groups support the need for a better understanding of 
alpha-synuclein and corresponding Met oxidation. One challenge of studying alpha-synuclein in 
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mice, including MsrA-/- mice, is that the protein has a few different residues at the primary 
structure than that of human alpha-synuclein. One difference between human and murine 
alpha-synuclein is the threonine at position 53, which is also found in the A53T genetic form of 
Parkinson’s disease. To overcome this, I have proposed to express human alpha-synuclein in 
MsrA-/- mice, which would create a model for studying Met redox cycles and the alpha-synuclein 
substrate. Integrative knowledge from our research group and others lead us to propose the 
central hypothesis that the Parkinsonian characteristics of substantia nigral neurodegeneration, 
gait and locomotor activity deficits, and alpha-synuclein modification and aggregation will 
develop progressively over time in mice that lack Msr with nigrostriatal-targeted overexpression 
of human alpha-synuclein (from my comprehensive example proposal). The overall goal of the 
following proposed experiments will be to analyze this mouse as a potential model of 
Parkinson’s disease.  
In addition to studies on alpha-synuclein, we have discovered that MsrA ablation disrupts 
DA signaling and the D2DR is a substrate for Msr (DB Oien et al., In Press). One major difficulty 
in this study was the purification of the mouse D2DR, which still remains to be accomplished. 
Once the D2DR is purified from MsrA-/- mice, mass spectrometry analysis may indicate which 
methionine residues in the receptor are oxidized. This information, and purification of D2DR 
from Parkinson’s disease patients, will provide for a possible new area of research based on 
abnormal DA signaling and associated molecular mechanisms. One possibility may be changes 
to D2DR phoshorylation. 
Phosphorylation is a well-accepted method of regulation via posttranslational modifications. 
We have found new evidence for methionine sulfoxides that inhibit phosphorylation on alpha-
synuclein (D. B. Oien et al., 2009b). This may be more of a general phenomenon, and remains 
to be investigated in the D2DR and other physiological systems. Overall, our research has been 
inspired by the hypothesis that Met redox cycles have a physiological role in cellular regulation, 
from scavenging ROS to changing the functions of Msr substrates. One method to uncover this 
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possibility is by examining when the Msr system is compromised, and this also assists in the 
understanding of abnormalities in Met redox cycles and disease. 
 
 C. Other Relevant Research of the Msr System 
In contrast to the previous research presented, the Msr system and its respective impact extend 
far beyond the nervous system. There are several reports on the Msr system in other fields of 
research. Two of our studies on the Msr system are presented below. These studies were never 
continued, but like many other orphan reports on Msr they may become more important as new 
information on the Msr system in uncovered. 
 
  1. MsrA and Cystiene Dioxygenase  
(D. B. Oien & Moskovitz, 2007b) 
Msrs are able to reduce MetO to Met both in proteins and free amino acids. By their action it is 
possible to regulate the function of specific proteins and the cellular antioxidant defense against 
oxidative damage. Similarly, cysteine dioxygenase (CDO) may be involved in the regulation of 
protein function and antioxidant defense mechanisms by its ability to oxidized Cys residues. The 
two enzymes’ involvement in sulfur amino-acids metabolism seems to be connected. Lack of 
MsrA in liver of MsrA-/- led to a significant drop in the cellular level of thiol groups and lowered 
the CDO level of expression. Moreover, following selenium deficient diet (applied to decrease 
the expression levels of selenoproteins like MsrB), the latter effect was maintained while the 
basal levels of thiol decreased in both mouse strains. We suggest that both enzymes are 
working in coordination to balance cellular antioxidant defense. 
 
  2. MsrA and Non-Replicative Senescence of Yeast  
(D. Oien & Moskovitz, 2007a) 
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The major enzyme of the Msr system is MsrA. Senescing msrA knockout mother yeast cells 
accumulated significant amounts of protein-carbonyl both at 5 generation-old (young) and 21 
generation-old (old) cultures, while the control mother cells showed significant levels of protein-
carbonyl mainly in the old culture. The Msr activities of both yeast strains declined with age and 
exposure of cells to H2O2 caused an accumulation of protein-carbonyl especially in the msrA 
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